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Abstract 
 
 
Fibronectin (FN) protein was discovered in the early 1970s by Richard Hynes.1 Since 
then this large, multidomain glycoprotein present in the extracellular matrix and in 
body fluids has been intensively research, and has been found to play a fundamental 
role in cell adhesion, cell migration, cell survival, angiogenesis, and other important 
biological processes. In recent years the interest in FN has risen; the novel FN 
isoform, termed Migration Stimulating Factor (MSF) has been cloned and 
characterized, and new results documenting the involvement of FN and MSF in 
wound healing, cancer progression and bacterial metastasis have been presented.2 
 
The recent findings have shown that MSF’s bioactivities (e.g. stimulation of cell 
motility, hyaluronan synthesis and angiogenesis) are mediated by the highly 
conserved amino acid motif Ile-Gly-Asp (IGD), and are mimicked by small synthetic 
peptides containing this sequence. The aim of this project was to design and 
synthesize first generation non-peptidic compounds which could mimic the 
biological activity of MSF (i.e. IGD peptidomimetics).   
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The first generation IGD peptidomimetics 
 
 
The second part of this thesis describes the role of FN in bacterial pathogenesis. 
Staphylococcus aureus is commonly present in the nose and on the skin of one third 
of all people, and is normally harmless at these sites. However, the microorganism 
possesses the ability to enter the body, invade cells and cause infection. The 
mechanism for S. aureus adhesion to, and invasion of, human cells has been 
extensively studied. It is now postulated that bacterial invasion is mediated by FN, 
that acts as a bridge between bacterial proteins adhesins and integrin receptors 
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present on the cell surfaces.3 The biologically active motif, by which FN mediates its 
adhesion to bacterium, has not been unambiguously identified. However, the 
preliminary, unpublished studies point towards a short terapeptide sequence, Gly-
Arg-Ile-Ser (GRIS), which is highly conserved within FN. We proposed to elucidate 
the role of the native GRIS motif by synthesising a small, nonpeptidic molecule, 
which could mimic its biological properties and activities.  
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The first generation GRIS peptidomimetic 
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THE IGD PROJECT 
 
 
1.0 Introduction 
 
 
The human extracellular matrix (ECM) is a complex network of proteins and 
macromolecules that fills the intercellular spaces. This three-dimensional matrix 
creates a living environment for cells and transmits external signals. Dynamic 
interactions between cells and proteins in the surrounding ECM regulate and 
stimulate most cellular functions and processes. One of the most remarkable ECM’s 
proteins is fibronectin (FN). Fibronectin is a biologically active macromolecule 
engaged in a variety of events that take place in the ECM. Some of the processes that 
depend on FN and one of its isoforms termed Migration Stimulating Factor (MSF) 
are: wound healing, cancer and bacterial metastasis.2,3,4 
 
In recent years, new ideas and theories have arisen around two “hot” topics: wound 
healing and cancer pathogenesis.5 However, despite decades of research, current 
treatment of both lesions is still very difficult and often unsuccessful. Difficulties rise 
from the fact that both processes are complex and engage a cascade of cellular 
events, signalling molecules and receptors.  As a result, pharmacological drugs and 
approaches tend to suffer from poor selectivity and efficiency. 
 
Due to the histological similarities between tumour “microenvironment” and that of a 
healing wound, Harvard pathologist Harold Dvorak described cancer growth as 
“wound healing gone awry.” Both impaired tissues and tumours induce very similar 
biochemical and cellular responses. They both need rapid cell proliferation, cell 
migration and angiogenesis. However, in wounds these processes are normally 
reparative and end after the wound heals; in cancer they become invasive, aggressive 
and uncontrollable.  
 
FN has long been linked to malignant diseases and is considered as a target for 
tumour therapy.6 Special attention has been focused on FN isoforms which included 
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an extra domain B (EDB), a sequence of 91 amino acids. The EDB domain has been 
shown to be expressed in tissues undergoing remodelling during angiogenesis or 
tumour invasion.7 Recently, another FN isoform was proved to be associated with 
angiogenesis and cancer. This new protein, termed Migration Stimulating Factor, is a 
truncated version of FN that exhibits interesting biological activities. Experiments 
conducted so far showed that MSF induces angiogenesis, cell migration and 
hyaluronan synthesis.2 All these bioactivities, but especially stimulation of cell 
movement, make the MSF molecule relevant and interesting target for research in 
both areas: wound healing and tumour progression.  
 
 
1.1 Fibronectin protein 
 
 
In the early 1970’s, during research on cancer development, scientists discovered a 
new protein that was present on the surface of normal cells but rarely on tumour 
cells. The protein was the first clear molecular difference observed between normal 
and cancer cells. Although further investigations proved that this molecule was not  
a central, single factor that could explain cancer progression, research on this new 
structural protein, termed fibronectin, started and has been continuing since.  
 
Throughout 40 years of research, FN has been shown to stimulate many key cellular 
processes; i.e. cell adhesion, migration and differentiation, thrombosis and wound 
healing. Much information about FN has been gained, regarding its structure, 
distribution, receptors, and other potential functions. FN was also proved to be, after 
all, involved in cancer pathogenesis and angiogenesis. As interest in FN protein has 
prevailed, the new theories around FN and its role in biological processes have 
emerged:  “I think that we all feel that fibronectin has been an incredible conceptual 
gold mine” (Kenneth Yamada, M.D., Ph.D).8 
 
Until now, human fibronectin remains imperfectly understood. Fibronectin is not 
only structurally complex molecule with many independent binding sites, but also, 
during genetic processes, as many as 20 variants of FN are produced in humans. 
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Each variant has a different structure and activity. To further complicate the 
situation, fibronectin fragments (resulting from proteolysis) also have unique 
biological properties. Since all these molecules are coded by a single gene, 
fibronectin is also a term that describes a family of structurally and immunologically 
related glycoproteins.  FNs are of crucial importance while researching complex and 
concerted molecular processes.9 
 
 
1.1.1 Forms of fibronectin and fibrillogenesis 
 
 
Fibronectin is a large, adhesive glycoprotein, with high molecular weight ca. 500 
kDa, characteristically present only among vertebrates.10 Like many other ECM 
glycoproteins, FN is a multifunctional molecule that not only attaches cells to the 
ECM, but also mediates a range of biological processes throughout its active 
sequences. FN has been shown to be critically important in normal vertebrate 
development, what was demonstrated by the early embryonic lethality of mice with 
targeted inactivation of the FN gene.11  In the human body FN exists in two 
distinctive forms: as plasma FN (pFN), present in body fluids, and cellular FN (cFN), 
crucial component of the ECM.   
 
The plasma form of fibronectin is produced predominantly by hepatocytes and 
secreted into blood, to circulate as a soluble dimer in relatively high (micromolar) 
concentrations. In contrast to pFN, cellular FN is synthesised locally by various types 
of cells (e.g. fibroblasts, chondrocytes, macrophages and intestinal epithelial cells) 
and released as a compact globular molecule that has high affinity to quickly self-
polymerise into insoluble fibrils.12,13 Cellular FN, along with collagen, is the main 
constituent of ECM that forms a highly dynamic network of fibres. This fibrillar 
matrix creates the necessary environment for cells’ embryogenesis, growth, survival, 
differentiation and many other primary processes.14  
 
Our understanding of how globular, soluble cFN molecules self-assemble into this 
functional fibrillar meshwork is limited. The mechanism of fibrillogenesis is 
complex and has been shown to be stepwise, proceeding from initiation, through 
 16
elongation to stabilization faze.15 There is nothing spontaneous about fibrillogenesis; 
each step is highly regulated by cells and their transmembrane receptors, integrins. 
Integrins initiate the fibrillogenesis process by binding soluble FN molecules and 
attaching them to cell surfaces. In order to do this, receptors have to be present in 
high affinity (active) conformation. The continuous binding of FN molecules 
eventually leads to relatively high local concentration of integrin-FN clusters, and 
finally become high enough to promote self-association of FN molecules (Figure 1).  
 
 
 
 
Figure 1. Assembly of fibronectin: (A) soluble FN binds to integrins (gold), (B) FN binding 
to integrins and other receptors (pink bars) induces stretching of FN molecules, (C) Fibrils 
form through FN–FN interactions.  
 
Reprinted from Matrix Biology, 24, Y. Mao, J. E. Schwarzbauer, Fibronectin fibrillogenesis, a cell-
mediated matrix assembly process, p. 389-399, Copyright 2005, with permission from Elsevier 
 
 
Interestingly, initiation of fibrillogenesis requires not only molecular interactions, but 
also the application of mechanical forces generated by cells.16,17 It is speculated, that 
in the early stage of fibrillogenesis, cell-generated tension stretches the bound FN 
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protein and induces conformational changes within it. These force-induced changes 
in the FN three-dimensional structure are believed to uncover multiple binding sites 
that were cryptic within the molecule.18 These buried motifs are termed ‘self-
association’ sites that allow binding between cell-associated FN molecules. The 
chain reaction of FN’s self-assembly eventually results in dense network of matured, 
elastic and highly stretched fibrils that form a stable matrix (Figure 2).17,19 
 
 
 
Figure 2. Fibrillar FN matrix. 
 
Reprinted from Matrix Biology, 24, Y. Mao, J. E. Schwarzbauer, Fibronectin fibrillogenesis, a cell-
mediated matrix assembly process, p. 389-399, Copyright 2005, with permission from Elsevier 
 
 
The fibrillogenesis in tissues is an active and dynamic everyday process. On the 
contrary, normal fibrillogenesis in blood is required only under certain physiological 
conditions, when formation of thrombus is necessary. However, both processes, 
fibrillogenesis of cFN in tissues and pFN in blood are controlled by the same 
mechanism. The difference in demand for cellular and plasma fibrillogenesis is 
regulated by integrins present on cell surfaces. In tissues, cells normally express 
activated integrins that subsequently bind FN molecules. In the blood, integrins on 
hematopoietic cells remain in a low affinity conformation, what prevents FN’s 
adhesion.20 However, during vascular injuries, platelets are activated and integrins on 
their surfaces shift into high affinity conformation what initiate FNs assemble and 
fibrils formation. Recent studies have shown that pFN matrix assembly contributes to 
the stability and proper growth of thrombus.21 It is postulated that FN supports 
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platelets aggregation by crosslinking other adhesive proteins present in blood 
(fibrinogen, thrombospondin) to platelets.22   
 
Control over the fibrillogenesis process is also necessary for proper deposition of the 
fibronectin matrix. Formation of biologically active FN fibrils is crucial for normal 
cell function, but incorrect accumulation of insoluble FN contributes to development 
of several pathological states. Experimental evidence has associated an increased 
deposition of FN and collagen with asthma and inflammatory diseases,23 whereas 
reduced FN matrix deposition is correlated with impaired wound healing.24 
 
 
1.1.2 Structure of fibronectin molecule 
 
 
The plasma and cellular FN forms play different roles in the human body but share 
structural similarities. Regardless the cell type, secreted and soluble FN molecules 
are dimers, composed of two similar or identical polypeptide chains of 220-250 kDa, 
held together by two disulphide bonds located near the carboxyl terminus of the 
protein (Figure 3).13 Each chain is a polypeptide composed of three types of 
homologues modules, repeated in the molecule in a highly organised manner. Each 
chain consists of 12 copies of type I module (FNI), 2 of type II (FNII) and 15-17 of 
III (FNIII), which together accounts for 90% of the FN sequence. The number of 
type III modules in FN depends on inclusion/exclusion of two extra domains of type 
III: A and B (EDA and EDB). Additionally, individual chains might also contain one 
variable region (V) that is not homologues to any other part of the FN protein (Figure 
3).9 The modular structure of FN’s chain is often compared to “beads on a string”, 
because of the way the globular modules are connected to each other by short, linear 
amino acid sequences.  
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Figure 3. Schematic diagram of modular structure of FN dimer; individual modules are 
numbered according to their positions from N- to C-terminus along the FN molecule. 
 
 
Structural studies on the isolated fibronectin modules clearly showed that all modules 
types are independently folded proteins, despite being part of the same polypeptide 
chain. They all have strictly organised, compact, three-dimensional structures that 
comprise of antiparallel β-sheets and turns (Figure 4). The tightly packed 
conformations of the fibronectin types I and II modules are stabilized, in addition to 
hydrophobic interactions between β-sheets, by two highly conserved disulphide 
bonds. The type I and II modules are rich in cysteine residues, which are involved in 
forming the disulphide bonds. Interestingly, the FNIII modules have no disulphide 
bonds, which evoke some flexibility within the proteins.16 This mechanical property 
of the FNIII modules has been linked to fibrillogenesis; individual FNIII modules 
have been proposed to undergo partial unfolding, providing for the elasticity of FN 
fibrils and also exposing the cryptic binding sites (i.e. buried binding sites that 
remain inactive until certain trigger expose them), needed for fibrils assembly.18,25 
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                                type I          type II          type III 
Figure 4. The ribbon structures of FN modules of types I, II and III. The cysteine residues 
and disulfide bonds are shown in purple (type I and II modules). 
 
Reprinted from Matrix Biology, 24, Y. Mao, J. E. Schwarzbauer, Fibronectin fibrillogenesis, a cell-
mediated matrix assembly process, p. 389-399, Copyright 2005, with permission from Elsevier 
 
 
Structurally, the FNI and FNII modules are composed of approximately 45 and 60 
amino acid residues respectively. The detailed primary sequence is known for several 
examples of both types of module. Modules of the same type share low sequence 
homology, which may be linked to their diverse biological functions.26 
 
In order to understand the structure-function relationships in FN, another interesting 
and important feature, which rises from the FN modular nature has to be considered. 
The individually folded modules of types I, II and III rarely exhibit biological 
functions independently. Instead, there are organized in larger fragments that act as 
functional domains capable of interacting with other macromolecules and cells. 
These functional domains, which are comprised of sets of modules and loops 
between them, have distinct conformational properties compared to separately 
considered modules and hold within their structures a range of active and cryptic 
sequences. These characteristics are diverse and unique to every individual domain, 
and are the reason for the broad biological activity of fibronectin protein.9 
 
Several distinct functional domains of fibronectin have been identified by proteolytic 
fragmentation or recombinant DNA analyses.27,28 Starting from the N-terminus, mild 
proteolysis revealed several independent domains that retained their biologically 
activity after being “cut off” from the FN polypeptide (Figure 5). The most important 
are:  
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• N-Terminal fragment FNI1-5 (modules 1 to 5), abbreviated Fib-1/Hep-1, 
binds to fibrin, heparin and bacteria.  
• Collagen/gelatine binding domain (GBD) includes modules FNI6-9 and 
FNII1-2. This binds more effectively to denaturated collagen (gelatin) than 
to native collagen, suggesting a role in “cleaning” denaturated collagen 
materials from tissues and blood. 
• Cell-binding domain, which includes modules FNIII9-10, binds to integrins 
present on cell surfaces.  
• Second heparin-binding domain (Hep-2), located in the C-terminal part of 
FN chain, and Fib-2 (second fibrin-binding site).29 
 
 
 
Figure 5. Schematic representation of functional domains of FN. 
 
 
Since the FN modules of type III are the most ubiquitous of all modules, they have 
attracted the most attention and have been extensively studied.30 The type III 
modules have been indentified in many different proteins in species ranging from 
bacteria to humans.31 FNIII modules are present in the ECM protein tenascin, in cell 
surface adhesion molecules or cytokine receptors like growth hormone receptor. 
They are also present in the largest, central part of FN polypeptide chains.   
 
Each FNIII module is composed of approximately 90 amino acid residues, organized 
in seven antiparallel β strands, arranged in two sheets E-B-A and G-F-C-D (Figure 
6).10 The three-dimensional structure of FNIII units is highly conserved, unlike their 
primary sequences, as individual FNIII modules share only 20-40% of amino acid 
sequence homology within the FN protein. Interestingly, the primary sequence 
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homology for the same FNIII modules across different species is significantly higher, 
80-90%, suggesting that sequence variability among the modules in each FN 
molecule is functionally important.16 
 
 
 
 
 
 
 
Figure 6. Schematic structure of FN module type III.10 
 
Reprinted from Journal of Pathology, 216, E. S. White, F. E. Baralle, A. F. Muro, New insights into 
form and function of fibronectin splice variants, p. 1-14, Copyright 2008, with permission from John 
Wiley & Sons 
 
 
1.1.3 Fibronectin and integrins 
 
 
Fibronectin, as one of most important signalling proteins that exists in the ECM, 
interacts actively with other ECM macromolecules and also cells. Biological 
information, in the form of mechanical and biochemical signals, are transmitted 
between cells and FN through a number of receptors located on cell surfaces.  
Distinct FN domains bind, via active sequences, to different receptors such as 
integrins and syndecans.15 
 
The primary and most studied receptors that recognise FN protein are integrins. 
Integrins are a family of large transmembrane receptors, present on cell surfaces, 
which connect cells with ECM and transmit signals inside and outside the cells. 
Integrins are heterodimers, composed of 18 types of α and 8 types of β subunits that 
are variably paired. To date, 24 αβ heterodimers have been identified in mammals.32 
Each αβ combination has its own binding specificity and signalling properties 
(Scheme 1).33 The integrins mediate adhesion to many matrix protein (e.g. collagen, 
laminin), as well as between neighbouring cells through surface counterreceptors. 
Equally important as their adhesive function is their previously mentioned signalling 
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ability: integrins transduce information that control fundamental cell processes such 
as growth, proliferation and survival.34 
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Laminin receptors  
Scheme 1. The integrin family; solid lines indicate αβ pairings that have been identified to 
date on mammalian cells. 
 
 
The adhesive ability of integrins plays a key role in cells’ organization into tissues 
and organs. This process requires not only association between cells themselves but 
also connections between cells and ECM. One of the processes that contribute to the 
establishment of tissues composition, architecture and functions is fibrillogenesis. 
The initiation of fibrillogenesis requires binding of FN molecules to cell surfaces, 
what is mediated by α5β1 integrins. The FN’s motif, necessary for intergrin 
recognition, is a tripeptide Arg-Gly-Asp (RGD), located on the loop in FNIII10 
module (Figure 7).16 The recognition of this short sequence is complex and depends 
on flanking residues, its three-dimensional presentation and individual features of the 
integrin-binding pockets. For example, during the binding event, integrins recognise 
also another active motif, Pro-His-Ser-Arg-Asn (PHSRN), called synergy sequence, 
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located in the adjacent FNIII9 module.35 The synergy site promotes α5β1 integrin 
binding to FN via interactions with the α5 subunit (Figure 7). The importance of the 
PHSRN motif in integrin-mediated cell adhesion was recently evaluated. It was 
shown that mutations in the synergy site, as well as mechanical stretching of FNIII9–
10 fragment, could reduce FN binding to integrins α5β1 by up to 90%.16,35 
 
 
FNIII9 FNIII10
PHSRN RGD
extracellular space
intracellular space
cell membrane
type I modules
type IIImodules
type II modules
EDA, EBA, V region
fibronectin
integrin
 
Figure 7. Model representation of fibronectin bound to integrin via RGD motif. 
 
 
Interestingly, the RGD sequence is not specific to FN; this active motif has been 
found in other ECM proteins, such as tenascin, fibrinogen, trombospondin and 
vitronectin.30 Moreover, recent research has questioned the importance of RGD motif 
in fibril formation. According to new findings, replacement of active RGD motif 
with the inactive RGE (Arg-Gly-Glu) didn’t compromise assembly of FN molecules 
into normal, fibrillar matrix.36  
 
Nevertheless, the α5β1 receptor remains the most important integrin that promotes 
cell binding to FN molecules. However, other integrins are also capable of RGD 
sequence recognition. These are: all members of αv subfamily, α5β1, α8β1 and the 
platelet-specific αIIbβ3 integrins (see Scheme 1).37 Moreover, integrin-mediated cell 
binding of FN molecules was shown to be promoted by additional active sites 
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recently discovered in the FN sequence, such as Gly-Asn-Gly-Arg-Gly (GNGRG) 
loop in FNI5 module.36 
 
The signalling functions of integrins are a broad and not fully understood subject. 
Through linking ECM proteins, such as FN, with cells’ cytoskeleton, integrins 
assemble large signalling complexes and activate multiple signalling pathways.38 The 
ability of integrins to form aggregates of active molecules on both sites of cellular 
membrane is critical in initiating a variety of biochemical processes. Integrin-
mediated cell-ECM interactions regulate cell migration, proliferation, spreading and 
survival.38    
 
 
1.1.4 Alternative splicing of the fibronectin gene 
 
 
Fibronectin is one of many proteins that undergo the genetic process called 
alternative splicing. Alternative splicing in higher eukaryotes is a common method to 
generate diversity of proteins from a single gene. The complexity of human organism 
cannot be a result of the number of genes, since the human genome is surprisingly 
small, having 20,000 to 25,000 protein-coding genes, which is less that the smallest 
genome in the plant world.39 Hence, additional processes have to take place in order 
to generate the 500,000 proteins present in the human body. One of these processes 
is alternative splicing of pre-mRNA. During alternative splicing, a pre-mRNA 
molecule can be spliced at different junctions to produce a variety of mature mRNA 
molecules, each containing different combinations of exons. As a result, various 
mRNAs can direct the synthesis of structurally and functionally different proteins, 
despite being coded by a single gene.40 
 
The FN gene was one of the first to be reported to undergo alternative splicing.41,42  
In humans, alternative splicing of FN depends on cell type, developmental stage and 
age, and can result in as many as 20 different FN proteins (isoforms) with molecular 
masses in the region of full-length FN. Some of these FN isoforms are preferentially 
expressed by tumour cells and are believed to contribute to cancer pathogenesis.43  
In human fibronectin, there are three major sites of alternative splicing; two within 
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the type III modules and one in a V region. The post-translational variations in V 
region are the most complex. In the human body, the V region can be spliced in 
several places, producing 5 different V structural variants. In most species this region 
can be either partially or completely included or excluded; for example, in plasma 
fibronectin the V region is fully incorporated into one chain but entirely absent from 
the other.10 Importantly, since the V region has two integrin binding sites (Leu-Asp-
Val (LDV) and Arg-Glu-Asp-Val (REDV) that are recognised by α4β1 and α4β7 
integrins, its presence or absence has unquestionable affect on adhesion of some 
types of cells (e.g. endothelial cells,44 lymphocytes45). 
 
The alternative splicing that occurs within the central type III modules (FN III7 to FN 
III15) defines the unique amino acid sequences of pFN and cFN. Two extra domains 
of type III, termed A (EDA) and B (EDB), could be included or excluded from the 
FN mRNA. As a consequence, matured cellular FN protein contains EDA and EDB 
in various combinations and variable proportions,9 whereas these both domains are 
totally absent from pFN molecule.46  
 
The biological functions of EDA and EDB are currently under investigation; so far 
increased inclusion of both exons in FN mRNA has been shown during embryonic 
development. However, once development is complete, the EDA and EDB gradually 
“disappear” from FNs in wide range of tissues, and are almost absent from adult 
tissues.47 Those findings indicate that EDA and EDB are necessary for proper 
development. However, experiments have also shown that mice that constitutively 
include or exclude EDA developed normally, despite the fact that some biological 
functions were impaired.46 In contrast, simultaneous ablation of both EDA and EDB 
exons in the FN gene leads to embryonic lethality of mice, caused by multiple 
cardiovascular defects.48 Moreover, in vivo studies on transgenic mice with targeted 
mutation in the FN gene have confirmed that the presence of at least one of the extra 
domain EDA/EDB is critical for normal heart and blood vessel development.10 
 
The exact roles of the EDA and EDB domains in development are not yet fully 
understood. However, knowledge of the EDA and EDB functions in pathological 
processes is better established. It is known that splicing patterns that again includes 
the EDA and/or EDB domain into the FN sequence is temporally re-established in 
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adult tissues under certain circumstances, such as tissue repair, tissue fibrosis and 
angiogenesis. Studies conducted have shown that in mature tissues EDA is locally 
expressed as a response to pathologies such as rheumatoid arthritis,49 wound healing 
(along with EDB),50 and pulmonary fibrosis.51  
 
In recent years, attention has been directed to FN isoforms containing the EDB 
domain. The EDB-FN is expressed in tissues undergoing angiogenesis and 
remodelling, and is also totally absent from normal vessels and organs in adults (with 
exception of the female reproductive system where angiogenesis is a physiological 
process).7 Due to this selective expression, the EDB domain is an excellent marker of 
angiogenesis. Rapid angiogenesis is a characteristic feature of aggressive tumours, 
which requires new blood vessels for growth beyond certain size and spread. The 
tumour-associated markers known to date are often lacking the important feature: to 
be selectively expressed in cancerous cells. For instance, markers like integrins α5β3 
and α5β5 are also wildly expressed in normal tissues.52 As a result, drugs and 
therapies cannot selectively target abnormal cells. The discussed EDB domain that is 
expressed selectively in tissues undergoing remodelling is therefore a very promising 
angiogenesis marker and possible target for therapy of malignant diseases.53 
 
 
1.2 Migration Stimulating Factor (MSF) 
 
 
The family of FN proteins remains of great importance for studying and 
understanding cellular processes. Recently, novel information about structures and 
functions of alternatively spliced isoforms of FN has been documented.54 
Furthermore, studies conducted by Prof. Schor and Dr Schor allowed identification 
of a new protein that turned out to be also a member of FN family.55 The novel 
protein was termed Migration Stimulating Factor (MSF) because of the first 
biological activity ascribed to it: stimulation of cells movement. 
 
Since its discovery, the MSF protein has been intensively studied. The molecule was 
shown to differ in structure and biological activities from FN itself and all other 
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known FN isoforms. The unique MSF’s bioactivities include stimulation of cell 
migration, promotion of angiogenesis and hyaluronan synthesis, that is, processes 
that are primary in cancer and wound healing. It is believed that further studies on 
MSF will give significant insight into our understanding of these lesions.2  
 
Migration Stimulating Factor is a product of the FN’s gene, generated by alternative 
splicing of mRNA. Unlike FN, MSF is not a part of extracellular matrix, but a 
soluble protein, excreted by cells. Elucidation of MSF’s structure revealed that the 
protein is a truncated isoform of FN, with a molecular mass of only 70 kDa. Primary 
sequence analysis of MSF showed its high homology with FN: MSF is identical to 
the N-terminus of FN, composed mainly by type I modules with included Fib-1/Hep-
1 and gelatin-binding (GBD) domains (Figure 8). Moreover, the MSF protein differs 
from all other FN isoforms not only in size, but also by unique 10 amino acid 
sequence on the carboxyl terminus.56 
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Figure 8. Comparison of the domain structure of fibronectin and MSF protein.  
 
 
MSF was first indentified as a soluble protein excreted by foetal fibroblasts.57 Further 
work showed that MSF is almost not detectable in healthy adults skin fibroblasts, but 
is re-expressed in cells that undergo remodelling, for instance during malignant 
diseases. Schor and co-workers analysed the serum from breast cancer patients to 
reveal significant concentration of MSF in more then 90% of the group, in 
comparison to only 10% of healthy individuals.58 Further immunohistochemical 
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studies extended the range of cells, which express MSF, from tumour-associated 
fibroblasts to carcinoma cells, and tumour-associated vascular endothelial cells.2 
 
It has long been known, that cancerous “onkofetal” cells resemble foetal cells in 
terms of phenotype, and through the excretion of several biologically active 
molecules. The foetal and cancerous cells also have the ability to undergo directed 
and elevated migration.55 Cell migration is a fundamental process that starts in the 
embryo, and contributes to tissues organization, organogenesis and homeostasis. It is 
also an essential component of tissue repair, angiogenesis and tumour invasion. The 
complexity of this process is reflected by the number of molecules that have been 
shown to affect motility and positioning of mammalian cells.59 In a healthy human 
body, cell migration is induced periodically, as a response to situations such as tissue 
injury, and can be turned off and on by the highly specialised “machinery”, that 
engages actin cytoskeleton.60 However, during malignant diseases, the control over 
cell motility is lost, and escalated cell migration causes spread of cancer to distant 
organs and body parts. 
 
Initial work linked the expression of MSF protein with the enhanced motility of cells 
such as foetal and cancerous fibroblasts. This hypothesis was first tested in vitro 
using three-dimensional gels of native type I collagen. It was observed that foetal and 
oncofetal cells migrated into the matrix to much greater extent then normal adult 
cells.55 Furthermore, experiments showed that when non-producing normal adult 
fibroblast were confluent with exogenous MSF, they also exhibited enhanced 
motility. Thus, although adult cells do not produce MSF, they clearly respond to it.61 
The motogenic activity of MSF is however, also highly dependent on external factors 
and conditions, such as cell density, presence of other molecules and type of matrix. 
For example, the MSF displayed motogenic activity on fibroblasts that were attached 
to physiologically relevant matrix, in this case native type I collagen. Conversely, the 
protein did not show the expected bioactivity when tests were performed on 
denatured collagen.62  
 
All of the currently obtained information prompted the hypothesis about the direct 
involvement of MSF in cancer development. The vast majority of data collected 
strongly suggested that MSF plays an important role in both the initiation and 
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progression of cancer. This protein was shown to be expressed not only by cells of 
breast cancer patients but also in other common human cancers, such as lung, 
colorectal, oral and prostate.2 Furthermore, MSF is believed to contribute to tumour 
pathogenesis by a number of mechanisms, which include stimulation of tumour cell 
motility, hyaluronan synthesis and angiogenesis. It is speculated, that peptidic or 
non-peptidic MSF antagonist could prevent tumour invasion and angiogenesis by 
inhibition of MSF activity.  
 
The presented findings on the role of MSF in tumour pathology are equally important 
in the area of wound healing research. Histological analyses performed in mid-1980s, 
showed great similarities between a tumour microenvironment and that of a healing 
wound.  These two processes induce very similar emergence response, that engage 
rapid cell proliferation, remodelling of tissues and the ECM, cell migration and blood 
vessels formation (angiogenesis).63 Thus, cell migration and angiogenesis have been 
long a primary targets in understanding and fighting cancer, but also in the area of 
would healing research. 
 
As presented before, the MSF protein is persistently over-expressed in a number of 
common human cancers but it was also found to be transiently expressed during 
human acute wound healing. In both lesions MSF is targeting the same processes: 
cell motility and angiogenesis. However, while enhanced cell motility and rapid 
angiogenesis promote cancer by supporting tumour spread and growth, these 
processes are restorative during wound repair.5 
 
Wound healing is a complex process of restoring cellular structure and tissue layers. 
It involves activation of keratinocytes, fibroblasts, endothelial cells, macrophages, 
platelets, as well as wide range of signalling molecules such as cytokines and 
chemokines.64 The process, however, could be, under certain circumstances, 
interrupted and impaired, which might lead to the formation of a chronic wound that 
does not heal.  There are several factors and diseases that contribute to the 
development of non-healing wounds; one of the major ones is diabetes. People with 
diabetes are in a constant danger of developing chronic wound that could result in 
amputation. Research and analysis have allowed the identification of pathogenic 
markers and phenotypic changes on the tissue level that correlate with delayed 
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wound healing. For instance, keratinocytes from the non-healing edge of diabetic 
foot ulcers (DFU) had shown an absence of migration and incomplete differentiation, 
whereas fibroblasts demonstrated decreased migration and proliferation.64 
Insufficient cell motility is therefore one of the most important factors that contribute 
to development of chronic non-healing wounds.  
 
Initial work on MSF showed its involvement in the normal wound repair process. 
MSF was demonstrated to be produced during human acute wound healing by 
keratinocytes.65 These findings combined with the ability of exogenous MSF to 
stimulate adult cell migration rendered it a candidate for therapeutic applications. It 
is believed, that topical application of MSF’s agonists could speed-up cell movement 
and tissue repair in difficult, diabetic wounds.  
 
Moreover, it is hypothesised, that pro-angiogenic properties of MSF could also 
contribute to wound healing by stimulating the growth of new capillary vessels. 
Successful wound closure depends on angiogenesis, because proliferating capillaries 
bring oxygen and micronutrients to growing tissues and remove catabolic waste 
products. Thus, MSF agonists could act in the wound site as both potent motogenic 
and angiogenic factor.66 
 
 
1.2.1 The IGD motif of MSF 
 
 
MSF mediates a unique range of bioactivities that are not expressed by any other 
member of FN family (i.e. stimulation of cell migration, hyaluronan synthesis and 
angiogenesis). However, some of MSF-like activities were ascribed previously to 
gelatine-binding domain (GBD) of FN. The free GBD fragment was shown to 
stimulate fibroblasts migration into three-dimensional matrixes of native collagen 
type I.67 Under the same conditions, the full-length FN and other FN’s proteolytic 
fragments were devoid of this activity. 
 
The motogenic activity of GBD was believed to be mediated by a novel, active 
sequence, since the GBD fragment does not contain any already known functional 
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motifs of FN, such as RGD, LDV or REDV (Figure 9). Thus, thought a series of 
experiments the new amino acid sequence, isoleucine-glycine-aspartate (IGD), 
located within GDB was identified as a potential active motif responsible for GBD 
bioactivity.68 The IGD tripeptide is highly conserved and repeated within type I 
modules of FN and GDB. Subsequent work showed that synthetic tri- and 
tetrapeptides containing IGD motif stimulated migration of human dermal 
fibroblasts.68 Based on these experiments the motogenic activity of GBD fragment 
was assigned to its IGD sequence. 
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Figure 9. The modular structure of FN and MSF; known binding sequences (PHSRN, RGD, 
LDV, REDV) and novel IGD active motif are highlighted. 
 
 
The motogenic activity of MSF has also been attributed to the IGD tri-amino acid 
motif. The MSF protein is essentially constructed of two FN’s proteolytic fragments: 
Fib-1/Hep-1 and GBD (Figure 9). Each of these functional domains contain two IGD 
motifs located, respectively, in the third and fifth (Fib-1/Hep-1), seventh and ninth 
(GBD) type I modules of FN (Figure 9). However, only IGD sequences present 
within GBD of MSF appears to be active and available for relevant cell receptor. 
This was observed when a mutation of IGD to DGI in repeats seventh and ninth 
completely abolished MSF’s bioactivity.2 Consistently, proteolytically derived FNI1-5 
fragment was inactive. Thus, motogenic activity of MSF has been assigned only to 
IGD sequences presented within these two type I modules of FN (FNI7 and FNI9) 
(Figures 9 and 10).  
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Figure 10. Schematic representation of IGD motif within the 9th type I module of FN, with 
neighbouring FNI8.  
 
Reprinted from Current Opinion in Cell Biology, 20, M. Leiss, K. Beckmanna, A. Girósa, M. 
Costella, R. Fässler, The role of integrin binding sites in fibronectin matrix assembly in vivo, p. 502-
507, Copyright 2008, with permission from Elsevier 
 
 
All three discussed proteins, MSF, GBD and full-length FN, contain number of IGD 
sequences. However, full-length FN is devoid of activity attributed to IGD. 
Preliminary results allow the speculation that the tertiary structures of these 
molecules play here a major role.68 For instance, IGD-mediated bioactivity might be 
cryptic in native FN because of steric hindrance around the IGD amino acid 
sequences. However, the proteolytic digestion produces shorter GBD peptide with a 
different three-dimensional structure and possibly different conformational stability. 
As a result, IGD sequences of GBD are exposed through conformational change, 
hence no longer cryptic and fully available for interaction with cellular receptors. 
Similar reasoning applies to MSF. Potent motogenic activity mediated by MSF 
suggests that some IGD motifs had been exposed within this protein as a result of its 
native conformation.69 
 
Recently, Campbell and co-workers studied two active IGD motifs of MSF, present 
in the seventh and ninth FNI (FNI7, FNI9).69 For the purpose of the experiments they 
cloned a series of human FN fragments, each containing at least one IGD motif: 
FNI7-FNI8, FNI8-FNI9, and FNI7-FNI8-FNI9. A series of mutations within the active 
sequence, together with NMR studies and migration test assays, lead to several 
conclusions. Firstly, isoleucine is critical for the observed bioactivity of IGD motif, 
and secondly, any constrained protein with an IGD motif was more potent than short, 
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linear amino acid sequences carrying the IGD unit.69 Thus, it seems that 
conformational constraints imposed on the IGD geometry may affect its interactions 
with its receptor. 
 
 
1.2.2 First generation IGD peptidomimetics 
 
 
The motogenic activity of MSF has rendered the protein a promising new drug 
candidate, and prompted work towards development of a synthetic, non-peptidic 
compound that could mimic its bioactivity. The early experiments showed that tri- 
and tetrapeptides that contain MSF active motif, the IGD sequence, exhibit 
significant motogenic activity.68 Two of the tested synthetic peptides, Ile-Gly-Asp-
Ser (IGDS) and Ile-Gly-Asp-Gln (IGDQ), were found to stimulate cell migration into 
a three-dimensional collagen gel at a concentration of 0.1μM.  
 
However, the use of peptides as drugs tends to be associated with few problems.  
Synthetic peptides are usually poorly absorbed in the gastrointestinal tract and 
rapidly broken down by enzymes what results in their low bioavailability.70 
Therefore, efforts have been made to create non-peptidic molecular fragments that 
could “replace” active parts of native peptides and proteins in their biological 
functions. These compounds, termed “peptidomimetics”, have the advantage of 
being small, stable against human enzymes and able to cross biological membranes. 
However, they also carry higher risks of toxicity and potential of accumulation in the 
body. Despite these disadvantages, it is believed that peptidomimetic can display 
more favourable pharmacological properties than their prototypic peptides/proteins, 
such as improved receptor selectivity and potency.70 
The first generation of IGD peptidomimetics was design with respect to steric and 
electronic properties of the native IGD motif, identified as a minimal sequence 
required for biological activity of MSF.71 Firstly, the spatial arrangement of IGD 
tripeptide within FNI modules was analysed. The solution structures of several FNI 
modules of FN, including FNI5 and FNI7, have been previously calculated by high-
resolution NMR.72,73 These studies revealed that IGD tripeptide is present within the 
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modules as a tightly constrained loop (Figure 11). The fact that the IGD motif is 
highly structured and has limited conformational mobility, strengthens the hypothesis 
that this motif is responsible for the binding and activation of the natural, and yet 
unidentified, MSF receptor. 
 
 
Figure 11. Three-dimensional structure of the FNI7 module with highlighted IGD tripeptide 
motif. 
 
Molecular BioSystems, 1, N. Shpiro, I. R. Ellis, T. J. Dines, A. M. Schor, S. L. Schor, D. G. Normand, 
R. Marquez, Synthesis of an IGD peptidomimetic with motogenic activity, p. 318-320, Copyright 
2005, Reproduced by permission of The Royal Society of Chemistry 
 
 
Computational methods, such as modelling studies and GAUSSIAN calculations 
were then used to design the IGD peptidomimetics’ conformation to closely resemble 
the spatial arrangement of IGD tripeptide motif in native peptides (FN and MSF). 
Thus, the backbone dihedral angles observed in the native IGD sequences in FNI5 
and FNI7 were measured. Based on this information, a number of small molecular 
weight entities that could potentially mimic the geometrical features of the IGD 
motif were selected. These structures were than optimised and their energy 
minimised using GAUSSIAN ab initio level calculations (using the hybrid SCF (self-
consistent field) - DFT (density functional theory) method). 71  
 
Ultimately, it was determined that a benzodiazepine (BDP) unit (Figure 12, (B)) 
could exhibit structural similarity to the backbone conformation of native IGD 
tripeptide (Figure 12, (A)), while limiting the conformational mobility of the new 
molecule.71   
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Figure 12.  (A) Highlighted backbone bonds of the IGD tripeptide of MSF; (B) Highlighted 
bonds of the IGD peptidomimetic, which can mimic the IGD tripeptide conformation. 
 
Molecular BioSystems, 1, N. Shpiro, I. R. Ellis, T. J. Dines, A. M. Schor, S. L. Schor, D. G. Normand, 
R. Marquez, Synthesis of an IGD peptidomimetic with motogenic activity, p. 318-320, Copyright 
2005, Reproduced by permission of The Royal Society of Chemistry 
 
 
Secondly, the electronic properties of the natural IGD tripeptide were considered. 
The amino acid sidechain functionalities are very important in terms of structure and 
biological activity of native IGD. Hydrophobic and steric effects might govern the 
protein folding and contribute to spatial arrangement of IGD sequence. Moreover, 
ionic interactions between amino acid residues and relevant receptor are likely to be 
responsible for the bioactivity of IGD motif. Thus, it was proposed that substitution 
at the C-2 and C-9 positions of the BDP skeleton should mimic, respectively, the 
aspartic acid and isoleucine residue of the native IGD tripeptide. Ultimately, 
combined model studies allowed designing the structure of first generation IGD 
peptidomimetics 1 as shown in Figure 13.71 
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1 
Figure 13.  The IGD peptidomimetic with highlighted 1,4-benzodiazepine core (blue), 
substituted in positions C-2 and C-9. 
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1.2.3 First synthesis of the IGD peptidomimetic 
 
 
The first, model and racemic synthesis of IGD peptidomimetic ester 2, bearing a 
methyl group at the nitrogen atom, was reported in 2005 (Figure 14).71  
 
 
2 
Figure 14. The targeted IGD peptidomimetic ester 2. 
 
 
The synthesis of IGD mimetic 2 began with commercially available nitro-cresol 3, 
which was alkylated and then brominated under radical conditions to generate 
compound 4. Unfortunately, during the desired bromination of the benzylic methyl, 
the bromination of the alkyl side chain also took place, and led to significant amount 
of undesired compound 5. Moreover, the separation of 4 and 5 was not possible 
(Scheme 2). Despite extensive investigation, the best yield obtained for the 
bromination step was 43%.  
 
 
 3     4    5 
     
Scheme 2. Reagents and conditions: a) isobutyl bromide, K2CO3, DMF, rt, 25 h, b)  
N-bromosuccinimide, azobisisobutyronitrile, CCl4, reflux, 12 h, 43% over 2 steps. 
 
 
The synthesis was continued using the mixture of compounds 4 and 5. Nucleophilic 
substitution of the benzylic bromides 4 and 5 with methylamine produced 6 and 7 
respectively. Following protection of benzylic amines 6 and 7 with the tert-
butyloxycarbonyl (Boc) group provided 8 and 9. At this stage, Pd/C catalysed 
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hydrogenation reduced both the nitro functionality of 8 and 9 along with the tertiary 
bromide of 9 to produce cleanly the free amine unit 10 as a single compound 
(Scheme 3).  
 
  
 
Scheme 3. Reagents and conditions: a) CH3NH2 (40% in water), THF, 12 h, rt, b) (Boc)2O, 
Et3N, DMAP, CH2Cl2, 0 °C to rt, 84% over 2 steps, c) Pd/C (10%), H2, CH3OH, rt, 3 h, 75%. 
 
 
As anticipated, condensation of aniline 10 with dimethyl acetylenedicarboxylate 
(DMAD) furnished compound 11. The Pd-catalysed reduction of the double bond of 
11 produced intermediate 12. The next step, removal of Boc group, was 
accomplished by treatment of 12 with trifluoroacetic acid (TFA). The resulting free 
amine 13 was then exposed to basic conditions to furnish final compound - IGD 
peptidomimetic 2 (Scheme 4). 
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Scheme 4. Reagents and conditions: a) DMAD, CH3OH, reflux, 1 h, 85%, b) Pd/C (10%), 
H2, CH3OH, 30 min, 58%, c) TFA, DCM, 0 °C, 1 h, 96%, d) NaOCH3 (25% in CH3OH), 1 h, 
45−77%. 
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The anticipated motogenic activity of racemic IGD mimetic 2 was tested using a cell 
migration assay.71 This method measured the movement of human fibroblast into a 
three-dimensional collagen matrix. The IGD mimetic 2 was found to stimulate cell 
migration in a dose-dependent fashion, as shown in Figure 15. Importantly, the 
potency of mimetic 2 was comparable with that of previously synthesised tripeptide 
IGDS.68 The control reverse peptide Ser-Asp-Gly-Ile (SDGI) was devoid of 
biological activity under conditions of the assay.  
 
 
  
 
 
 
Figure 15. The motogenic activity of IGD mimetic 2 (here denoted as BDP1), synthetic 
peptide IGDS and control compound SDGI. Data are expressed as fold-stimulation of 
migration relative to control fibroblast in the absence of the test compound. The range of 
baseline migration is indicated by dotted lines.  
 
Molecular BioSystems, 1, N. Shpiro, I. R. Ellis, T. J. Dines, A. M. Schor, S. L. Schor, D. G. Normand, 
R. Marquez, Synthesis of an IGD peptidomimetic with motogenic activity, p. 318-320, Copyright 
2005, Reproduced by permission of The Royal Society of Chemistry 
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2.0 Results and discussion 
 
 
2.1 The aim of the project 
 
 
The ultimate objective of the IGD project was to synthesise the IGD peptidomimetic 
2 (Figure 16) and its derivatives that could mimic the biological activity of the MSF 
in terms of stimulation of cell migration. The MSF protein is known to modulate 
diverse biological processes, and hence provides opportunity to research several 
different human disorders. However, our project is primarily focusing on studying 
the motogenic activity of MSF. Through our research we are hoping to gain better 
knowledge about cell migration in wound healing processes. We are expecting that 
synthetic IGD mimetics could be a first step towards a new treatment of wounds with 
impaired healing.  We are planning to evaluate the anticipated agonistic activity of 
IGD peptidomimetics in series of biological tests.  
 
 
 
2 
Figure 16. The structure of the IGD peptidomimetic 2. 
 
 
The IGD mimetic ester 2 (Figure 16) was previously synthesised in the Marquez 
group.71 However, this prototypic synthesis suffered from several problematic and 
low-yielding steps. Therefore, the first objective of the project was to revise and 
optimise the existing synthetic route to mimetic 2. The new synthesis should be high-
yielding, and relatively simple because of the view for possible industrial application. 
After optimising the reaction conditions via a model, racemic synthesis, we planned 
to develop a stereospecific synthesis for both enantiomers of IGD peptidomimetic 2.  
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We are also planning to assess the biological activity of synthesised IGD mimetics. 
Preliminary results showed that IGD mimetic 2 can efficiently stimulate cell 
migration.68 Hence, it is speculated that enantiomers of 2 and its structural derivates 
can show increased potency or altered biological action.  
 
For the purpose of evaluating the biological profile of the IGD peptidomimetics, and 
also considering further applications, we proposed to synthesise a photolabile trigger, 
which can be coupled to derivatives of the IGD peptidomimetic 2. The photolabile 
group was chosen carefully, taking into consideration its chemical and biochemical 
properties. The photolabile protecting group should mask the bioactivity of the IGD 
mimetic, thus making it inert, until it reaches the target site. It should allow us to 
carry out kinetic and biological investigations that might lead to identification of the 
receptor for MSF.  
 
 
2.1.1 Model synthesis of the IGD peptidomimetic 
 
 
A revised strategy to the IGD peptidomimetic 2 is outlined in Scheme 5. Our new 
approach required several changes in the previously established synthesis. Thus, we 
anticipated that benzodiazepine 2 could be obtained from enamine 13 via a ring-
closing reaction. Requisite enamine 13 would in turn be prepared by condensation of 
aniline 10 and DMAD, followed by double-bond reduction and Boc-deprotection, 
accordingly to the previously established procedure.71 Finally, we envisioned that 
aniline 10 could be accessed from a new key intermediate, nitrobenzaldehyde 14. We 
anticipated to prepare the crucial aldehyde 14 in a few simple, high yielding steps 
from commercially available materials.  
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Scheme 5. Retrosynthetic analysis of IGD peptidomimetic 2. 
 
 
Our initial efforts focused on the synthesis of nitrobenzaldehyde 14. We investigated 
two distinct approaches to the aldehyde 14, utilizing either 3-hydroxybenzaldehyde 
15 or 3-chloro-2-nitrobenzoic acid 16 (Scheme 6). 
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Scheme 6. Two different starting materials for the preparation of intermediate 14. 
 
 
The first synthetic approach anticipated that nitrobenzaldehyde 14 could be quickly 
obtained from commercially available 3-hydroxybenzaldehyde 15. This two-step 
synthesis required alkylation of hydroxyl functionality and nitration of the aromatic 
ring (Scheme 7). Thus, we began the synthesis of compound 14 by alkylation of 15 
that lead successfully to aldehyde 17. Nitration of aromatic aldehyde 17 with 
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nitronium tetrafluoroborate generated the desired o-substituted aromatic aldehyde 14, 
together with nitration side products in good yield. After careful separation, however, 
the desired nitroaldehyde 14 was isolated in an acceptable 23% yield. Investigation 
of the reaction conditions allowed us to identify that the most suitable reaction 
temperature is −28 °C. Maintaining this temperature while extending reaction time to 
22 hours provided the desired isomer 14 in 53% yield. Unfortunately, despite our 
effort, we weren’t able to reproduce this yield on a larger scale (4 g), mainly due to 
troublesome separation (Scheme 7).   
 
 
 
Scheme 7. Reagents and Conditions: a) K2CO3, 1-bromo-3-methylbutane, DMF, 96%, b) 
NO2BF4, DCM, −28 °C, 22 h, 53%. 
 
 
While nitration with nitronium tetrafluoroborate gave moderate yields, application of 
other mild reagents failed to generate o-nitrobenzaldehyde 14. Treatment of 
compound 16 with reagent system Ph3P/Br2/AgNO3 afforded cleanly and almost 
exclusively one of the mono-nitrated regioisomers, but not the desired one.74 A 
splitting pattern that appeared on 1H NMR spectrum in the aromatic region, 
combined with two-dimentional NMR data (COSY, HSQC, HMBC), clearly 
suggested that we synthesised one of two nitro regio-isomers, 18 and 19 (Scheme 8). 
This result indicated a clear preference for an electrophilic substitution under applied 
conditions to proceed at the one of the less sterically hindered position on the 
aromatic ring. 
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Scheme 8. Reagents and Conditions: a) Ph3P/Br2/AgNO3, MeCN, rt, 98%. 
 
 
Suprisingly, nitration of 17 with ceric ammonium nitrate (CAN) generated only 
traces of nitrated compound, leaving the starting material almost untouched.75 (Table 
1).  
 
O O
NO2
OO
 
17                                                       14 
Entry Reaction conditions Yield of 14 (%) 
1 BH4NO2, MeCN, −23 °C, o/n 23 
2 BH4NO2, MeCN, −28 °C, 22 h 53 * 
3 Ph3P, Br2, AgNO3, MeCN, rt 0 
4 CAN, MeCN, rt untouched SM 
              * yield not reproducible during scale-up  
Table 1. Aromatic nitration of compound 17. 
 
 
Finally, we applied alternative conditions for the regioselective, ortho-directed 
nitration of aromatic phenols.76 Thus, we began the synthesis by treatment of free 
phenol 15 with a reagent system, comprising of tetrabutylammonium hydrogen 
sulphate (TBAHS), isopropyl nitrate (IPN) and sulphuric acid. While conducted in 
room temperature, the reaction delivered o-nitrobenzaldehyde 20 in 40% yield. 
Lowering the reaction temperature to −15 °C improved the yield to 56%. The 
advantage of this nitration method was easy purification of desired nitroaldehyde 20, 
which precipitated from diethyl ether, and could be isolated by filtration. Moreover, 
in contrast to the results obtained previously (with nitronium tetrafluoroborate as 
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nitrating agent), this procedure produced comparable yields during scale-up (10 g). 
The next step, alkylation of compound 20, was accomplished routinely with 1-
bromo-3-methylbutane in the presence of a mild base to give ether 14 in very good 
78% yield (Scheme 9).  
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15 20 14  
Scheme 9. Reagents and Conditions: a) TBAHS, IPN, H2SO4, DCM, −15 °C, 56%, b) 
(CH3)2CHCH2CH2Br, K2CO3, DMF, 78%. 
 
 
In parallel, we investigated the synthesis of 14 starting from commercially available 
3-chloro-2-nitrobenzoic acid 16. The plan assumed nucleophilic aromatic 
substitution of chlorine by alkoxide, which can be achieved with mixture of 3-
methylbutanol/NaH. The acid 21 could then be treated with borane-tetrahydrofuran 
complex to furnish alcohol 22, which in turn can be oxidised to the desired aldehyde 
14 under Swern conditions (Scheme 10). This sequence, if successful, would allow 
us to prepare compound 14 without the need for nitration of the aromatic ring. 
 
 
Cl
CO2H
O
CO2H
O
NO2
OH
NO2
NO2
O
NO2
O
16 21 22 14  
Scheme 10. Alternative route to intermediate 14. 
 
 
However, rather surprisingly, this synthetic approach resulted in the formation of an 
unexpected product, which was isolated and characterised. The 1H NMR analysis 
revealed that the new compound was an aromatic aldehyde substituted in the ring by 
3-methylbutoxy group. It was also deduced that aromatic ring carried a third 
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substituent; however, since the splitting pattern in the aromatic region of the 
spectrum differed from the one of previously synthesised aldehyde 14, the presence 
of nitro group in the molecule was in doubt. In order to rule out any influence of the 
sample concentration on the NMR spectrum, aldehyde 14 and unexpected product 
were combined in one sample which was then analysed by 1H NMR. The obtained 
spectrum revealed the presence of two different aldehyde signals.  The presence of 
two separate species was further confirmed by TLC analysis and a series of 1-D and 
2-D NMR experiments. Mass spectrum of the new product also failed to provide the 
required molecular ion peak (expected at m/z = 237.2), previously detected for the 
aldehyde 14. 
 
Interestingly, the mass spectrum of the ‘new’ aldehyde showed a characteristic 
fragmentation pattern, notably a chlorine isotopic signature. The molecular ion peak 
at 226 was accompanied by an additional molecular peak at 228, which strongly 
indicated the presence of a single chlorine atom in the molecule. The natural 
abundance of 35Cl (75%) and 37Cl (25%) was reflected in the observed 3:1 ratio of 
relative peak intensities. Further, analysis of other fragment ions revealed additional 
sets of peaks separated by two m/z units, confirming the presence of chlorine 
isotopes.  
 
Further structural evidence was obtained from IR analysis. The IR spectrum of the 
previously synthesised aldehyde 14 showed two strong absorption bands at 1535 
cm−1 and 1284 cm−1; a result of N-O asymmetric and N-O symmetric stretching 
respectively. Moreover, NO2 scissor vibrations gave rise to band of medium strength 
at 837 cm−1. On the contrary, spectrum of new aldehyde was lacking all infrared 
bands characteristic for the aromatic nitro group.77 
 
Based on all the collected experimental evidence we concluded that the newly 
obtained aldehyde was one of two possible structures, 23 and 24 (Figure 17).  For 
example, mass spectra analysis with an electron impact ionisation (EI) detected the 
molecular ion [M]+ at 226, which supports both structures 23 and 24. The accurate 
mass of the product was then further confirmed by HRMS (observed m/z 226.0762).  
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Figure 17. Two possible structures of new aldehyde. 
 
 
Based on the obtained analytical results, differentiation between regioisomeric 
aldehydes 23 and 24, and unambiguous identification of the product structure was 
not possible. However, we proposed a reaction mechanism that can rationalise the 
formation of aldehyde 23. We postulate that the nitro group was lost during 
nucleophilic aromatic substitution on acid 16, which was the first step of the 
alternative synthetic approach (see Scheme 10). We had hoped for this reaction to 
proceed according to the expected addition-elimination mechanism, whereby an 
alkoxide anion would attack the chlorine position ortho to the nitro group of the acid 
16 (Scheme 11). Electrons from the ring would then be delocalised on the strongly 
electron-withdrawing nitro group in the intermediate 25 (Scheme 11). 
Rearomatisation of the ring and expulsion of the chloride ion would generate desired 
aromatic nitro benzoic acid 21, which could be converted to the aldehyde 14 
according to the proposed alternative route.   
 
 
Scheme 11. Expected addition-elimination mechanism. 
 
 
However, as established, the product of the alternative synthetic approach was 
lacking the nitro group. Thus, in order to account for the loss of nitro functionality, 
we propose an alternative mechanism. We speculate that alkoxide anion could attack 
the nitro group position ortho to the carboxylic acid functionality of compound 16 
(Scheme 12). Delocalization of electrons from the ring onto electron-withdrawing 
 48
carboxylic acid group would form intermediate 26. Rearomatisation of the ring and 
elimination of nitrous acid would produce benzoic acid 27. Reduction of the acid 
function as proposed in the alternative approach could ultimately generate the 
aldehyde 23.  
 
 
Scheme 12. Speculative mechanism to explain formation of acid 27 and aldehyde 23. 
 
 
In the postulated mechanism the nitro group acts as a leaving group. This 
characteristic of nitro function has been reported previously; it was shown that nitro 
group in nucleophilic aromatic substitution may rival the leaving group capacity of 
e.g. chloride78 of fluoride79. Thus, it is not unusual for nitro group to undergo 
nucleophilic displacement.  
 
We also speculate that the presence of the carboxylic acid functionality ortho to the 
nitro group is the reason for the observed loss of nitro group during the nucleophilic 
aromatic substitution reaction. It was thought that by masking the electron-
withdrawing capacity of carboxylic acid group of 16 it would be possible to displace 
chlorine ion with alkoxide, retaining the nitro group. Hence, in order to investigate 
this theory, we were carried out additional experiments, in which the carboxylic acid 
16 was reduced to alcohol 28 and subsequently protected as the silyl ether 29 
(Scheme 13). Compound 29 was then exposed to mixture of 3-methylbutanol/NaH, 
but the reaction failed to generate even traces of desired nitrobenzaldehyde 30.  
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Scheme 13. Reagents and Conditions: a) BH3·THF, THF, 0 °C to rt, b) imidazole, TBSCl, 
DMF, rt, 84% over 2 steps, c) NaH, (CH3)2CHCH2CH2OH, DMF. 
 
 
Finally, supported by mechanistic consideration, we postulate that structure of 
alternative aldehyde is more likely to be represented by compound 23 than 24. There 
is no known mechanism that could account for the formation of regioisomeric 
aldehyde 24.  Hence, we believe that the alternative synthetic route which utilise acid 
16 as starting material, ultimately produced the benzaldehyde 23 as presented in 
Scheme 14. 
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Scheme 14. Reagents and Conditions: a) NaH, (CH3)2CHCH2CH2OH, DMF, b) BH3·THF, 
THF, 0 °C to rt,  93% over 2 steps, c) oxalyl chloride, DMSO, Et3N, 84%. 
 
 
At this stage of our investigations, the nitration of aromatic phenol 15 followed by 
alkoxy group introduction, proved to be the most successful, efficient and suitable 
sequence for the synthesis of nitrobenzaldehyde 14 (see Scheme 9). Thus, having 
established the method for preparation of intermediate 14, we turned our attention 
towards the next transformation, the reductive amination of the aldehyde group. We 
followed the work of Sato who reported a one-pot reductive amination with α-
picoline borane (pic-BH3).80 α-Picoline borane and other amine-borane complexes 
are classical reducing agents for a variety of functional groups, including aldehydes, 
ketones, esters and nitriles. More importantly, they are capable of reducing a nitro 
group only in the presence of metal complexes via transition metal catalysed 
hydrogenation.  Thus, under applied conditions, we expected the nitro functionality 
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of 14 to be unaffected. However, in our hands application of α-picoline borane as a 
reducing agent failed to generate amine 32 (Scheme 15).  
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Scheme 15. Reagents and Conditions: a) CH3NH2, pic-BH3, MeOH, rt. 
 
 
Since the one-pot transformation proved unsuccessful, a two-step reductive 
amination procedure was employed. Benzaldehyde 14 was reacted with aqueous 
methylamine in heptane to form an imine intermediate 33, which was then extracted 
from the biphasic mixture and immediately reduced to amine 32 with sodium 
borohydride.81 It has been reported previously, that sodium borohydride could be 
successfully used for the preparation of nitro-containing amines.82 Indeed, under 
these conditions, imine 33 was selectively reduced in the presence of the nitro 
group. The reaction was clean, rapid and produced an amine 32 in excellent yield 
(94% from aldehyde 14) (Scheme 16). Both compounds, 33 and 32, could be 
isolated and stored for several weeks at low temperature (−20 °C).  
 
 
Scheme 16. Reagents and Conditions: a) CH3NH2, heptane, rt, b) NaBH4, MeOH, rt, 94% 
from 14. 
 
 
To complete the synthesis of the racemic IGD peptidomimetic, we followed the 
procedure previously developed in the Marquez group. Thus, to reduce the nitro 
functionality efficiently, we protected amine 32 with a Boc group. Subsequent 
palladium catalysed hydrogenation of the nitro group of 34 gave expected aniline 10 
in excellent yield (100%). Condensation of 10 with dimethyl acetylenedicarboxylate 
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(DMAD) generated enamine 11 as a single compound, which was then successfully 
converted to 12 by catalytic hydrogenation. Treatment of the racemic compound 12 
with trifluoroacetic acid afforded the free amine 13 in good yield. After careful 
work-up, amine 13 was submitted to final ring closure reaction under basic 
conditions (Scheme 17). This transformation successfully accomplished the model 
synthesis of racemic IGD peptidomimetic 2.    
 
 
Scheme 17. Reagents and Conditions: a) (Boc)2O, Et3N, THF, 93%, b) Pd/C, H2, MeOH, 
quantitative, c) DMAD, MeOH, reflux, 80%, d) Pd(OH)2, H2, MeOH, 90%, e) TFA, DCM, 
82%, f) NaOMe, MeOH, reflux, 62%. 
 
 
2.1.2 Enantiospecific synthesis of (R)-IGD peptidomimetic  
 
 
Having developed an efficient, model synthesis of racemic IGD peptidomimetic 2, 
we focused our efforts on establishing an analogues route to enantiomerically pure 
(R)-IGD ester 2a. The IGD molecule has one asymmetric carbon atom in position 
two of benzodiazepine skeleton, enabling it to exist in two enantiomeric 
configurations (Figure 18). Previously performed modelling studies and GAUSSIAN 
calculations suggested that the (R) stereoisomer of IGD molecule would more closely 
resemble the geometrical features and spatial orientation of IGD tripeptide motif of 
MSF. Therefore we speculated that the (R)-IGD mimetic 2a might have higher 
binding affinity to natural receptor of MSF than the (S)-IGD 2b. Hence, the (R)-IGD 
mimetic would be potentially a more potent agonist of MSF than racemic IGD 
molecule or its (S) enantiomer. Moreover, the chirality of the IGD mimetic could 
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also have an effect on its toxicity as well as overall pharmacokinetic and 
pharmacodynamic profile.  
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Figure 18. Racemic IGD peptidomimetic ester 2 and its enantiomers. 
 
 
The previously established approach to the synthesis of racemic IGD mimetic 2 was 
now adapted towards the synthesis of (R)-IGD ester 2a. Therefore, we started the 
synthesis of ester 2a by preparation of common intermediate, aniline 10, utilising our 
optimised synthetic procedures. Nitration of 3-hydroxybenzaldehyde 15, followed by 
alkylation of intermediate 20, afforded aldehyde 14, which was transformed to amine 
32 via two-steps reductive amination (Scheme 18). After Boc-protection, the 
resulting compound 34 was submitted to catalytic hydrogenation to furnish aniline 
10.   
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Scheme 18. Reagents and Conditions: a) TBAHS, IPN, H2SO4, DCM, −15 °C, 56%, b)  
(CH3)2CHCH2CH2Br, K2CO3, DMF, rt, 77%, c) CH3NH2, heptane, rt, d) NaBH4, MeOH, rt, 
94% from 14, e) (Boc)2O, Et3N, THF, rt, 93%, f)  Pd/C, H2, MeOH, rt, quantitative. 
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At this point of the synthesis, we turned our attention towards introducing the desired 
chirality into the molecule. Although a number of approaches and methods were 
considered, we had found that SN2 displacement of enantiopure triflate 36 (Scheme 
19) with aniline 10 could provide us with both the required functional unit and the 
requisite stereochemistry.83 Thus, optically pure triflate 36 was prepared in one step 
from commercially available dimethyl (S)-(−) malate 35 in excellent yield (100%) 
(Scheme 19).  
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Scheme 19. Reagents and Conditions: a) (Tf)2O, 2,6-lutidine, DCM, −78 °C, 100%.   
 
 
As expected, the employed SN2 reaction of chiral agent 36 with aniline 10 proceeded 
with inversion of configuration and furnished compound 37 as single (R) enantiomer 
(Scheme 20).  
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Scheme 20. Reagents and Conditions: a) 2,6-lutidine, DCM, reflux, quantitative 
 
 
Having successfully introduced the desired stereocentre, we focused our effort on the 
final stages of the synthesis. Subsequent treatment of compound 37 with 
trifluoroacetic acid failed to remove the Boc protecting group as expected. This was 
surprising, since the same transformation under these conditions had been readily 
achieved during the synthesis of the racemic IGD ester 2. Thus, after investigation of 
other reagents for Boc-deprotection, the removal of Boc group was finally 
accomplished using 5% HCl in ethyl acetate to furnish amine 38 (Table 2).84 
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Table 2. Boc-deprotection of compound 37. 
 
 
During the course of investigation of reaction conditions for removal of Boc group, 
we had found that this transformation could produce directly an ester 2a. It was 
observed that Boc-deprotection of compound 37 with HCl/EtOAc, followed by 
purification of crude reaction mixture by FCC with MeOH/DCM as a solvent system, 
resulted in a formation of final ester 2a. Experimental evidence indicated that Boc-
deprotection reaction did not itself produce the ester 2a, but expected amine 38, as 
confirmed by TLC and NMR of the crude reaction mixture. Therefore, it is believed 
that basic elution conditions on a column catalysed the cyclization of amine 38 to 
benzodiazepine 2a. Consequently, in a next experiment, an amine 38 was isolated 
only upon aqueous work-up, analysed and judged clean by NMR and MS analysis. 
Next, crude amine 38 was treated with sodium methoxide, what furnished cleanly 
and in a very good yield (85%) the final (R)-IGD ester 2a (Scheme 21).  
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Scheme 21. Reagents and Conditions: a) 5% HCl in EtOAc, rt, quantitative, b) NaOMe, 
MeOH, reflux, 85%, c) 5% HCl in EtOAc, then FCC 5% MeOH/DCM, 43%. 
Entry Reaction conditions Yield (%) 
1 TFA (1 eq), DCM 0 
2 TFA (2 eq), DCM 0 
3 5% HCl in MeOH 40 
4 5% HCl in EtOAc 100 
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To verify the optical purity of the synthesised (R)-IGD mimetic ester 2a, analytical 
chiral HPLC analyses were performed. The racemic IGD ester 2 and (R)-IGD ester 
2a were fractioned on OD-H chiral column that had a stationary phase consisting of 
cellulose tris(3,5-dimethylphenylcarbamate). Firstly, the racemic mixture was 
successfully resolved and shown to contain equal amounts of (R) and (S) enantiomers 
(49.3% and 50.7%). Then, the enantiomeric purity of the (R)-IGD 2a was assessed, 
and was found to have satisfactory enantiomeric excess of 94.9% (Figure 19).  
 
 
 
A      B 
    
Figure 19. Chiral HPLC analysis; A) Racemic IGD ester, B) (R)-IGD ester. 
 
 
In conclusion, the (R)-IGD peptidomimetic ester 2a was synthesised in 9 steps and 
32.4% overall yield. In addition to the satisfactory yield, the established 
methodology allows scaling up the synthesis without losing the excellent yields for 
each conversion step. Moreover, purification by FCC is required only for 1 
intermediate and a final product. Thus, our synthetic protocol has great potential for 
possible industrial applications.  
 
 
2.1.3 Short synthesis of a photolabile group 
 
 
Photolabile protecting groups, also termed “caging” groups, have been known since 
the early 1960s.85 Such compounds differ from traditional protecting groups in being 
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removable by the use of light at various wavelengths, instead of chemical reagents. 
Many different classes of caging groups, like benzoin, cinnamoyl, coumaryl, 2-
nitrobenzyl or phenacyl, have found applications in synthetic chemistry86, biology 
and biotechnology87. Besides their application in organic synthesis as orthogonal 
protecting groups, they have been extensively used in biology for caging various 
biologically active molecules, such as antibodies,88 Ca2+ ions,89 nucleotides,90 
peptides,91 and mRNA.92  
 
Currently, photolabile protecting groups are one of the most powerful tools for 
studying physiological processes as well as the properties of bioactive molecules.  
Many different classes of small molecules, such as amino acids, steroids, ATP and 
neurotransmitters have been caged in order to gain a better understanding of their 
actions on a cellular level.93 Broadly, “caging” involves the coupling of a bioactive 
molecule with a photolabile protecting group, what creates an inert precursor, devoid 
of biological activity. Exposure to light then rapidly releases the active compound by 
cleaving off the caging group. Light-mediated activation of caged compound 
provides a high level of control over when and where a bioactive molecule is 
released. In addition, by controlling light exposure time, intensity, or the number of 
laser pulses, it is possible to regulate an amount of active compound that is generated 
per time unit.94  
 
Application of caged compounds to study processes in living tissues is therefore very 
favourable, because it avoids using additional chemical reagents, and gives greater 
spatial and temporal control. However, to be useful in biological experiments, 
photolabile protecting groups must satisfy certain criteria. Firstly, the phototrigger 
and the resulting precursor must be biologically inert, soluble and stable in water and 
at physiological pH. Secondly, photochemical release of the active molecule should 
proceed at wavelengths in the near UV region (350-360 nm) or, ideally, in visible 
region, to minimize cell damage. It is also important that photolysis is fast and 
resulting by-products are both non toxic and inactive.  
 
Among the photolabile protecting groups that have been commonly and successfully 
applied to the investigation of biological systems are ortho-substituted nitroaromatic 
compounds.95 The photochemical properties of these compounds 39 can be modified 
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by varying the nature of the substituents at the benzyl carbon (R1) and around 
aromatic ring (R2 and R3) (Figure 20, (A)). For example, one of the most popular 
photolabile groups, 6-nitroveratroyloxycarbonyl group (NVOC) 40, incorporates two 
methoxy functionalities (Figure 20, (B)), and shows a maximal absorbance and 
reactivity at wavelengths longer than 320 nm. This characteristic of NVOC allowed 
its application as a caging group for light-sensitive amino acids such as tryptophan or 
tyrosine.96 More recently, the photochemistry of nitroindolines, which represent 
another class of nitroaromatic compounds, have attracted considerable attention.97 
For example, 1-acyl-7-nitroindoline 41 (Figure 20, (C)) was found to be promising 
phototrigger for rapid release of carboxylic acids in aqueous solutions.  
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Figure 20. Examples of caging groups bearing nitro functionality. 
 
 
The unique photochemical properties of the compounds discussed result from the 
presence of the nitro functionality, which serves as an intrinsic chromophore. As a 
result, nitro aromatic photolabile groups absorb light directly and generate, during 
photolysis, products that are readily detectable by optical methods.98 Moreover, 
nitroaromatic compounds are chemically stable and compatible with many functional 
groups (e.g., phosphate, carboxylates, hydroxyl and amines), which have made them 
the most wildly used photoremovable protecting groups for application in organic 
synthesis, biochemistry and biology.  
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However, the extensive application of nitro compounds as caging groups has also 
brought attention to their weaknesses, such as toxicity and reactivity of by-products 
generated upon photolysis. Indeed, investigations of biological systems with nitro 
aromatic cages require tools and methods that allow to prevent or control these 
negative effects. For example, synthetic modifications can optimize reactivity and 
the light absorbing properties of photolabile groups and their by-products. Moreover, 
manipulations of the experimental solution, such as buffering or adding hydrophilic 
thiols, suppress reactivity of by-products towards proteins present on cell surfaces.  
 
The growing interest in application of photolabile groups in biology and 
biotechnology has prompted detail studies of the mechanism underlying their photo-
liability. Many photoreactions, which lead to the release of active molecule from 
“caged” precursor, were shown to be complex processes that proceed via a cascade 
of reactive intermediates. Moreover, the efficiency of the release of the active 
substrate from inert precursor may depends on solvent type, pH and, in some cases, 
on buffer concentration.99  
 
The mechanism of photolysis was studied for many different photoremovable groups 
and chromophores.100 Generally, the process of uncaging is an intramolecular 
reaction, initiated by the absorption of a photon by the caged precursor that leads to 
the cleavage of the chemical bond. The model example is a photoreaction of o-
nitrobenzyl derivatives 42, which proceeds according to the mechanism showed in 
Scheme 22. The release of biologically active compounds, such as alcohols, 
carboxylic acids or phosphates, from o-nitrobenzyl cages, starts with the excitation of 
the nitro group that generates a highly reactive diradical species 43. The species 43 
could undergo further transformations via many possible reaction pathways. 
However, theoretical and experimental studies showed that species 43 undergoes the 
Norrish type II reaction, which is an intramolecular abstraction of a γ-hydrogen by an 
excited nitro group.95 This transformation, driven by the greater strength of the O-H 
bond compared to C-H bond, is fast and produces a 1,4-diradical species 44. A series 
of computational and experimental studies performed in recent years suggested that 
the more correct representation for the product of H-atom transfer to be an aci-nitro 
form 45.98 The formation of this ground state, active aci-nitro intermediate 45 was 
monitored by its strong absorption around 400 nm.  The subsequent reactions leading 
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to the release of active molecule from caged precursor are not yet fully 
understood.101,102 However, it is accepted that next step involves the energetically 
favorable cyclization of the protonated form 45, which produces intermediate 46. 
The intermediate 46 rearranges to acetal 47, which spontaneously collapses to release 
biologically active carbonyl compound 48 and nitrosoaldehyde 49. 
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Scheme 22. Mechanism of photolysis of o-nitrobenzyl compound 42. 
 
 
In 2003, Hess reported the synthesis and characterisation of a new caging group that 
included the nitro functionality, the 2-(dimethylamino)-5-nitrophenyl group 50 
(DANP) (Figure 21).103 The DANP group 50 was design originally as a caging group 
for the carboxyl functionality, and was shown to have a major absorption band in the 
visible wavelength region with the maximum near 400 nm. 
 
 
 
Figure 21. The photolabile DANP group 50. 
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In the experiments performed by Hess,103 the DANP group was used for caging the 
biologically active β-alanine, which activates the inhibitory glycine receptor in the 
mammalian central nervous system. Laser-pulse photolysis of caged precursor 51 
showed that β-alanine 52 is released within 5 µs, with a quantum yield around 0.03 at 
308 and 350 nm (Scheme 23). The efficiency of uncaging was, however, lower in 
visible region (0.002 at 400 nm and above). Nevertheless, experiments demonstrated 
the desired biological inertness of DANP-caged β-alanine and the DANP group 50 
towards the glycine receptors on cell surfaces. Furthermore, caged precursor 51 was 
water soluble and stable under physiological conditions (pH=7.4). These results of 
both the biological and photochemical investigations compared favourably with 
those obtained for other photolabile groups used for caging the biologically active 
carboxylic acids. Phenacyl caging groups,104 nitroveratrole,105 and substituted 
coumarins106 were shown to suffer from poor solubility in aqueous medium and often 
a slow rate of release (minutes) of the bioactive compounds in the visible region.    
 
 
 
Scheme 23. Photolysis of the DANP-caged β-alanine 51. 
 
 
These promising biological and photochemical properties for the DANP group 50 
prompted us to choose this compound as a photolabile protecting group that would 
be coupled to the derivatives of the IGD peptidomimetic 2a. We hoped that the 
caging of the IGD mimetics with DANP group would allow us to carry out biological 
and kinetic investigations of the IGD molecules and could potentially help identify 
the natural receptor of MSF protein. In the long term, we also considered the possible 
application of caged IGD mimetics in treatment of wounds with impaired healing. 
Thus, DANP-caged IGD compounds might be applied topically to a wound in the 
temporally inactive form. The molecules could be then excited with visible 
wavelengths, releasing biologically active IGD mimetics. In principle this method 
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should allow application of active IGD mimetic in spatially very restricted manner. It 
might also provide better control over concentration of active molecules at the site of 
action. Additionally, use of visible light for photocleavage of DANP group might 
assure minimal damage to the cells.  
 
The synthetic route to the DANP group 50, reported by Hess,103 started from 
commercially available 2-aminophenol 53 (Scheme 24). Compound 53 was 
methylated with dimethyl sulfate to produce intermediate 54. The acylation of 
phenolic hydroxyl group of 54 and nitration with nitric acid produced compound 55. 
Resulting nitrobenzene 55 was then treated with sodium hydroxide to generate the 
DANP group 50 in overall yield of 23% (from 53). The exact reaction conditions and 
yield for each step were not reported in the paper.103  
 
 
 
Scheme 24. Reagents: a) (CH3)2SO4, b) Ac2O, c) HNO3, HOAc, d) NaOH, 23% from 53. 
 
 
Hence, in our synthesis of the DANP group 50, we followed the general method 
reported by Hess; however we needed to determine suitable reaction conditions. The 
synthesis began with 2-aminophenol 53, and required, as a first step, the 
dimethylation of amine functionality. We examined various conditions for this 
transformation. Initially, we attempted the alkylation of 53 with methyl iodide, in the 
presence of different bases. Under these conditions the monomethylated amine 56 
was generated in good yields, however, only traces of desired dimethylated 
compound 54 were obtained (Table 3, entries 1-4). Treatment of aromatic amine 53 
with formaldehyde, formic acid and LiAlH4, seemed to be successful by TLC 
analysis, but only traces of compound 54 were isolated. We speculated that product 
54 was bound by aluminium derivatives, and the resulting complexes were lost on 
celite during reaction work-up. Eventually, methylation of 53 with sodium 
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borohydride and formaldehyde produced cleanly and in excellent yield the requisite 
N,N-dimethylated aniline 54 (Table 3, entry 6). 
 
 
 
 
 
Entry Reaction conditions Product 56 Product 54 
1 CH3I (1.2 eq), KHCO3 (1.1 eq), DMF 75% 0 
2 CH3I (2.2 eq), KHCO3 (3 eq), DMF 50% <10% 
3 CH3I (1.2 eq), Cs2CO3 (2 eq), DMF 90% 0 
4 CH3I (2.2 eq), Cs2CO3 (4 eq), DMF 92% 0 
5 
i. Ac2O, HCO2H, LiAlH4  
ii. Ac2O, HCO2H, LiAlH4  
 
0 8.5% 
6 
i. NaBH4 (3 eq), HCHO (2.5 eq), MeOH 
ii. NaBH4 (1.8 eq), HCHO (1.5 eq), MeOH 
30% 
 
70% 
100%  
Table 3. Dimethylation of 2-aminophenol 53. 
 
 
Having established the conditions for methylation, we continued the synthesis of 
DANP 50. The ring-activating, phenolic hydroxyl group of 54 was protected as 
acetate 57, which proved to be volatile (Scheme 25).  
 
 
N
OH
N
O
O
a
54 57  
Scheme 25. Reagents and Conditions: a) Ac2O, pyridine, DMAP, DCM, 75%. 
 
 
Next, we explored a number of reagents and conditions for a selective nitration of the 
aromatic ring. Firstly, we treated compound 57 with nitronium tetrafluoroborate. 
This transformation afforded exclusively the dinitro-substituted isomer, which 
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regiochemistry was not further investigated. Also another previously utilized 
nitrating reagent system, TBAHS/IPN, failed to deliver desired regioisomer 55 
(Table 4).76  
 
O2N O
N
O
N
O
O
57 55  
Entry Reaction conditions Yield (% of 55) 
1 BH4NO2, MeCN, rt 0 
2 TBAHS, IPN, H2SO4, DCM, 0 °C-rt 0 
3 CAN, MeCN, rt 30 
4 Ph3P, Br2, AgNO3, MeCN, rt 40 
Table 4. Nitration of acetate 57. 
 
 
The nitration of 57 with cerium (IV) ammonium nitrate (CAN) in acetonitrile 
provided desired compound 55 in moderate 30% yield along with di-nitro isomers as 
major byproducts.75 In an attempt to improve the yield of the nitration step, an 
alternative reagent system, Ph3P/Br2/AgNO3, was employed. Under these conditions 
mono-nitrated amine 55 was generated in a slightly higher, 40% yield.74 However, 
this method was found to be the most efficient for nitration step, as it requires only a 
very short reaction time (10 to 25 minutes) and allows relatively easy isolation of 
regioisomer 55 by flash column chromatography (FCC) (Scheme 26, Table 4). 
Purified nitroacetate 55 was then deprotected using sodium methoxide to furnish 
DANP group 45 in moderate yield (48%). However, the yield for deprotection step 
was greatly improved upon treatment of 55 with ammonium acetate (Scheme 26). 
These alternative, mild reaction conditions provided the final DANP molecule 50 in 
excellent 93% yield.107  
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Scheme 26. Reagents and Conditions: a) NaBH4, HCOH, MeOH, 77%, b) Ac2O, pyridine, 
DMAP, DCM, 75%, c) Ph3P/Br2/AgNO3, 40%, d) NH4OAc, MeOH/H2O, 93%.  
 
 
2.1.4 Coupling of the IGD mimetic with the DANP group 
 
 
Since the synthesised DANP group had been design as a caging group for carboxylic 
acid functionality, we needed to convert IGD ester 2a to its respective acid.  
 
For this purpose of this transformation the (R)-IGD ester 2a was added to suspension 
of potassium trimethylsilanolate in diethyl ether.108 The reaction produced anhydrous 
acid salt 58, which was then treated in situ with diluted hydrochloric acid to give free 
carboxylic acid 59 in excellent 97% yield (Scheme 27). 
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Scheme 27. Reagents and Conditions: a) KOSiMe3, Et2O, 0 °C, b) 1N HCl, 0 °C, 97% from 
2a 
 
 
Having successfully synthesised both the (R)-IGD acid 59 and DANP caging group 
50, we turned our attention to the remaining coupling between these two molecules. 
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The coupling was based on simple esterification, thus we initially applied standard 
and mild Steglich conditions. This transformation, promoted by DCC 
(dicyclohexylcarbodiimide), was successful according to the 1H NMR, however 
following purification of the crude reaction mixture by flash column chromatography 
failed to separate the DCC derivatives from product 60 (Scheme 28). Therefore, we 
decided to change the coupling reagent to EDC (1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide), which is a water soluble carbodiimide. These esterification conditions 
cleanly afforded ester 60 (Scheme 28).109  
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Scheme 28. Reagents and Conditions: a) EDC, DMAP, DCM, 0 °C to rt, 80% 
 
 
The synthesised ester 60 is a novel compound that requires series of tests to elucidate 
its photochemical, chemical and biological properties and potential application as a 
caged molecule. Among the strict requirements that compound 60 would have to 
meet to become a likely candidate for investigation of biological systems are: its 
solubility in aqueous media, inertness of precursor and efficiency of photorelease of 
(R)-IGD mimetic 59. If successful, ester 60 could then be used in biological 
investigations on a cellular level.  
 
For the purpose of studying the chemical and biological qualities of ester 60, we also 
synthesised a control compound 61. This molecule was created by coupling of (R)-
IGD mimetic acid 59 with 2-dimethylamino-phenol 54, which is an intermediate in 
the synthesis of DANP group 50 (Scheme 29). The phenol 54 is lacking a nitro 
group, which is responsible for photolabile properties of DANP molecule. For this 
reason, it is expected that photo-stimulation of ester 61 would not result in release of 
(R)-IGD molecule 59.  
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Scheme 29. Reagents and Conditions: a) EDC, DMAP, DCM, 0 °C to rt, 31% 
 
 
2.2 Biological tests 
 
 
An important part of the IGD project was an evaluation of biological activity of 
synthesised (R)-IGD ester 2a and (R)-IGD acid 59. Those compounds were tested in 
a series of in vitro and in vivo experiments, together with (S)-IGD ester 2b and (S)-
IGD acid 59a, which were synthesised by Dr. Philip McGivern (the Marquez group) 
(Figure 22). The aim of biological studies was to determine whether the synthesised 
compounds could mimic the biological activity of the MSF in terms of stimulation of 
cell migration. The work was carried out by Dr. Ian Ellis in collaboration with Dr. 
Ana Schor and Prof. Seth Schor from the University of Dundee.110 A brief synopsis 
of the results is herein presented.  
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(R)-IGD acid 59
(S)-IGD acid 59a  
Figure 22. Structures of tested IGD peptidomimetics.  
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The ability of IGD peptidomimetics to stimulate cell migration was assessed in two 
in vitro assays, transmembrane assay and 3-D collagen gel, conventionally utilised to 
study cell chemotaxis. These experiments were performed with human skin 
fibroblast and endothelial cells, using different concentrations of DMSO solutions of 
peptidomimetics 2a, 2b, 59 and 59a.  As predicted by the initial modelling studies, 
the enantiomerically pure (R) methyl ester 2a showed significant motogenic activity 
on both fibroblasts and endothelial cells (i.e. caused the cells to migrate and initiate 
angiogenesis), whereas the (S) methyl ester 2b proved to be inactive under the assays 
conditions (results for peptidomimetics 2a and 2b are summarised in Table 5). The 
(R)-IGD acid 59 was significantly less potent than (R)-IGD ester 2a, whereas (S)-
IGD acid 59a showed no motogenic activity on cells.  
 
 
Table 5. Motogenic effect of (R)-IGD ester 2a and (S)-IGD ester 2b on fibroblasts and 
endothelial cells. Cells were tested on two migration assays: 3D collagen gels and 
transmembrane assay, as indicated. Figures show mean ± SD (n=3-6). 
 
 
The methyl esters and the free acids were then evaluated for the ability to promote 
wound closure on genetically diabetic mice. Due to stringent Home Office 
regulations and the need for licenses to carry out animal testing, this work was 
outsourced to Cica Therapeutics. In the experiment, mice were anaesthetised on day 
0 using isofluorane and air. Then their dorsal skin was clipped and cleansed 
according to protocol. A single standardised full thickness wound (10 mm x 10 mm) 
was created on the back of each experimental animal. Test variants or control 
 Number of cells migrated (relative to control) 
 Fibroblasts Fibroblasts Endothelial 
 3D collagen assay transmembrane assay transmembrane assay 
            IGD-ester 
 
concentration 
R S R S R S 
0 (controls) 1.0 
± 0.10 
1.0 
± 0.10 
1.0 
± 0.08 
1.0 
± 0.10 
1.0 
± 0.03 
1.0 
± 0.04 
1ng/ml 
 
1.53  
±  0.14 
0.82 
± 0.06 
1.07 
± 0.08 
1.01 
± 0.08 
1.03 
± 0.02 
1.0 
± 0.06 
10ng/ml 
 
2.17 
±  0.17 
0.89 
± 0.10 
1.39 
± 0.11 
1.0 
± 0.08 
2.14 
± 0.05 
0.98 
± 0.02 
100ng/ml 
 
3.32 
± 0.07 
1.0 
± 0.0 
2.03 
± 0.06 
0.99 
± 0.11 
2.17 
± 0.03 
1.0 
± 0.05 
1µg/ml 
 
3.37 
± 0.06 
0.92 
± 0.07 
2.53 
± 0.10 
0.98 
± 0.12 
2.27 
± 0.10 
1.04 
± 0.05 
10µg/ml 3.46 
± 0.17 
1.03 
± 0.07 
2.53 
± 0.09 
0.98 
± 0.10 
2.04 
± 0.05 
1.07 
± 0.06 
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preparations were applied to each animal. Solutions of the IGD mimetics were 
applied directly to the wound base and were evenly distributed using the 
micropipette tip. A 1.5 cm2 piece of ReleaseTM non-adherent film (i.e. ReleaseTM 
dressing [Johnson & Johnson Wound Management, UK] with the absorbent centre 
removed) was then placed over the wound and held in place with a circumferential 
band of the occlusive film dressing Bioclusive™ (Johnson & Johnson Wound 
Management, UK). All animals were re-anaesthetised and treatments were re-applied 
on days 2, 4, 7 and 10 post wounding.  
 
The wound-healing effects of IGD peptidomimetics were then examined 
histologically. The results indicated that wounds treated with (R)-IGD ester 2a and 
(R)-IGD acid 59 healed faster and showed significant difference in percent of wound 
size reduction as compared to control group (selected results presented in Figure 23). 
This may indicate that both mimetic variants can act to promote wound contraction 
in the diabetic mouse model.  Interestingly, the (S)-IGD acid 59a was, however, also 
found to promote a reduction in wound width, relative to the control groups, although 
not to the same extent as the higher doses of the two (R) mimetics 2a and 59.  
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A. Control group 
 
 
B. (R)-IGD ester 1a 
 
Figure 23. Effects of (R)-IGD ester 2a on wound closure; (A) control group, (B) (R)-IGD 
ester 2a treated group.  
 
 
Taken together, the results of in vivo studies suggested that the (R)-IGD ester 2a can 
promote wound healing in the diabetic mouse – an effect that was most apparent in 
terms of wound closure, wound contraction (wound tissue compaction), re-
epithelialisation and cellular maturity. Similar, though somewhat less pronounced, 
effects were observed following application of the highest dose of (R)-IGD acid 59. 
As expected, lower concentrations of both compounds tended to have reduced effects 
and higher concentrations may give rise to more substantial effects. 
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2.3 Conclusions 
 
 
In summary, the syntheses of a “first generation” of IGD peptidomimetics was 
successfully accomplished according to the protocols reported in this thesis. The IGD 
peptidomimetic ester was synthesized in both racemic (2) and optically active (2a) 
forms. Optimization of the reaction conditions for the enantioselective route to (R)-
IGD ester 2a allowed us to produce this mimetic in 9 steps and 32.4% overall yield. 
Hence, the developed synthetic route proved to be efficient, high yielding, and 
produced 2a in an enantiomeric excess of 94.9%. Our methodology utilizes simple 
transformations, easy to handle reagents and mild reaction conditions. As such, we 
speculate, that our synthetic protocol could be successfully adapted for use on an 
industrial scale.  
 
We also synthesized the (R)-IGD mimetic acid 59 from (R)-IGD ester 2a. Both 
compounds, 2a and 59, have been evaluated for their anticipated motogenic activity 
on cells, in a series of in vitro and in vivo experiments. The biological tests were 
performed by Dr. I. Ellis in collaboration with Prof. S. Schor and Dr. A. Schor. The 
initial results of these studies are promising. The (R)-IGD ester 2a was shown to 
stimulate cell migration both in vitro and in vivo. Since (R)-IGD ester 2a exhibits 
significant bioactivity, it is currently regarded as a likely lead-candidate for a drug in 
the topical treatment of wounds with impaired healing. Its clinical potential is 
currently being extensively investigated.  
 
The DANP photolabile group 50 was synthesized and coupled to (R)-IGD acid 59. 
The biological and chemical qualities of the obtained caged IGD mimetic 60 will be 
tested with a view to potential application in medicine as a drug delivery tool.  
 
Future work will be also devoted to expanding the class of IGD mimetics. It is 
proposed to synthesize series of analogues of IGD peptidomimetic 2, by modifying 
the substituents at nitrogen and carbon C-9 (Figure 24). It is hypothesized that these 
modifications might alter such important properties of compounds as receptor 
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affinity and bioactivity. Hence, it is hoped to develop analogues with high potency 
and specificity for MSF receptor. 
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Figure 24. IGD peptidomimetic 2 with highlighted areas that will be modified. 
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THE GRIS PROJECT 
 
 
3.0 Introduction  
 
 
Although the vast majority of human diseases are caused by a combination of 
genetic, environmental and lifestyle factors, we cannot underestimate the risks of 
infections by pathogenic bacteria. Bacteria have been evolving for nearly 3.5 billion 
years and have acquired a high degree of flexibility and capacity for rapid growth 
and reproduction. Moreover, evolutionary success of bacteria relies on the constant 
mutation of genes resulting in their abilities to adapt and survive in a changing 
environment. These changes in genetic make-up are also responsible for the emerge 
of antibiotic-resistant bacterial strains that cause infections which are often difficult 
to treat.111 
 
A microorganism which has shown to be particularly adaptable to antibiotics is the 
bacterium Staphylococcus aureus, commonly present in the nose and on the skin 
of one third of people. Although S. aureus is usually harmless at these sites, when it 
breaks into the body causes infections, ranging from mild conditions like pimples or 
impetigo to serious diseases such as pneumonia, meningitis, toxic shock syndrome 
(TSS), or septicemia.112 Historically, infections caused by S. aureus were treated 
with penicillin and since 1960 also with the derivative methicillin. However, the 
World Health Organization (WHO) recently reported that more than 95% of S. 
aureus worldwide is resistant to penicillin, and 60% to methicillin.113  
 
Since the resistance of pathogenic bacteria, including S. aureus, to antibiotics has 
been steadily increasing and is predicted to become a major world health problem, 
there is an urgent need for new forms of therapeutic treatments for bacterial 
infections. The most plausible alternative approaches that have been of interest to 
scientists include; bacterial interference, bacteriophage therapy, and bacterial 
vaccines.114 Many of these approaches have been addressing the mechanism 
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underlying bacterial adhesion to eukaryotic cells, which is a crucial stage in 
colonization of tissues that leads to infection.  
 
In recent years many research groups have presented new information regarding the 
mechanism for S. aureus adhesion to and invasion of human cells.115,116  This 
mechanism has been studied mostly in relation to cardiovascular diseases, and as 
such emphasis was placed on researching bacterial interactions with endothelial cells 
and platelets. As a result, it has been postulated that bacterium S. aureus can adhere 
to endothelial cells indirectly, utilising interactions between bacterial proteins 
adhesins, such as FnBPA, and the extracellular matrix protein fibronectin of the 
host.115 Since FN binds also to integrin receptors present on endothelial cell surfaces, 
it is believed to serve as a bridge between S. aureus and integrins and hence mediate 
bacterial adherence and presumable also internalization to endothelial cells. 
Furthermore, based on published NMR and X-ray structures of FnBPs of S. aureus in 
complex with 1F12F1 of FN, novel mechanism of interactions between these two 
proteins has been proposed.117  
 
Despite the growing information regarding S. aureus adherence to and invasion of 
host endothelial cells, there is still a lot to be discovered. For example, there are no 
doubts about the role played by fibronectin in bacterial pathogenesis, however, it 
remains unanswered how interactions with bacterium affect the structure of FN, and 
if there exists a biologically active motif within FNI modules necessary to exhibit 
binding of bacterial adhesins.  
 
 
3.1 Bacteria Staphylococcus aureus 
 
 
The Staphylococcus aureus bacteria are gram-positive spherical cocci that can be 
observed microscopically as individual organisms, in pairs or in clusters resembling 
grapes (Figure 25). This bacterial species are a common inhabitant of nose, skin or 
gastrointestinal tract of almost a third of all humans, and their presence is normally 
harmless and asymptomatic. 
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Figure 25. The scanning electron micrograph shows a strain of Staphylococcus aureus 
bacteria taken from a vancomycin intermediate resistant culture.  
 
(by J. H. Carr, Public Health Image Library (PHIL)) 
 
 
However, the S. aureus is also the most virulent pathogen among the Staphylococcus 
species, and simple skin damage or other injury can be enough for the bacteria to 
enter the body, overcome the natural protective mechanisms and initiate infection. 
The most common infections caused by this pathogen are skin conditions, such as 
pimples and boils which are usually uncomplicated and easy to treat. However, if S. 
aureus enters the bloodstream and spreads to other organs it can produce wide range 
of serious and damaging illnesses like staphylococcal pneumonia,118 meningitis,119 
endocarditis120 or severe bone inflammation.121 Moreover, the bacterium is capable 
of excreting several toxins122 that induce toxic shock syndrome (TSS), food 
poisoning or pneumonia in children. 
 
In recent years, infections caused by S. aureus have become more difficult to combat 
and widespread to such a scale that they have become a serious public health 
concern. The reason for that is the extraordinary ability of this pathogen to become 
resistant to antibiotics. The infections caused by S. aureus were originally treated 
with penicillin only for a short period of time; already in 1950 penicillin-resistant 
strains of bacterium were reported (Scheme 30). Currently, according to WHO, more 
then 95% of S. aureus worldwide is resistant to penicillin, 60% to methicillin 
(methicillin-resistant Staphylococcus aureus termed MRSA),123 and since 1997 cases 
of vancomycin resistant S. aureus infections have been reported.124  
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Scheme 30. Timeline of MRSA. 
 
 
The resistance of S. aureus to antibiotics can be acquired through number of different 
mechanisms, such as spontaneous nucleotide base mutations, conjugations and from 
recombination with other bacterial DNA following transformation.125 Although not 
all mutations of genes have to confer resistance to antibiotics, many of them actually 
do. Moreover, because of the rapid rate of division of bacterial cells, it is likely that 
bacterial population in an infected organism would ultimately consist mostly of 
mutants caring resistance genes. To further complicate treatment, recent findings 
show that some mutants of S. aureus have certain phenotypes that suggest prevalence 
of multidrug resistant strains.126,127 
 
Thus, since antibiotics that once cured bacterial infections caused by S. aureus are no 
longer effective, and only few new classes of antibiotics are under development, 
there is an urgent need for the design and implementation of alternative treatments 
with novel modes of action. One way of combating the antibiotic resistant S. aureus 
pathogen is to directly inhibit the infection process by disrupting the first stage of 
bacterial invasion which is adhesion to the host cells.  
 
The idea itself is not novel; however, only recent years have delivered enough 
information regarding the molecular basis of S. aureus adherence to host cells that 
could allow the development of new drugs capable of disrupting this process.  
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3.2 Molecular basis of bacterial invasion 
 
 
The bacterial invasion of the human body is a complex process that often leads to the 
development of infectious diseases.  Bacteria S. aureus is responsible for many 
topical and localised infections in humans, however the most dangerous and often 
fatal are systemic infections, such as bacteraemia, staphylococcal sepsis and 
infective endocarditis (IE), which start when the pathogen gains access to the 
bloodstream or other body fluids.128 Once in the system, bacteria S. aureus begin 
exploitation of the host organism by adhesion to the cells, replication and growth of 
the colony that could potentially spread to distinct organs.  
 
Until recently, there was little information available on the mechanism and 
consequences of cellular invasion in S. aureus pathology. However, in the last two 
decades this subject has been intensively studied by several research groups and as a 
result, new information has been gained regarding interactions between human cells 
and bacteria S. aureus on a molecular level. For instance, in contrast to the previous 
beliefs that S. aureus is an extracellular pathogen, it has been shown that it can 
invade and persist within a variety of non-professional phagocytes, such as human 
endothelial cells, bovine epithelial cells and murine fibroblasts. This internalization 
of pathogen by the host cells has obvious advantage for bacteria: it creates a 
protected environment where pathogens are shielded against host defenses and 
antibiotic treatment.129 Furthermore, S. aureus has been found to actively replicate 
inside pulmonary epithelial cells and cause their apoptosis, what could be a strategy 
to facilitate pathogen survival in the host organism.129  
 
In addition to these discoveries, there has been significant progress in understanding 
the mechanism of invasion of cardiovascular system by S. aureus, and hence in 
understanding the interactions between bacterium and endothelial cells. The 
endothelium lining blood and lymphatic vessels is a key barrier separating body 
fluids from tissues, and an important component of the immune system, producing 
inflammatory cytokines and regulating leukocyte trafficking. Thus, the endothelium 
is a major target for many bacteria, including pathogenic strains of S. aureus, which 
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can adhere to and invade endothelial cells causing disruption of their protective 
functions. Moreover, rupture and breaching of the endothelial barrier might be a first 
step in bacterial dissemination into surrounding tissues and organs,130 leading to 
various diseases (e.g. endocarditis, osteomyelitis). 
 
Studies on the pathogenesis of S. aureus have shown that the initial adherence of 
bacterium to the host endothelial cells is mediated by certain adhesins expressed on 
its cell surfaces.131 Adhesins are wall-anchored proteins that belong to family of 
microbial surface components recognising adhesive matrix molecules 
(MSCRAMM), and are produced by many microorganisms. In line with the name, 
the MSCRAMM molecules specifically bind to a wide range of host extracellular 
matrix components. Moreover, some of the adhesins can also bind receptors on 
eukaryotic cells, thereby directly promoting bacterial internalisation into host cells.132 
The biological importance and roles of MSCRAMMs proteins are only now 
beginning to be addressed; however, research performed so far suggests that 
MSCRAMMs are important virulence factors utilised by bacteria to engage host 
proteins and use them to exploit host cellular signalling.  
 
Accordingly, adhesins expressed by many strains of S. aureus have been shown to 
promote bacterial pathogenesis by recognising components of ECM, such as 
fibrinogen, collagen and fibronectin. Since FN is strongly connected with cellular 
invasion, the interactions between bacterial adhesins and FN are currently the most 
widely investigated.133,134 
 
Among the many adhesins expressed by S. aureus, there are two major fibronectin-
binding proteins (FnBPs): FnBPA and FnBPB. These FnBPs share a similar gene 
structure and domain organisation; both consist of four regions, termed A, D, C (also 
termed Du), and D, with multiple binding sites, that mediate bacterial association to 
fibrinogen, fibronectin and elastin.135 Both FnBPA and FnBPB have been found to 
be expressed by a majority of clinical isolates of S. aureus, and have been shown to 
promote bacterial adherence to cultured human endothelial cells,136 trigger active 
internalization into eukaryotic cells in vitro and in vivo, and cause platelet activation 
and aggregation.137 FnBPA was recently implicated in the mediation of endothelial 
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cell invasion and development of experimental endocarditis by the synergistic 
binding of two host ECM proteins, fibronectin and fibrinogen.138 
 
The mechanism of association of the FnBPs of bacterium S. aureus with fibronectin 
molecule was recently investigated by U. Schwarz-Linek.117 Schwarz-Linek studied 
the solution structure of a streptococcal FnBP peptide in complex with the 1FNI2FNI 
module pair of fibronectin. The NMR analysis of the complex structure, sequence 
analysis and isothermal titration calorimetry data allowed the team to not only 
propose a novel β-zipper mode of interactions, but also to identify an additional 
fibronectin-binding region in the bacterial FnBPs.  The association of a bacterial 
peptide with fibronectin requires specific interactions between specialised regions of 
both proteins. It has been demonstrated that the bacterium-binding site is located in 
the N-terminal region of FN and consist of five sequential FN type I modules (1-
5FNI). The tertiary structure of type I modules of FN were previously resolved and 
found to be rather elongated, consisting of two antiparallel β-sheets linked together 
by disulphide bridge. The dominant, large β-sheet was shown to be triple-stranded 
(strands C, D, E), whereas the smaller one is build by two strands A and B (Figure 
26).139  
 
 
Figure 26. Ribbon diagram of the F1 module fold of 1F1 with labelled β-strands (blue) and 
disulphide bonds indicated. 
 
Reprinted from Molecular Microbiology, 52, U. Schwarz-Linek, M. Höök J. R. Potts, The molecular 
basis of fibronectin-mediated bacterial adherence to host cells, p. 631-641, Copyright 2004, with 
permission from John Wiley & Sons 
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The other binding partner, FnBPA of S. aureus was initially believed to mediate FN-
association through C-terminal “D-region”. However, studies performed by 
Schwarz-Linek extended the binding region to the B and C (Du) domains (Figure 
27). According to the novel model, FN-binding activity is mediated by 11 binding 
sites, composed of a series of short motifs arranged in the correct order to bind the 
sequential FNI-type modules of FN (Figure 27).140,141 
 
 
 
 
 
 
Figure 27. FnBPA from S. aureus contains 11 FN-binding sites predicted to bind FN with 
varying affinity. (A) Schematic representation of FnBPA from S. aureus showing the 
approximate position of the 11 predicted FN-binding regions (FnBRs marked in red) within 
the bacterial protein sequence. (B) The amino acid sequences of the 11 FnBRs with 
highlighted conserved residues (white text). 
 
This research was originally published in Journal of Biological Chemistry, 282, N. A. G. Meenan, L. 
Visai, V. Valtulina, U. Schwarz-Linek, N. C. Norris, S. Gurusiddappa, M. Hook, P. Speziale, J. R. 
Potts, The tandem β-Zipper model defines high affinity fibronectin-binding repeats within 
Staphylococcus aureus FnBPA, p. 25893-25902, Copyright 2007, with permission from the American 
Society for Biochemistry and Molecular Biology 
 
 
During the binding event, the bacterial peptide (denoted B3) was found to contribute 
to the fourth β-strand that aligns antiparallel to the existing triple-stranded β-sheets of 
FNI modules in a tandem β-zipper interaction (Figure 28). Further work on this 
protein-protein recognition mechanism suggested that actually each of 11 binding 
motifs of FnBPA binds to FNI using β-zipper model. Moreover, it was shown that 
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upon binding, the bacterial peptide undergoes a transition from a disordered state to 
an extended β-strand-like conformation, while the three-dimensional structure of FI 
modules doesn’t change significantly.141 It has been hypothesised that since FnBPA 
contains multiple FN-binding sites, it could associate several FN molecules at a 
time.142 
 
 
 
Figure 28. a) Molecular surface of 1F12F1 in a complex with bacterial peptide B3 (in grey). 
b) Ribbon diagram of the lowest-energy structure showing β-strands of the F1 module (cyan) 
and the fourth strand formed by B3 (red). 
 
Reprinted by permission from Macmillan Publishers Ltd: Nature U. Schwarz-Linek, J. M. Werner, A. 
R. Pickford, S. Gurusiddappa, J. Hwa Kim, E. S. Pilka, J. A. G. Briggs, T. S. Gough, M. Hook, I. D. 
Campbell, J. R. Potts, 423, p. 177-181, copyright 2003 
 
 
The tight association of FnBPA of S. aureus with FN present in the ECM of the host 
is only the first step in a cellular adhesion. Bacterium is simply using fibronectin as a 
molecular “bridge” to bind to specific integrin receptors of endothelial cells. It is 
well known that FN binds with high affinity to integrins α5β1 through well-
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characterised tripeptide motif, Arg-Gly-Asp (RGD), localised in FNIII module in the 
central part of molecule. Therefore, since association of bacterium with fibronectin is 
mediated by the N-terminal region of the latter, it leaves the crucial RGD motif free 
and ready to interact with integrins. In this way fibronectin with adhered bacterium 
can simultaneously bind to integrins of endothelial cells. These interactions not only 
tightly anchor S. aureus to host cells but also trigger a cascade of signals that 
eventually lead to pathogen internalisation and dissemination.130,143 
 
The recent findings rapidly advanced our knowledge of how S. aureus manipulate 
crucial intracellular pathways in its host in order to enter and invade endothelial 
cells. It was shown, that this bacterium, similarly to other pathogens, can attack, 
subvert and eventually control the host cell machinery to its advantage. Hence, it is 
speculated, that FN-mediated adherence of S. aureus to receptors α5β1 initiates a 
cascade of signals that prompts integrin clustering and recruitment of focal adhesion 
proteins to the activated integrins. Recent work indicates the importance of tensin, an 
actin-binding protein, which is believed to transmit signals from integrin-bound 
bacterium to the actin cytoskeleton.143 This message in turn triggers the 
reorganisation of actin cytoskeleton in a way that promotes bacterial movement on 
the surface of endothelial cells (Figure 29). This enhanced motility of S. aureus 
delays assembly of actin phagocytic cups and bacterial uptake into host cells. Such a 
phenomenon is thought to be an intended process that allows bacterium to persist at 
the cell surfaces. Supposedly, the pathogen is simply “buying some time” in order to 
synthesise certain cell-damaging toxins, which will allow it to survive within 
cells.130,143 This hypothesis is consistent with other findings, which showed that 
unless bacteria S. aureus exerted high molecular toxicity before uptake, most of the 
examined strains were efficiently eliminated in lysosomes of keratinocytes or 
endothelial cells.144,145 Thus, delay in the uptake process could be considered as an 
alternative strategy developed by S. aureus, a bacterium poorly adapted to 
transcystosis, by which it could efficiently cross the endothelial barrier and 
disseminate to surrounding tissues.   
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Figure 29. Simplified representation of S. aureus attachment to and invasion of endothelial 
cells. 
  
 
3.3 First generation GRIS peptidomimetics 
 
 
There has been a significant progress in our understanding of pathogenic strategies 
utilised by S. aureus in invasion of the host cells and organs. The combined results of 
many interdisciplinary studies gives a plausible explanation of S. aureus virulence on 
a molecular level, from the interaction mechanism between bacteria S. aureus and 
transmembrane receptors integrins to intracellular uptake scenario. Another 
important finding of these works was the identification of fibronectin protein as an 
active and crucial mediator of S. aureus adhesion to the endothelial cells. However, 
despite great progress, there is still a limited amount of information regarding 
whether and how the FN structure and functions are altered upon binding to 
bacterium S. aureus. Extensive investigations are also required in order to determine 
whether FN type-I modules carry a biologically active motif, specifically responsible 
for recognition of FnBPs of S. aureus.  
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The results reported to date indicate that FN protein is binding FnBPs of S. aureus 
through the N-terminal region (NTR), composed of a string of five type-I modules. 
The three-dimensional structure of type I modules has been provided based on NMR 
studies and showed to consists of two antiparallel β-sheets, the first one being a 
double-stranded one, and linked by a disulphide bond to the other, triple-stranded β-
sheet. The second conserved disulphide bridge links the C-terminal adjacent strands 
of the domain.139 Furthermore, important information regarding the conformation of 
the NTR has been obtained from NMR structures of the 4FNI-5FNI modules pair.146 
The NMR studies of the FnBP-derived peptide in complex with 1F12F1 from the 
NTR have also identified the protein-protein recognition mechanism as a tandem β-
zipper.117  
 
Thus, according to the accepted β-zipper model, the bacterium is primarily binding to  
1-5FNI region of FN by forming a β-strand along the triple-stranded β-sheet. The 
detailed analysis of structural results indicated the importance of electrostatic 
interactions, which might contribute to the binding event. Moreover, it was suggested 
that FNI proteins could carry highly conserved motifs specifically responsible for 
binding to FnBPs of S. aureus.117 
 
The biologically active motif, by which FN mediates its adhesion to bacterium, has 
not yet been unambiguously indentified. However, the preliminary results of 
unpublished studies147 point towards short, terapeptide sequence Gly-Arg-Ile-Ser 
(GRIS) highly conserved within type-I modules of fibronectin (Figure 30). 
Presumably, the GRIS peptide could constitute a crucial motif mediating the binding 
of FnBPs to FN.  
 
 
 84
 
Figure 30. Cartoon structure of the part of 2FNI of FN; the GRIS motif is shown with sticks 
(R. Marquez). 
 
 
Thus, in an effort to contribute to research on FN-mediated invasion of S. aureus, we 
proposed to elucidate the role of GRIS motif present in type-I FN modules. For this 
reason we propose to synthesise the small, nonpeptidic molecule, which could mimic 
the biological properties and activity of the native GRIS motif. We speculate that if 
the GRIS sequence is crucial for FN interactions with S. aureus, the “GRIS 
peptidomimetic”, when introduced to the system, could compete with FN in binding 
to bacterial adhesins. Therefore, a GRIS peptidomimetic would disrupt the 
interactions between FN and bacterium, necessary for bacterial adherence to host 
endothelial tissues. It is also possible, that if successful, this strategy and compound 
might be used in combating bacterial diseases. The idea behind our project isn’t 
novel; in 1981, Beachey wrote that an understanding of the mechanisms whereby 
bacteria attach to host cell surfaces would lead to new approaches to preventing 
serious bacterial infections by interrupting the interactions of bacterial adhesins 
with host receptors.148 This concept seems relatively straightforward; however 
implementation of this type of approach proved to be difficult, due to the complex 
nature of bacterial infections.149  
 
We now propose to synthesise and elucidate the biological properties of a GRIS 
peptidomimetic. The first generation GRIS mimetic was designed taking into account 
the steric and electronic properties of native GRIS tertapeptide motif, and it is shown 
on Figure 31. 
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Figure 31.  The first generation GRIS peptidomimetic 62. 
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4.0 Results and discussion 
 
 
4.1 The aim of the project 
 
 
The aim of GRIS project was to design, develop and execute an efficient synthetic 
route to the novel GRIS bicyclic peptidomimetic 62 (Figure 32).  
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Figure 32. The structure of GRIS peptidomimetic 62. 
 
 
Despite possessing a deceptively simple structure, the GRIS molecule 62 presents 
several synthetic challenges. Firstly, little information is available in the literature on 
the synthesis of similar units, especially in respect to the 1,3 relation between the 
ketone and amine functionalities. Another potential difficulty rises from defined 
stereochemistry at both ring junctions, which needed to be addressed in the course of 
synthesis.  Therefore, our efforts were focused on exploring different synthetic 
transformations that would allow the synthesis of GRIS mimetic in an efficient 
manner. In our first approach we referred to work carried out by Marko Ciufolini and 
Albert Padwa on the aza-Achmatowicz reaction. This oxidative rearrangement 
allows access to substituted piperidines and other nitrogen containing heterocycles in 
an elegant and simple manner.150 The second approach that we attempted relies on 
Diels-Alder cycloaddition, and allows unique control over the stereochemistry of the 
product.151  
 
 
 87
4.1.1 The aza-Achmatowicz approach 
 
 
Our initial work towards the synthesis of the GRIS peptidomimetics 62 were based 
on a synthetic strategy that employed the aza-Achmatowicz rearrangement in 
combination with ring closing metathesis (RCM) as the key transformations. It was 
decided to first focus our efforts on the development of model and racemic synthetic 
route to GRIS molecule 62 and to address stereochemical problems later.    
 
Our principal disconnections in the deconstruction of GRIS peptidomimetic 62 are 
outlined in Scheme 31. The final GRIS molecule 62 was envisioned to arise from 
attachment of the side chain on to the nitrogen-containing ring of compound 63. That 
could be achieved by Wittig reaction and series of functional group transformations. 
The requisite 6,6-bicycle 63 could be accessed via ring expansion reaction from the 
5,6-bicycle 64. Enone 64 could be obtained by allylic oxidation of alkene 65. We 
anticipated that the 5-membered ring of 65 might be constructed via RCM of diene 
66, which in turn could be accessed from pyridinone 68. Finally, we expected to 
obtain the nitrogen-containing compound 68 via single oxidative rearrangement of 
furylamine 69. 
 
H
N
NH2
H
O
R
N
O
X
R
N
O
R
N
O
R
N
O
R
N
O
O
NH2
OH
R
N
X
O
62 63 64 65
66 67 68 69  
Scheme 31. Retrosynthetic analysis of GRIS peptidomimetic 62. 
 
 
We have chosen to pursue the synthesis of mimetic 62 via the 5,6-bicyclic system 65 
in order to avoid regioselectivity problems during the oxidation step. We realised that 
it might be possible to prepare the 6,6-bicycle 71 directly via RCM reaction of 70, 
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however, it became apparent that the alkene 71 might not be able to undergo a 
selective allylic oxidation, and it would likely give rise to two different enones 72 
and 73 (Scheme 32). Therefore, in our synthetic approach we decided to overcome 
this problem by constructing firstly the 5,6-bicycle 65, which would provide the 
starting point for the allylic oxidation step. Moreover, it was also assumed that the 
biological activity of compound 64 would be evaluated along with the final GRIS 
peptidomimetic 62 (see Scheme 31). 
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Scheme 32. Alternative RCM and allylic oxidation.  
 
 
Execution of our synthetic plan required as a first step the aza-Achmatowicz 
rearrangement of furylamine 69. The aza-Achmatowicz reaction deserves special 
mention as it is one of the key transformations in our synthetic route.   
 
Since Achmatowicz reported in 1971 an oxidative rearrangement of furfuryl alcohols 
74 into dihydropyranones 75 (Scheme 33) that could be further easily converted into 
sugars,152 similar oxidation of  furylamines attracted considerable attention.153  
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Scheme 33. Oxidative rearrangement of furfuryl alcohols 74 into dihydropyranones 75. 
 
 
It was quickly recognised that if successful, analogous rearrangement of furfuryl 
amine derivatives 76 could become a new synthetic strategy towards 6-membered 
nitrogen-containing heterocycles 77. Furthermore, easy access to this type of 
nitrogenous substances would provide very useful building blocks for biologically 
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active carbacephems 78,154 unusual aminoacids,155 piperidine and izidine alkaloids 
79,156,157 and azasaccharides 80.158 (Scheme 34).   
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Scheme 34. Aza-Achmatowicz rearrangement and its possible applications in organic 
synthesis of loracarbef 78 (carbacephem antibiotic), swainsonine 79 (indolizidine alkaloid) 
and azasaccharide 80 (general structure). R1 and R2 maybe independent or joined into a ring. 
 
 
The pioneering work on the aza variant of Achmatowicz reaction was performed by 
Ciufolini, who in 1986 reported the successful rearrangement of functionalised 
tetrahydrofurans into 6-membered nitrogenous rings.153 Ten years later, Ciufolini 
applied this methodology for the preparation of structurally complex intermediate 84 
in his synthesis of carbacephems antibiotics (Scheme 35, entry 2).154 Recent studies  
have demonstrated the power of the aza-Achmatowicz reaction in preparing the 
highly functionalised molecule 82 with 4 stereocentres as a core building block 
during the total synthesis of swainsonine (Scheme 35, entry 1).159  
 
The presented examples illustrate an important feature of the aza-Achmatowicz 
rearrangement; the chirality at the furylic position as well as existing stereocentres, 
are conserved during rearrangement. For this reason, the aza-Achmatowicz products 
(e.g. 82 and 84) derived from chiral starting materials are versatile intermediates in 
the asymmetric syntheses of biologically active and pharmaceutically important 
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compounds such as antibiotic loracarbef 78154 or alkaloid swainsonine 79,159 a 
potential chemotherapy drug (Scheme 34 and 35). 
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Scheme 35. Synthetic applications of the aza-Achmatowicz reaction; (1) Rearrangement 
during the synthesis of 8a-epi-swainsonine;159 (2) Preparation of key intermediate in the 
synthesis of loracarbef (carbacephem antibiotic).154 
 
 
The aza-Achmatowicz rearrangements reported to date have been achieved with a 
variety of oxidative conditions, such as TFA/CH3Cl, TfOH, mCPBA, as well as 
under the original conditions reported by Achmatowicz that employed Br2 in MeOH, 
followed by mild acidic hydrolysis. In our synthesis we aimed to carry out aza-
Achmatowicz rearrangement with mCPBA, influenced by the work of Padwa and co-
workers.157 
 
Execution of our synthetic plan began with the protection of free amine functionality 
of 5-methylfurfurylamine 69 with tosyl chloride. The tosyl protecting group was 
chosen because of its compatibility with the relatively acidic conditions of the 
rearrangement, and the documented ease of purification of the resulting 
product.160,161 The obtained N-tosylaminofuran 85 was then treated with mCPBA to 
furnish aza-Achmatowicz product 86 (Scheme 36).  
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Scheme 36. Reagents and Conditions:  a) TsCl, Et3N, DCM, quant., b) mCPBA, DCM, 
100% conversion by NMR. 
 
 
A plausible mechanism for the aza-Achmatowicz rearrangement of furfurylamine 69 
under oxidative conditions is presented (Scheme 37). This process begins with the 
nitrogen-directed epoxidation of the double bond of 85, proximal to the amine group, 
to furnish epoxide 87. Epoxide 87 then rearranges to generate zwitterion 88, which 
opens to form diketone 89. Finally, intramolecular attack of the nucleophilic nitrogen 
on the carbonyl group generates the aza-Achmatowicz product as hemiaminal 86.  
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Scheme 37. The mechanism of aza-Achmatowicz rearrangement. 
 
 
However, pyridinone 86 proved to be extremely unstable and none of attempts to 
modify it under Lewis acid catalysed conditions were successful. On the basis of 
NMR spectroscopy it was deduced that compound 86 which bears hemiaminal 
functionality favoured the open-chain form 89. 13C NMR analysis showed two 
carbonyl signals, at 193.87 ppm and 197.98 ppm. It is suspected that the rate of ring 
opening of cyclic hemiaminal 86 was greatly increased by catalytic proton transfer 
(Scheme 38).   
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Scheme 38. The ring-opening mechanism of hemiaminal 86. 
 
 
Since our initial strategy failed due to the instability of cyclic hemiaminal 86, a 
different starting material was considered for the aza-Achmatowicz reaction. To our 
knowledge, the synthetic work reported thus far in the literature have focused on the 
rearrangement of variety of furylamines 92 and furylamides 93 with unsubstituted 
furan rings (Figure 33).150 Moreover, the reported rearrangement products were 
stable and successfully underwent a number of further modifications. Thus, it seems 
that the presence of methyl group in position 5 of the furyl framework in starting 
material 69, although required in the final product 62, was causing our synthetic 
approach to fail.  
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Figure 33. General structure of furylamines 92 and furylamides 93 utilised as starting 
materials for the aza-Achmatowicz rearrangement (PG=protecting group; R1, R2 might be 
independent or joint into a ring).150 
 
 
For this reason, it was decided to investigate the rearrangement of a furfurylamine 99 
that could serve as a new starting material in the synthesis of GRIS molecule. At this 
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point of our investigation the successful rearrangement of compound 99 was critical 
to pursue the synthesis via an aza-Achmatowicz route. The revised synthetic plan 
followed in principle the first approach (see Scheme 31), but required assembling of 
the methyl group at the ring junction later in the synthesis as shown in Scheme 39.  
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Scheme 39. Revised retrosynthetic analysis of GRIS peptidomimetic 62. 
 
 
Execution of our modified approach began with the protection of furfurylamine 99 
with tosyl chloride. The resulting tosyl amide 100 was then rearranged under 
oxidative conditions to furnish cleanly the aza-Achmatowicz product 101. 
Pyridinone 101 was stable enough to undergo aqueous work-up, after which it was 
treated with allyltrimethylsilane in the presence of Lewis acid (i.e. boron trifluoride 
ethyl etherate). This reaction produced piperidone 102. Due to its sensitive nature, 
enone 102 was not purified but reacted in crude form with the in situ generated vinyl 
cuprate reagent to furnish the 1,4 conjugate addition product 103.157  The stable diene 
103 was produced as a single diastereoisomer in 67% yield over four steps (Scheme 
40).  
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Scheme 40. Reagents and Conditions: a) TsCl, Et3N, DCM, quant., b) mCPBA, DCM, rt, c) 
allyltrimethylsilane, BF3·OEt2, DCM, 0 °C, d) CuI, vinylMgBr, THF, −78 °C then −30 °C 
then −78 °C, 67% from 99. 
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At this stage in our synthetic investigation we focused our attention on another 
crucial transformation: the ring closing metathesis (RCM) of diene 103. According to 
our synthetic plan this reaction would generate the desired 5,6-bicycle.  
 
The catalytic ring closing metathesis (RCM) is undoubtedly one of the most 
important and powerful methods for the generation of ring structures of various sizes 
and classes.162 The most developed and utilised method in synthetic organic 
chemistry is the alkene RCM, however, in recent years also the ring-closing 
alkyne162 and enyne163 metatheses have found impressive applications (Figure 34). 
Nevertheless, for the purpose of our synthetic route, we were interested in the 
application of an olefin ring closing metathesis.  
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Figure 34. Different types of ring-closing metathesis. 
 
 
In this process two terminal alkenes react with the catalyst to ultimately generate the 
cyclic olefin. A generalised pathway illustrating how this transformation proceeds is 
shown on Scheme 41.164 
 
Mechanistically, the catalytic cycle consists of two phases: initiation and 
propagation. The initiation phase began with the association of the metal with one of 
the two olefins of the substrate 104 to generate metallacyclobutane 105 (Scheme 41, 
catalyst initiation). This active complex might revert to starting materials via path B 
because all olefin metathesis reactions are in principle reversible; but it could also 
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proceed via path A, in which the existing bonds break to furnish intermediate 107. If 
this route is favoured, the metal (M) ends up within the substrate. Then formation of 
metallacyclobutane 108 followed by its break down produces desired cyclic 
molecule 110 and the metal-bearing compound 109 that serves as a catalyst during 
propagation phase (Scheme 41, catalyst propagation).  In the propagation phase the 
active catalyst 109 promotes additional cycles. What typically drives the RCM 
reactions is that the cyclic product 110 does not easily react with the catalyst 109 to 
undergo ring-opening metathesis. The release of by-product, the volatile olefin (i.e. 
ethylene) easily removed by evaporation, also forces the equilibrium towards the 
production of the cyclic olefin.   
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Scheme 41. The general mechanism for ring-closing olefin metathesis (adapted from 
reference 164). 
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Although complexes of several metals (such as tungsten, rhenium and osmium) were 
shown to promote metathesis reactions, the most reactive and stable, and therefore 
wildly use are molybdenum (Mo) and ruthenium-based (Ru) catalysts. The routinely 
utilised Ru complexes have the advantage of being stable to air and moisture. 
Moreover, they tolerate wide range of substrates that carry hydroxyl, carboxylic acid, 
or aldehyde functionalities, but can be rendered inactive in the presence of 
structurally exposed amines and phosphines. On the contrary, the commercially 
available Mo catalyst, developed by Schrock, is more reactive, especially in the 
presence of amino groups, but need to be handled under an inert atmosphere because 
of its sensitivity to moisture and oxygen (Figure 35).164 
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Figure 35. Common ruthenium (A) and molybdenum (B) complexes used in metathesis 
reaction (Ph = phenyl, Cy = cyclohexyl). 
 
 
In our synthesis of the GRIS molecule, an alkene RCM was required for the 
construction of a 5-membered carbocycle, fused to the existing nitrogenous ring. We 
decided to start the synthesis of bicycle 112 by employing the first-generation 
Grubbs catalyst. This metal complex proved to be very successful in Padwa’s 
syntheses of octahydroquinoline ring systems, that share some structural homology 
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with bicycle 112.157 Under these reaction conditions the desired 5-membered ring of 
112 was formed, albeit in relatively low 37% yield (table 6, entry 1). Thus, we 
investigated other metal carbenes, which could catalyse the conversion of diene 103 
to bicycle 112 more effectively. Therefore, we employed a more active, thermally 
stable and convenient to handle 2nd generation Grubbs catalyst. We also carried out 
the reaction with Hoveyda-Grubbs 2nd generation catalyst which is considered a good 
RCM initiator, tolerates wide range of substrates and is usually more reactive then 
Grubbs 2nd at lower temperature. The RCM reaction was conducted under varied 
temperatures, with different solvents and catalysts loading (Table 6, entry 2-4). 
However, the desired cyclic product 112 was not isolated under any of the conditions 
employed.  
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Entry Catalyst Catalyst 
loading 
Lewis acid 
(20 % mol.) 
Solvent Conc. Temp. Yield 
1 Grubbs 1st gen. 10% mol _ DCM c=0.06 rt-37 °C 37% 
2 Grubbs 2nd gen. 7 + 7% mol _ DCM c=0.05 rt <1% 
3 Grubbs 2nd gen. 7% mol _ PhMe c=0.05 rt <1% 
4 Hoveyda-Grubbs 2 5 + 5% mol _ DCM c=0.05 reflux _ 
5 Hoveyda-Grubbs 2 5% mol Ti(OiPr)4 DCM c=0.05 reflux _ 
6 Grubbs 2nd gen. 10% mol Ti(OiPr)4 DCM c=0.005 reflux 82% 
Table 6. Optimisation of the catalyst and the reaction parameters of the RCM. 
 
 
Finally, after careful analysis of the obtained results, the conditions reported by Yu 
for Lewis acid assisted RCM were employed.165 To our gratification, in the presence 
of Grubbs 2nd generation catalyst and Ti(OiPr)4 as a co-catalyst, the cyclization of 
diene 103 proceeded in excellent 82% yield (Table 6, entry 6). 
 
On the basis of the experiments performed and NMR analysis we believe that the 
major problem in the cyclization of diene 103 originates from the nature of precursor 
103. Usually in the RCM reaction the major challenge comes from the competitive 
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cross-metathesis. However in this case there was no evidence that dimerisation or 
oligomerisation of compound 103 occurred. Thus, we focused out attention on the 
structure of diene 103 and its implication for the RCM reaction.  
 
The diene 103 carries a Lewis-basic and potentially catalyst-deactivating nitrogen 
containing group. The Ru-based catalysts, utilised in our RCM reaction, are 
especially sensitive to the presence of nucleophilic nitrogen. Although the nitrogen 
atom is not a part of the newly formed 5-membered ring of compound 112, its 
presence in the molecule seemed to affect the outcome of the reaction. According to 
the literature, a major issue associated with the use of amine-containing substrates for 
RCM concern their ability to coordinate to metal-alkylidine complexes.166,167 It is 
postulated that this interaction is responsible for the catalysts’ inactivation, and hence 
unsuccessful RCM reactions. 
 
Thus, several strategies have been developed and adopted to prevent catalyst 
deactivation by the Lewis-basic nitrogen atom. There are two principal approaches; 
the first relies on increasing the steric hindrance around an amine group, hence 
making it less accessible for the metal complex. The second relies on reducing the 
basic character of the amine unit. Consequently, widely used methods include 
conversion of amines to carbamates, sulphonamides, amides or ammonium salts.166 
Alternatively, RCM reaction of free amines can also be carried out in the presence of 
protonating agent, such as p-toluenesulfonic168 or camphorsulfonic acid.169 Also the 
tosyl protecting group, utilised in our synthetic strategy, should in principle have 
favoured the RCM by decreasing the electron density on the nitrogen atom. 
However, examples in the literature indicate that this effect is not always sufficient to 
achieve successful RCM.166 
 
The approach, eventually adopted in our synthesis, was developed by the group of 
Yu, during their work on the synthesis of amine-containing heterocyclic structures by 
RCM. Yu and co-workers reported a methodology for a mild, Lewis-acid assisted 
ring-closing olefin metathesis of diallylamine substrates.165 Their model studies 
showed that introduction of a Lewis acid to the RCM of amine-containing 
compounds could significantly increase the yield or in some cases help the reaction 
to proceed. The Lewis acid is believed to compete with ruthenium species in 
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coordination to nitrogen atom, leaving Ru-catalyst available for olefinic part of the 
molecule. 
 
Yu and co-workers studied different Lewis acids as co-catalysts for the RCM 
reaction of diallylamines. Of the Lewis acids tested, they found titanium isoproxide 
to be the most promising for this transformation, with the second generation Grubbs 
as the preferred catalyst. Thus, as presented in Table 6, after employing Yu’s 
conditions for the RCM of diene 103 we were able to successfully synthesise the 
bicyclic compound 112. However, it should be noted that scaling-up of the RCM, 
while maintaining reaction parameters, proved to be troublesome and resulted in a 
significant drop in yield (40% on a 2g scale).   
 
Since bicycle 112 was crystalline in nature, the relative stereochemistry was 
established using X-ray diffraction methods. The X-ray structure of 112 clearly 
showed an anti-relationship between the protons at the ring junction (Figure 36).  
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Figure 36. Crystal structure of bicycle 112. 
 
 
With the intermediate 112 in hand, the introduction of the amine-containing side 
chain was attempted. The assembly of the side chain began with the Wittig 
olefination of ketone 112 that worked in good yield (84%), and, as expected, 
produced compound 113 as a mixture of E/Z isomers (1:1 ratio based on NMR data). 
Subsequent reduction of ester functionality of 113 smoothly generated alcohol 114 as 
a mixture of diastereoisomers that weren’t separable by flash column 
chromatography (Scheme 42).  
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Scheme 42. Reagents and Conditions: a) Grubbs 2nd gen., Ti(OiPr)4, DCM, reflux, 82%, b) 
Ph3PCHCO2Et, DCM, reflux, 84%, c) DIBAL-H, Et2O, 0 °C, quant. 
 
 
The next step in the synthesis involves the selective hydrogenation of hydroxy olefin 
114. For this purpose it was decided to employ the homogenous rhodium catalyst 
Rh(Cl)(PPh3)3 (Wilkinson’s catalyst), which reduces alkenes under mild conditions. 
Previous studies from several laboratories have established that allylic and 
homoallylic alcohols can be selectively reduced in the presence of rhodium 
complexes.170,171 The hydroxyl group has been shown to direct the site of the 
hydrogenation, whilst accelerating the rate of hydrogenation.172 
 
Mechanistically, the hydroxyl group remains bound to the metal during the catalytic 
cycle and hence controls the stereochemical course of hydrogen delivery through 
chelation.173 However, the level of diastereoselection during the hydrogenation of 
olefin 114 in our synthesis couldn’t be determined as the starting material 114 was a 
mixture of E/Z isomers. Hence, it was expected, that the reduction of 114 will 
produce alcohol 115 as a mixture of stereoisomers (Scheme 43).174 The NMR 
analysis suggested the presence of two diastereoisomers, which again, due to the 
similarities in their Rfs, weren’t separable by preparative chromatography. 
Additionally, the complexity of the NMR spectra made assignment of individual 
signals impossible.   
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Scheme 43. Reagents and Conditions: RhCl(PPh3)3, H2, EtOH 
 
 
 
 101
Since based on NMR analysis it was not possible to confirm that we indeed 
synthesised the alcohol 115, the recrystallization of one of the expected 
diasteroisomers from the complex mixture of 115 was attempted. For this purpose 
115 was coupled with para-nitrobenzoic acid (Scheme 44). This transformation was 
expected to produce two compounds, 116 and 117. The reaction generated yellow-
orange solid, which was treated with various solvents and solvent mixtures. 
However, recrystallization failed to separate any pure compound from the mixture 
115. 
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Scheme 44. Reagents and Conditions: a) p-nitrobenzoic acid, DCC, DMAP, DCM 
 
 
At this stage of the synthesis, we decided to focus our efforts on building the final 
bicyclic core, and postpone addressing the issue of the side chain assembly until later 
in the synthesis. In order to explore the remaining reactions, such as allylic oxidation, 
ring expansion and installation of methyl group at ring junction, the model 
compound 118 was envisioned and prepared (Figure 37). The simplified derivative 
118 would allow us to carry out the synthetic investigations without the confusion 
caused by the presence of non-separable diastereoisomers.  
 
N
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∗ OH
H
118  
Figure 37. Model compound 118. 
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Synthesis of model system 118 was initiated by reduction of ketone 112 to the 
alcohol 119 under the influence of L-Selectride (Scheme 45). The application of the 
bulky reagent at low temperature was anticipated to give us a degree of stereocontrol 
for the reduction step. Alcohol 119 was obtained as a single diastereoisomer, as 
confirmed by NMR analysis. It was attempted to establish the relative 
stereochemistry of the crystalline 119 by X-ray analysis. However, that was not 
successful due to crystals quality.  
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Scheme 45. Reagents and Conditions: a) L-Selectride, THF, −78 °C, 87%, b) NaH, 
CH3CH2I, DMF, 0 °C, 79% 
 
 
Based on NMR data it is reasonable to assume that we indeed synthesised 119 as a 
single diastereoisomer, as required for the purpose of our model studies. Alkylation 
of 119 protected the sensitive alcohol functionality (Scheme 45), and provided the 
requisite compound 118 that could then be used to define the conditions for allylic 
oxidation and to explore the subsequent steps in the synthesis.  
 
Allylic oxidation is a well documented process that allows regioselective 
functionalization of an allylic C-H bond with oxygen. This transformation is known 
to be catalysed by a variety of transition metals, such as chromium (VI) manganese 
(III), bismuth (III), copper, cobalt and chromium. Usually, due to the cost of the 
catalysts and the toxicity of metallic by-products, the reaction is carried out with a 
substoichiometric amount of metal complex and a stoichiometric amount of a co-
catalyst, such as peroxide, which reoxidises the metal. Depending on the catalysts 
and the nature of the substrate, an allylic oxidation can produce either an allylic 
alcohol such as 120 or the corresponding 121 (Scheme 46).  
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Scheme 46. Possible products (120 and 121) of allylic oxidation of alkene 118. 
 
 
Our initial studies on the allylic oxidation involved treatment of alkene 118 with 
selenium dioxide (SeO2) and tert-butyl hydroperoxide.175 Based upon the 
regioselectivity rules for the allylic oxidation with the SeO2, we expected that 
oxidation would take place at the α-methylene carbon of the double bond of 118. A 
plausible pathway, illustrating how the oxidation of cyclopentene 118 by SeO2 would 
proceed, is shown in Scheme 47.  
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Scheme 47. The mechanism of allylic oxidation of alkene 118  
 
 
An allylic oxidation is initiated by the reaction of SeO2 with alkene 118 in an ene 
cycloaddition that produces allylic seleninic acid 123. This intermediate undergoes 
allylic rearrangement to give an unstable compound 124 that rapidly decomposes to 
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yield allylic alcohol 120. In some cases, the oxidation can continue to produce an 
aldehyde or ketone, depending on the nature of the substrate. 
 
However, the oxidation of alkene 118 with SeO2 failed to yield allylic alcohol 120 
(Table 7). We then employed various other catalysts that could affect the 
transformation of alkene 118 to alcohol 120 or ketone 121 (Table 7). Thus, olefin 
118 was subjected to a bismuth (III) chloride catalysed oxidation but, again, the 
reaction failed to produce the desired enone 121.176 Alkene 118 was also treated with 
tert-butyl hydroperoxide in the presence of catalytic manganese (III) acetate under an 
oxygen atmosphere.177 These conditions were reported as an alternative method for 
the mild and regioselective allylic oxidation of steroids and simple cyclic olefins, 
such as cyclopentene. However, despite prolonged reaction time (3 days), there was 
no evidence for the formation of enone 121.  
 
 
N
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118 120 X=H, OH
121 X=O  
 
 
 
 
 
 
Table 7. Catalysts and reaction parameters of allylic oxidation of alkene 118. 
 
 
There are reports in the literature of other promising methods for the allylic oxidation 
of olefins. Catino and co-workers reported in 2004 a novel protocol for the allylic 
oxidation of alkenes, using rhodium complex 125 as a catalyst (Figure 38).178  
 
 
Entry Reagents and conditions 
1 SeO2, tBuOOH (70% in H2O), salicylic acid, DCM 
2 BiCl3, tBuOOH, MeCN, 70 °C 
3 Mn3O(OAc)9, tBuOOH, O2, EtOAc 
4 Rh2(cap)4, K2CO3, tBuOOH, DCM, air 
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Figure 38. The structure of dirhodium (II) caprolactamate 125. 
 
 
These studies demonstrated that dirhodium (II) caprolactamate 125 (Rh2(cap)4) is an 
exceptionally efficient catalyst for methylene oxidations to a corresponding ketone, 
with the reaction being completely selective, tolerant of air and moisture, and could 
be performed with as little as 0.1 mol % catalyst loading. Unfortunately, allylic 
oxidation of alkene 118 under these conditions also failed to generate desired product 
121 (Table 7, entry 4).  
 
Thus, no progress was made in the installation of the crucial ketone group on 5-
membered ring of model compound 118. Careful inspection of the data on the allylic 
oxidation under all conditions applied revealed that neither the allylic alcohol 120 
nor enone 121 were formed. In addition to that principal drawback of our synthetic 
route, we also experienced a significant reduction in yield whilst scaling-up the RCM 
reaction and faced stereochemistry issues. For these reasons, a novel synthetic 
approach to the GRIS peptidomimetic 62 was designed.   
 
 
4.1.2 The Diels-Alder approach  
 
 
Since our studies on synthesis of GRIS molecule via aza-Achmatowicz route proved 
to be problematic, we turned our attention to other synthetic strategies that could 
allow us access to GRIS peptidomimetic 62 structure. 
 
Upon searching the literature it was noticed that the target GRIS peptidomimetic 62 
shares a number of structural similarities with an intermediate 126 (Figure 39) 
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synthesised by P. Stanetty and co-workers in their approach to the AB-ring system of 
certain 9-azasteroids.179 
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Figure 39. Intermediate 126 in the synthesis of  9-azasteroids 
 
 
The synthetic route, developed and executed by this group, is outlined in Scheme 48. 
Attention focused specifically on intermediate 126 that possess structural features, 
such as heterocyclic core, methyl group at the rings junction, fixed stereochemistry at 
the ring junction and a methoxy group, which are very close to or could be related to 
those of GRIS molecule 62.  
 
The synthetic route developed by Stanetty relied on the highly stereoselective Diels-
Alder (DA) cycloaddition of Danishefsky’s diene 128 with E-nitroalkene 127, which 
secured the stereochemistry required for the target product 132 (Scheme 48).  
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Scheme 48. Reagents and Conditions: a) benzene, reflux, 63%, b) (CH2OH)2, TSA, benzene, 
Dean–Stark separator, 98%, c) Al/Hg, THF/H2O, 79%, d) TiCl3, 75%, e) Red-Al®, 75%, f) 
C11H23COCl, NEt3, DMAP, 75%, g) Red-Al®, 88%, h) 6N HCl, 76%, i) H2, Pd/C, 97%, j) 
Red-Al®, 95%. 
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Thus, it was reasoned that an analogous DA transformation with the Z-nitroalkene 
133, and subsequent protection of the carbonyl group would generate a cyclohexene 
134 with the opposite stereochemistry at the carbon bearing the nitro group (Scheme 
49).  
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Scheme 49. Diels-Alder reaction and protection of carbonyl group to produce intermediate 
134. 
 
 
As outlined in our new synthetic strategy for the construction of GRIS mimetic 
(Scheme 50), reduction of nitro group of adduct 134 and subsequent Lewis-acid 
mediated ring closure would then produce the bicycle 135 in diastereoismerically 
pure form and with the desired cis stereochemistry at the ring junction.  
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Scheme 50. Diels-Alder approach to GRIS peptidomimetic 62. 
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The next step in the strategy would be to assemble the side chain using enolate 
chemistry. The resulting compound 136 could then undergo deprotection of the 
ketone functionality, followed by dual-reduction of both the ketone and amide 
functions to furnish alcohol 138. Further reduction/cleavage of the alcohol group of 
compound 138 would provide bicycle 139 that after several functional group 
interconvertions and deprotecion of amine functionality should present us with the 
desired GRIS peptidomimetic 62 (Scheme 50).  
  
Our studies towards the synthesis of the GRIS mimetic via a Diels-Alder strategy 
began with the preparation of both starting materials, the Z-nitroalkene 133 and 
Danishefsky’s diene 128. The Z-nitro olefin is not commercially available, it was 
therefore necessary to design a short synthesis that would allow us to access this 
compound. On the contrary, Danishefsky’s diene could be purchased, however, due 
to its sensitive nature we aimed to prepare it ourselves and use in the DA 
cycloaddition before degradation. 
 
Thus, the synthesis of Z-nitroalkene 133 began from acid chloride 140 which was 
reduced under Rosenmund conditions to cleanly furnished aldehyde 141 in excellent 
yield (94%) (Scheme 51).180 The subsequent Henry reaction of 141 with nitroethane 
proceeded smoothly and yielded cleanly nitroaldol adduct 142. However, as 
expected, β-nitro alcohol 142 was produced as a mixture of syn/anti diastereomers 
(de ratio 1.6:1) due to the reaction’s reversibility and the easy epimerization at the 
nitro-substituted carbon.181  
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Scheme 51. Reagents and Conditions: a) 2,6-lutidine, H2, Pd/C, THF, 94%, b) EtNO2, 
tBuOK, THF/tBuOH, 98%, c) TFAA, Et3N, DCM, 71%, d) i. (PhSe)2, NaBH4, EtOH, ii. 
solution of 127 in EtOH, then AcOH, −78 °C, iii. H2O2, DCM, 0 °C, 94% from 127. 
 
 
The next transformation, the dehydration of β-nitro alcohol 142, was extensively 
studied. The Henry product 142 was first treated with acetic anhydride in the 
presence of a catalytic DMAP to afford the nitro acetate that subsequently underwent 
elimination reaction upon treatment with base.181 This two-step procedure furnished 
the desired nitroalkene 127 as the single E isomer, albeit in poor yield (Table 8, entry 
1). The dehydration reaction was the attempted under a variety of alternative 
conditions, with a view to improve the reaction yield (Table 8). Unfortunately, all 
attempts to affect the elimination of the alcohol 142 via the mesylate intermediate 
failed to deliver the desired product 127 (Table 8, entry 2-4).182,183 However, 
treatment of nitroalcohol 142 with trifluoroacetic anhydride (TFAA) and 
triethylamine under precise temperature control (−35 °C to −60 °C (3h) and  −20 °C 
(2h)) over the course of reaction furnished 71% of the E-alkene 127 after purification 
(Table 8, entry 7).184 The NMR data obtained for the E-nitroalkene 127 was 
consistent with data previously published in the literature.185 
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Table 8. Reaction conditions of dehydration step. 
 
 
Having synthesised the desired E-olefin 127 as a single isomer, we focused on the 
transformation that would allow to access the Z-isomer 133. Hence, we adopted 
methodology reported by N. Ono and co-workers for the conversion of E-
nitroalkenes to Z-nitroalkenes via erythro-β-nitroselenides.186,187 Treatment of E-
isomer 127 with the sodium benzeneselenoate (generated in situ from diphenyl 
diselenide and sodium borohydride), followed by the subsequent protonation with 
acetic acid gave intermediate 145 (Scheme 52). The stereoselectivity of the 
protonation step could be explained by assuming that under the reaction conditions 
(−78 °C), the protonation of intermediate 144 took place from the less hindered site 
to produce predominantly erythro-isomer 145.  
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Scheme 52.  Stereoselectivity in the formation of erythro-isomer 145. 
Entry   Reagents and conditions Yield of 127  
1 i. Ac2O, DMAP, Et2O, 0 °C then rt  
ii. K2CO3, tBuOH, 35 °C 
32%  
2 MsCl, Et3N, DCM, 0 °C then rt  compounds mixture 
3 i. MsCl, Et3N, DCM, 0 °C then 35 °C 
ii. DBU, 0 °C then rt 
 
compounds mixture 
4 i. MsCl, DMAP, Et3N, DCM, 0 °C then rt 
ii. DBU, 0 °C then rt 
 
compounds mixture 
5 TFAA, Et3N, DCM, −20 °C 60%  
6 i. TFAA, Et3N, DCM, −20 °C 
ii. DBU, −20 °C 
 
32%  
7 TFAA, Et3N, DCM, −35 °C to −60 °C (3h) and  −20 °C (2h) 71%  
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Further oxidation of selenide 145 with hydrogen peroxide resulted in the subsequent 
syn-elimination of benzeneselenic acid, and furnished the desired Z-isomer 133. The 
mechanism of the elimination step, which is believed to proceed via 5-membered 
transition state, is shown on Scheme 53.188 The overall isomerisation procedure 
occurred in excellent yield (94%) and produced 133 as an inseparable mixture of Z/E 
double bond isomers in a satisfying 9:1 ratio.  
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Scheme 53. Mechanism of the conversion of E-nitro alkene to Z-nitro alkene via erythro-β-
nitroselenide. 
 
 
After completing the synthesis of Z-nitroalkene 133, we focused on the preparation 
of the Danishefsky’s diene 128. This highly reactive diene was synthesized 
according to standard procedures and it was immediately used in the Diels-Alder 
reaction, the crucial transformation in the synthetic route.189 
 
The Diels-Alder (DA) reaction is a one of the best known and fascinating [4+2] 
cycloadditions. This pericyclic transformation engages a conjugated diene (4 π-
electron component) and dienophile (2 π-electron component) to produce an 
unsaturated 6-membered ring. The versatility and potential of the DA reaction is 
reflected in the predictable regio- and stereochemistry of the resulting cyclohexane 
rings, possessing up to four contiguous stereocenters. Furthermore, careful choice of 
substrates allows introduction of many functional groups to the DA adduct. Since its 
discovery in 1928, the DA cycloaddition has found impressive applications in total 
synthesis of various classes of biologically active compounds and natural products.126 
Important advances in the DA reaction, such as development of hetero-DA, 
intramolecular and transannular variants, have significantly broadened the scope and 
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utility of the methodology. It has long been recognized that the DA is a powerful tool 
for the construction of complex molecules and cyclic systems (up to three 
carbocyclic rings) in only one transformation.190 
 
The original DA reaction involved the cycloaddition of cyclopentadiene 147 with 
quinone 148 induced upon heating (Scheme 54).191  
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Scheme 54. The discovery of the Diels-Alder reaction. 
 
 
However, recent studies in the area have focused on the use of Lewis acids as mild 
promoters of the cycloaddition. Various Lewis acids catalyse the DA reaction by 
decreasing the activation energy of the process. In a typical Lewis acid-mediated DA 
reaction, the metal complex coordinates reversible to the dienophile and substantially 
lowers the LUMO energy, thereby enhancing the interaction with the diene 
HOMO.192 The application of catalysts to induce the cycloaddition has not only 
expanded the scope of the reaction to heat-sensitive dienes and dienophiles, but has 
also resulted in greater control over the reaction regioselectivity.  
 
In our studies, the DA cycloaddition of Danishefsky’s diene 128 with Z-nitro olefin 
133 was attempted in both catalytic and thermal version (Table 9). Initially, DA 
reaction of 128 with 133 was attempted under standard thermal conditions. This 
method failed to deliver the desired product 151. Also the use of the Lewis acid 
catalyst, TiCl4, failed to promote the reaction. The presence of strong Lewis acid 
catalyst or high temperature was possibly causing the decomposition of 
Danishefsky’s diene. This diene has been previously demonstrated to be sensitive 
towards catalysts such as ZnCl2, AlCl3.193 Upon searching the literature we found a 
successful example of a Lewis acid-mediated DA reaction with Danishefsky’s 
diene.194 Lanthanide salts have been shown to be efficient and mild catalysts for the 
DA cycloaddtion of various dienophiles with Danishefsky’s diene. We examined two 
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lanthanide compounds: ytterbium (III) triflate (Yb(OTf)3) and europium(III)-
tris(1,1,1,2,2,3,3-heptafluoro-7,7-dimethyl-4,6-octanedionate) (Eu(fod)3). Under 
these conditions, the desired Diels-Alder adduct 151 was not formed (Table 9, entry 
3 and 4).  Furthermore, application of Eu(fod)3 as an catalyst resulted in the 
isomerization of the Z-nitroalkene 133 (Table 9, entry 4). 
 
NO2
CO2Et
O
Me3SiO
+
O
CO2EtH
NO2
O
133 128 151  
Entry Reagents and conditions Results 
1 toluene, 75 °C 133 and 128 decomposition  
2 TiCl4, DCM, −78 °C 133 and 128 decomposition 
3 Yb(OTf)3, toluene, 0 °C 133 recovered 
4 Eu(FOD)3, toluene, 0 °C to 40 °C 133 isomerisation (Z/E in 1:2) 
5 i. benzene, 80 °C 
ii. 0.1N HCl, THF, c = 0.05 133 and 128 decomposition 
6 i. benzene, 75 °C 
ii. 0.1N HCl, THF, c = 0.1 
 
20% of 151 
7 i. benzene, 60 °C 
ii. 0.1N HCl, THF, c = 0.05 
 
25% of 151 
Table 9. Conditions for the Diels-Alder reaction. 
 
 
Since catalytic DA failed to generate compound 151, the thermal version of DA 
reaction was re-examined. The thermally-induced cycloaddition of 133 with 128 in 
benzene, followed by subsequent desilylation, afforded 25% of desired methoxy 
ketone 151 (Table 9, entry 7).  
 
The relative configuration of DA adduct 151 was determined by 1H NMR 
spectroscopy. Analysis of the coupling constants clearly showed a large vicinal 
coupling (Jac 9.3 Hz) and thus the diaxial orientation of protons Ha and Hc (Figure 
40, (A)). This coupling constant, together with others, strongly suggested the 
equatorial orientation of ester chain and allowed us to conclude that the Diels-Alder 
product 151 is the exo-adduct (Figure 40, (A)).  
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Figure 40. Experimental coupling constants for Diels-Alder adduct 151 in Hz. 
 
 
The unusual exo-selectivity in DA reaction of nitro olefins with Danishefsky’s diene 
has been investigated and reported previously by Node.195 Node carried out a series 
of cycloadditions using Danishefsky’s diene and various nitro olefins, both aliphatic 
and aromatic. All the reactions clearly exhibit exo selectivity, regardless of the kind 
of nitro alkenes or bulkiness of the substituent at β-carbon of nitro olefin. 
Furthermore, the DA cycloaddition of the same nitroalkenes with other popular 
dienes, such as 1-methoxybutadiene and cyclopentadiene, produced preferentially the 
endo-adduct. On the basis of these observations, Node concluded that the exo-
selectivity in DA reactions of nitro olefins is a characteristic of Danishefsky’s diene.  
 
To rationalise the stereochemical outcome of the DA cycloadditions of nitroalkenes 
with Danishefsky’s diene, Node considered the geometry and electronic features of 
possible exo and endo transition states. Mechanistically, the enhanced endo-
selectivity of many DA reactions is governed by two factors: secondary orbital 
interactions and steric repulsions. However, as presented in Figure 41, in the reaction 
of nitro olefin 133 with Danishefsky’s diene 128, the endo transition state suffered 
from the electrostatic repulsions between the electron rich nitro group of the olefin, 
and the other electron rich group – OTMS of the diene. By applying Node’s 
reasoning to our DA cycloaddition, we also speculated that electrostatic repulsions 
plays a major role in controlling the stereoselectivity of the transition state, and 
hence favoured the formation of exo-isomer. Furthermore, in case of our Z-alkene 
133, the exo transition state is free from steric repulsions as the ester chain is oriented 
away from the OTMS group (Figure 41).  
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Figure 41. Proposed endo and exo transition states in the DA reaction of 133 and 128. 
 
 
NMR analyses of DA adduct 151 also allowed for assignment of the stereochemical 
configuration at the tertiary carbon bearing the methoxy group (Figure 40, (B)).  The 
vicinal coupling between proton Hc and two magnetically distinct Ha protons gave 
values suggesting the axial-equatorial and equatorial-equatorial orientation of these 
protons. Therefore, it was deduced that the methoxy group occupies the axial 
position (Figure 40, (B)).  
 
The structure of the major side-products furnished in the DA reaction of nitro olefin 
133 and Danishefsky’s diene 128 were identified as enones 153 and recovered 
starting material 133 (Scheme 55). The reaction suffered from poor conversion as 
well as acid-induced elimination of TMSOMe, concurrent with the desired 
hydrolysis of the silyl enol ether 152 to the ketone 151 (Scheme 55). Hence, by 
addressing the issue of elimination, it was hoped to improve the yield of DA 
cycloaddition.  
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Scheme 55. Diels-Alder cycloaddition of alkene 133 and diene 128. 
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Literature survey showed that the problem of methoxy group elimination after acidic 
treatment of silyl enol ethers was discussed by Danishefsky as part of his work on the 
dienic component 128 for DA reaction.196,197 These studies showed that the geometry 
of the methoxy group of adducts such as 152, could greatly affect the results of the 
acidic work-up. Upon treatment with diluted acid, the cleavage of the silyl protecting 
group is favourable for compounds bearing equatorially position methoxy unit. On 
the contrary, if molecule carries the axially oriented methoxy group, it is more likely 
that it will undergo the elimination of TMSOMe to yield enones, such as 153 
(Scheme 55). Danishefsky’s investigation postulated that utilization of stronger 
acidic conditions during the work-up of silyl enol ethers such as 152, might favour 
the hydrolysis of the silyl group. 
 
Therefore, on the basis of these results, the conditions of the DA cycloaddition were 
re-examined. The reaction was conducted in higher temperature, and with an 
alternative acidic work-up. When the cycloaddition was performed in 70 °C, and the 
subsequent work up carried out under stronger acidic conditions, the DA adduct 151 
was obtained in acceptable 32% yield (Table 10, entry 2).  
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Compound 
Entry Reagents and conditions 
151 153 133 
1 i. benzene, 60 °C 
ii. 0.1N HCl, THF, c = 0.05 
25% 26% 30% 
2 i. benzene, 70 °C 
ii. 0.1N HCl, THF, c = 0.1 
32% traces 15% 
Table 10. Improved conditions for the DA reaction. 
 
 
Having synthesized acceptable the DA adduct 151, the next steps in the synthetic 
route towards GRIS molecule 62 were explored. Thus, protection of ketone 
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functionality of 151 as the corresponding ketal was carried out under standard 
conditions, using ethylene glycol.198 NMR analysis of the purified fraction suggested 
the presence of two compounds 154 and 155 (Scheme 56).  
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Scheme 56. Reagents and Conditions: a) ethylene glycol, PPTS, 135 °C, Dean-Stark 
 
 
However, it was not possible to separate the two compounds using FCC. Hence, it 
was decided to explore the following reaction, i.e. reduction of nitro group to 
corresponding amine 156 or hydroxylamine 157, using unprotected ketone 151. 
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Scheme 57.  Predicted products of nitro group reduction.  
 
 
The investigation focused on the application of mild, catalytic hydrogenation 
procedures would allow for the selective reduction of the nitro group in the presence 
of ester function. The unprotected nitro compound 151 was subjected to 
hydrogenation over Pd/C (Table 11, entry 1). Transfer hydrogenation was also 
attempted using ammonium formate as the hydrogen source (Table 11, entry 2).199 
Unfortunately, both reactions failed to generate expected amine 156. 
 
Alternatively, the procedure developed by Maleczka et al. was adapted.200 Maleczka 
reported the use of silane as efficient reducing agents for the conversion of aliphatic 
nitro molecules to hydroxylamines. Thus, the nitro ketone 151 was treated with 
triethylsilane and catalytic amount of palladium (II) acetate (Table 11, entry 3). 
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Unfortunately, this procedure also failed; after the simple work-up the untouched 
starting material 151 was recovered.  
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157 R1=OH  
Entry Reagents and conditions Predicted product Yield (%) 
1 Pd/C, H2, MeOH, rt 156 0 
2 NH4HCO2, Pd/C, THF, rt 156 0 
3 Et3SiH, Pd(OAc)2, THF/H2O, rt 157 no reaction 
Table 11.  Conditions for nitro group reduction. 
 
 
Finally, reduction of nitro ketone using Adam’s catalyst in poly(ethylene glycol) 
(PEG 400) was attempted.201 Adam’s catalyst (platinum dioxide) is a very efficient 
catalysts for reduction of nitro group to amines and ketones to alcohols. Although 
under these conditions the unprotected ketone group was likely to undergo reduction, 
this would not be an issue, as the presence of ketone wasn’t required in the final 
product.  
 
However, the results of platinum catalysed reduction were disappointing; this 
reaction smoothly furnished corresponding alcohol 158 (Scheme 58), but left the 
targeted nitro group untouched. 
 
 
O
CO2EtH
NO2
O
∗
O
CO2EtH
NO2
HO
151 158
a
 
Scheme 58. Reagents and Conditions: a) PtO2, H2, PEG 400, rt, 50%. 
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4.2 Conclusions 
 
 
In summary, we have studied two distinct routes to GRIS peptidomimetic 62. The 
first approach relied on an aza-Achmatowicz rearrangement and RCM as the key 
transformations, and the second approach utilised a Diels-Alder cycloaddition.  
Unfortunately, neither of these approaches proved fruitful.  
 
During the work on the aza-Achmatowicz approach we successfully accomplished 
the construction of nitrogen-containing heterocycle 112, which is anticipated to be a 
crucial intermediate in the synthesis of GRIS peptidomimetic 62 via the aza-
Achmatowicz approach. Preparation of 112 was achieved via inter alia an aza-
Achmatowicz rearrangement of furfurylamines, yielding functionalised pyridinones 
in a fast and efficient synthesis.  
 
Preparation of pyridinone 86 via an aza-Achmatowicz rearrangement proved 
problematic. Regardless, we continued our synthetic approach to GRIS 
peptidomimetic 62 via the des-methyl pyridinone 101, in order to prove the 
feasibility of our methodology and with a view to introducing the methyl group later 
on in the synthesis.  
 
To this end, pyridinone 101 was converted to diene 103. RCM metathesis of 103 
produced nitrogen containing 5,6-bicycle 112, in good to excellent yield. 
Disappointingly, any further attempts to functionalise heterocycle 112 were 
unsuccessful. Introduction of the ketone to 112 via an allylic oxidation proved 
unsuccessful utilising a variety of reaction conditions. The problematic nature of the 
allylic oxidation combined with a lack of viable alternative methods and issues with 
stereochemistry and separation of isomers prompted us to explore another synthetic 
approach.  
 
In our alternative approach, the synthesis of GRIS mimetic 62 was attempted via a 
route that utilised a Diels-Alder (DA) reaction as a key transformation. We 
successfully executed a short and efficient synthesis of Z-nitro olefin 133, which 
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underwent a DA cycloaddition with Danishefsky’s diene to yield adduct 151 as a 
single diastereoisomer.  The adduct 151 was shown to possess the correct 
stereochemical configuration, which would be essential if we were to complete the 
synthesis of GRIS mimetic 62 in a stereoselective fashion. In addition to this, another 
benefit of our synthetic route via a DA cycloaddition is that the required quaternary 
stereocentre is introduced early on in the synthesis. 
 
Unfortunately, attempts at reduction of the nitro group of 151 to amine 156 or 
hydroxylamine 157 proved unsuccessful. One plausible explanation is that the nitro 
group is too sterically hindered to be susceptible to the attempted reaction conditions. 
However, only a few of the better known reduction conditions/reagents were 
investigated.  It is possible that alternative conditions/reagents (such as aluminium 
amalgam) might yet prove successful.  
 
 
 121
5.0 Experimental section 
 
 
General Information 
All reactions were carried out under an atmosphere of argon in oven-dried glassware 
with magnetic stirring. Syringes, needles, cannulas and magnetic stirrer bars were 
also oven-dried. Tetrahydrofuran, diethyl ether and dichloromethane were purified 
through a Pure Solv 400-5MD solvent purification system (Innovative Technology, 
Inc). Unless otherwise noted, reagents were commercially available and used without 
further purification. Solvents were evaporated under reduced pressure at maximum 
temperature 48 °C, using a Buchi Rotavapor. Purification of reaction products were 
carried out by flash column chromatography using Apollo Scientific Silica Gel 60 
(40-63 micron).  
 
Analytical thin layer chromatography (TLC) was performed on aluminium sheets 
pre-coated with silica gel 60 (Merck). Visualization was accomplished with UV light 
and/or by staining with aqueous ceric ammonium molybdate solution, anisaldehyde, 
potassium permanganate and ethanolic ninhydrin solution, followed by heating. 
Melting points were measured with a Stuart Scientific Melting Point SMP1 
apparatus, and are uncorrected. Optical rotations were determined using a JASCO 
DIP-370 digital polarimeter with a sodium lamp. [α]D values were measured at the 
concentration and temperature reported. 
 
Infrared spectra (IR) were recorded on a Shimadzu FTIR-8400 spectrophotometer 
with a Golden Gate ATR accessory, using CDCl3 solutions of compounds. Some 
spectra were recorded as thin films on sodium chloride (NaCl) plates using a JASCO 
FTIR 410 spectrometer. High resolution mass spectra were recorded under EI, CI, 
and FAB conditions by the analytical services of the University of Glasgow. 
 
1H NMR spectra were recorded on a Bruker DPX 400 and Bruker AV 400 
spectrometers at 400 MHz in room temperature and, in some cases, in 55 °C. Spectra 
were recorded in deuterochloroform (CDCl3), using residual chloroform as the 
internal standard (δ = 7.26 ppm), and in deuterated benzene (C6D6), using residual 
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benzene as the internal standard (δ = 7.15 ppm). J values are given in Hertz. Signals 
in NMR spectra are described as: br. = broad, app = apparent, s = singlet, d = 
doublet, t = triplet, q = quartet, s = sextet, m = multiplet, or combinations of these. 
Data are reported as follows: chemical shift in ppm, integration, multiplicity, coupling 
constant(s) and assignment. 13C NMR spectra were recorded on a Bruker DPX 400 and 
Bruker AV 400 spectrometers at 100 MHz in room temperature unless stated 
otherwise. Spectra were recorded in deuterochloroform (CDCl3) and in deuterated 
benzene (C6D6), using solvent as the internal standard (CDCl3 at 77.16 ppm and 
C6D6 at 128.06 ppm). Data are reported as follows: chemical shift in ppm and 
assignment. The proton and the carbon assignments were based on COSY, HSQC, 
HMBC and DEPT 135 experiments. 
 
 
3-hydroxy-2-nitrobenzaldehyde 20 
 
OH
O
NO2
OH
O
15 20  
 
To a stirred suspension of 3-hydroxybenzaldehyde 15 (3 g, 24.6 mmol, 1 eq) in dry 
DCM (250 cm3) were added tetrabutylammonium hydrogen sulphate (0.42 g, 1.23 
mmol, 5%mol eq) and isopropyl nitrate (6.2 ml, 6.46 g, 61.5 mmol, 2.5 eq) under an 
argon atmosphere. The resulting reaction mixture was cooled to −15 ºC and pure 
sulphuric acid (14.4 ml, 26.54 g, 270.6 mmol, 11 eq) was added slowly to it via 
dropping funnel with pressure equalizing arm (highly exothermic reaction).  After 
stirring at −15 ºC for next 20 minutes, TLC analysis indicated complete consumption 
of the starting material. The cooling bath was removed and reaction mixture was 
quenched with water (200 cm3) and diluted with diethyl ether (150 cm3). Resulting 
biphasic mixture was stirred for next 20 minutes at room temperature. After this time 
the layers were separated and aqueous layer was extracted with fresh diethyl ether (2 
x 200 cm3).  The organic phases were combined, washed with brine (400 cm3), dried 
over sodium sulphate, filtered off, and solvents were removed in vacuo. The 
remaining residue was suspended in small amount of diethyl ether and resulting pale 
yellow precipitate was filtered off and dried to give the desired nitrobenzaldehyde 20 
 123
(2.3 g, 13.7 mmol, 56% yield).  Nitrobenzaldehyde 20 was used in synthesis without 
any further purification.  
 
δH (400 MHz, CDCl3): 7.31 (1H, dd, J = 7.4 and 1.4 Hz, one of C6H3), 7.37 
(1H, dd, J = 8.4 and 1.4 Hz, one of C6H3), 7.67 (1H, ddd, J = 8.4, 7.4 and 0.7 Hz, 
one of C6H3), 10.31 (1H, appd, J = 0.7 Hz, CHO), 10.42 (1H, br. s, OH) 
δC (100 MHz, CDCl3): 121.6 (Ar-C), 124.4 (Ar-C), 135.1 (Ar-Cq), 136.8 
(Ar-C), 155.1 (Ar-Cq), 188.1 (CHO), 1 x Cq unresolved 
m/z [CI (+ve)], 168.13 ([M+H]+, 100%), 138.15 ([(M+H)−NO]+, 60%);  
Found [M+H]+, 168.0294, C7H6NO4 requires 168.0297 
ν max (CDCl3) / cm−1: br. 3221, 3097, 2893, 2804, 1678, 1535, 1315  
mp. 157-159 °C 
 
 
3-(3-Methyl-butoxy)-benzaldehyde 17 
 
OH
O
O
O
15 17  
   
To a solution of 3-hydroxybenzaldehyde 15 (5 g, 41 mmol, 1 eq) in dry DMF (300 
cm3) was added potassium carbonate (11.3 g, 82 mmol, 2 eq) under an argon 
atmosphere and resulting reaction mixture was stirred for 20 minutes. Then reaction 
was treated with 1-bromo-3-methylbutane (15.4 ml, 18.6 g, 123 mmol, 3 eq) and 
stirring was continued overnight at room temperature. After this time the reaction 
was quenched with water (300 cm3), and diluted with ethyl acetate (200 cm3).  After 
the biphasic mixture was stirred for 20 minutes, the phases were separated and the 
aqueous layer was extracted with fresh ethyl acetate (2 x 250 cm3). All the organic 
layers were combined, washed with water (2 x 500 cm3), brine (500 cm3), dried over 
sodium sulphate, filtered off, and solvents were removed in vacuo. The resulting 
aldehyde 17 (yellow liquid, 7.61 g, 39.6 mmol, 96% yield) was judged clean based 
on NMR analysis and was reacted further without any purification.  
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δH (400 MHz, CDCl3): 0.96 (6H, d, J = 6.6 Hz, CH(CH3)2), 1.69 (2H, appq, 
J = 6.7 Hz, OCH2CH2), 1.84 (1H, appsept., J = 6.7 Hz, CH(CH3)2), 4.03 (2H, t, J = 
6.6 Hz, OCH2), 7.15 (1H, m, one of C6H4), 7.37-7.38 (1H, m, one of C6H4), 7.42-
7.43 (2H, m, two of C6H4), 9.96 (1H, s, CHO) 
δC (100 MHz, CDCl3): 22.6 (CH(CH3)2), 25.1 (CH(CH3)2), 37.9 
(OCH2CH2), 66.7 (OCH2), 112.7 (Ar-C), 122.1 (Ar-C), 123.4 (Ar-C), 130.1 (Ar-C), 
137.8 (Ar-Cq), 159.8 (Ar-Cq), 192.4 (CHO) 
m/z [EI (+ve)], 192.1 ([M]+, 45%), 122.0 ([M−C5H10]+, 56%), 70.1 
([C5H10]+, 51%); Found [M]+, 192.1151, C12H16O2 requires 192.1150 
ν max (CDCl3) / cm−1: 3070, 2957, 2871, 2724, 1697, 1597, 1451, 1263, 1025  
 
 
3-(3-Methyl-butoxy)-2-nitro-benzaldehyde 14 
 
Procedure A 
 
OH
O
NO2 O
NO2
O
20 14  
 
Procedure B 
 
 
O O
NO2
OO
17 14  
 
Procedure A 
To a stirred solution of nitrobenzaldehyde 20 (4.8 g, 28.7 mmol, 1 eq) in dry DMF 
(300 cm3) was added potassium carbonate (7.9 g, 57.4 mmol, 2 eq) under an argon 
atmosphere. After being stirred for 30 minutes at room temperature, the reaction 
mixture was treated with 1-bromo-3-methylbutane (10.8 ml, 13 g, 86.1 mmol, 3 eq) 
and stirring was continued overnight. After this time the reaction was quenched with 
water (200 cm3) and biphasic mixture was stirred for 20 minutes. Phases were 
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separated and the aqueous layer was extracted with fresh ethyl acetate (2 x 250 cm3). 
All the organic layers were combined, washed with water (300 cm3), brine (300 
cm3), dried over sodium sulphate and concentrated in vacuo to give 
nitrobenzaldehyde 14 as a viscous orange oil, which was judged pure by NMR 
spectroscopy and reacted further without purification (5.23 g, 22.0 mmol, 100% 
conversion by NMR, 77% yield). 
 
Procedure B 
To a stirred solution of aldehyde 17 (2.6 g, 13.5 mmol, 1 eq) in dry dichloromethane 
(80 cm3) at −28 °C was added nitronium tetrafluoroborate (2.7 g, 20.25 mmol, 1.5 
eq) under an argon atmosphere. The reaction was stirred for 22 hours while 
temperature was maintained at −28 °C. After this time a cooling bath was removed, 
reaction was quenched by slow addition of water (60 cm3) and resulting biphasic 
mixture was stirred until reaching room temperature. The mixture was then diluted 
with ethyl acetate (60 cm3) and stirred for additional 20 minutes. Phases were 
separated, and aqueous layer was extracted with fresh ethyl acetate (2 x 60 cm3). 
Combined organic phases were washed with water (150 cm3), brine (150 cm3), dried 
over sodium sulphate and filtered off. The solvents were removed in vacuo to afford 
the residue that was purified by flash column chromatography (silica gel, gradient 
elution, eluting with 5% ethyl acetate in petroleum ether (40-60) to 25% ethyl 
acetate in petroleum ether (40-60)) to give nitrobenzaldehyde 14 as an viscous 
orange oil (1.71 g, 7.2 mmol, 53% yield). 
 
δH (400 MHz, CDCl3): 0.93 (6H, d, J = 6.6 Hz, CH(CH3)2), 1.67 (2H, appq, 
J = 6.5 Hz, OCH2CH2), 1.78 (1H, appsept, J = 6.6 Hz, CH(CH3)2), 4.12 (2H, t, J = 
6.5 Hz, OCH2), 7.33 (1H, dd, J = 8.3 and 1.2 Hz, one of C6H3), 7.46 (1H, dd, J = 7.7 
and 1.2 Hz, one of C6H3), 7.59 (1H, appt, J =  8.0 Hz, one of C6H3), 9.92 (1H, s, 
CHO) 
δC (100 MHz, CDCl3): 22.5 (CH(CH3)2), 24.9 (CH(CH3)2), 37.5 
(OCH2CH2), 68.6 (OCH2), 119.5 (Ar-C), 122.0 (Ar-C), 128.2 (Ar-Cq), 131.6 (Ar-C), 
140.6 (Ar-Cq), 150.7 (Ar-Cq), 187.0 (CHO) 
m/z [CI (+ve)], 238.28 ([M+H]+, 100%); Found [M+H]+, 238.1077, 
C12H16NO4 requires 238.1079 
ν max (CDCl3) / cm−1: 2958, 2935, 2874, 1701, 1604, 1535, 1462, br. 1284  
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Methyl-[1-[3-(3-methyl-butoxy)-2-nitro-phenyl]-meth-(E)-ylidene]-amine 33 
 
O
NO2
O
NO2
O
N
14 33  
 
A stirred solution of aldehyde 14 (1.71 g, 7.2 mmol, 1 eq) in heptane (40 cm3) was 
treated with methylamine (40 wt. % solution in water, 1.75 ml, 0.63 g, 20.16 mmol, 
2.8 eq). The biphasic mixture was stirred vigorously at room temperature until 
completion of reaction as indicated by TLC analysis (2 hours). Heptane was then 
removed in vacuo, and remaining crude imine 33 was taken directly to the next 
reaction without purification.  
 
δH (400 MHz, CDCl3): 0.93 (6H, d, J = 6.6 Hz, CH(CH3)2), 1.67 (2H, appq, 
J = 6.6 Hz, OCH2CH2), 1.79 (1H, appsept, J = 6.6 Hz, CH(CH3)2), 3.51 (3H, d, J = 
1.7 Hz, NCH3), 4.09 (2H, t, J = 6.6 Hz, OCH2), 7.07 (1H, dd, J = 8.2 and 1.1 Hz, one 
of C6H3), 7.41 (1H, m, one of C6H3), 7.48 (1H, dd, J = 7.9 and 1.2 Hz, one of C6H3), 
8.16 (1H, appq, J = 1.6 Hz, CHN)       
δC (100 MHz, CDCl3): 22.5 (CH(CH3)2), 25.0 (CH(CH3)2), 37.6 
(OCH2CH2), 48.7 (NCH3), 68.3 (OCH2), 115.2 (Ar-C), 119.5 (Ar-C), 128.7 (Ar-Cq), 
131.0 (Ar-C), 141.5 (Ar-Cq), 150.4 (Ar-Cq), 156.1 (CHN)  
m/z [CI (+ve)], 251.3 ([M+H]+, 72%); Found [M+H]+, 251.1397, C13H19N2O3 
requires 251.1396 
ν max (CDCl3) / cm−1: 2955, 2874, 1651, 1604, 1531, 1465, 1280  
 
 
Methyl-[3-(3-methyl-butoxy)-2-nitro-benzyl]-amine 32 
 
NO2
O
N
H
NO2
O
N
33 32  
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A stirred solution of imine 33 (1.8 g, 7.2 mmol, 1 eq) in methanol (40 cm3) was 
cooled to 0 °C and sodium borohydride (0.4 g, 10.8 mmol, 1.5 eq) was added to it 
carefully in portions. The resulting reaction mixture was stirred at room temperature 
until complete consumption of starting material as indicated by TLC analysis (3 
hours).  The reaction mixture was then cooled to 0 °C and slowly quenched with 
water (40 cm3). After stirring for 20 minutes at 0 °C, a cooling bath was removed, 
the reaction was diluted with ethyl acetate (80 cm3) and resulting biphasic mixture 
was allowed to warm to room temperature. Phases were separated and the remaining 
aqueous layer was extracted with ethyl acetate (2 x 80 cm3). All the organic phases 
were combined, dried over anhydrous sodium sulphate and organics were removed 
in vacuo to give amine 32 in excellent yield (orange liquid, 1.72 g, 6.8 mmol, 94% 
from aldehyde 14). 
 
δH (400 MHz, CDCl3): 0.92 (6H, d, J = 6.6 Hz, CH(CH3)2), 1.65 (2H, appq, 
J = 6.6 Hz, OCH2CH2), 1.78 (1H, appsept, J = 6.7 Hz, CH(CH3)2), 2.4 (3H, s, 
NCH3), 3.7 (2H, s, CH2N), 4.06 (2H, t, J = 6.6 Hz, OCH2), 6.93 (1H, d, J = 8.4 Hz, 
one of C6H3), 7.03 (1H, d, J = 7.8 Hz, one of C6H3), 7.35 (1H, dd, J = 8.2 and 7.9 
Hz, one of C6H3) 
δC (100 MHz, CDCl3): 22.5 (CH(CH3)2), 24.9 (CH(CH3)2), 36.1 (NCH3), 
37.6 (OCH2CH2), 51.3 (CH2N), 68.0 (OCH2), 112.3 (Ar-C), 121.3 (Ar-C), 130.9 (Ar-
C), 133.3 (Ar-Cq), 141.7 (Ar-Cq), 150.4 (Ar-Cq) 
m/z [CI (+ve)], 253.4 ([M+H]+, 100%); Found [M+H]+, 253.1551, 
C13H21N2O3 requires 253.1552 
ν max (CDCl3) / cm−1: 2958, 2874, 1535, 1284  
 
 
Methyl-[3-(3-methyl-butoxy)-2-nitro-benzyl]-carbamic acid tert-butyl ester 34 
 
NO2
O
N
Boc
NO2
O
N
H
32 34  
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To a stirred solution of amine 32 (5.06 g, 20.05 mmol, 1 eq) in dry DMF (200 cm3) 
was added triethylamine (5.6 ml, 4.06 g, 40.1 mmol, 2 eq) under an argon 
atmosphere. After being stirred for 20 minutes, the reaction solution was treated with 
di-tert-butyl-dicarbonate (5.7 g, 26.06 mmol, 1.3 eq). Stirring was continued at room 
temperature until completion of reaction as indicated by TLC analysis (2.5 hours).  
After this time, the reaction was quenched with water (150 cm3) and diluted with 
ethyl acetate (150 cm3). Then phases were separated and the aqueous layer was 
extracted with fresh ethyl acetate (2 x 150 cm3).  All the organic layers were 
combined, dried over anhydrous sodium sulphate, filtered off, and concentrated in 
vacuo. The remaining residue was purified by flash column chromatography (silica 
gel, eluting with 5% ethyl acetate in petroleum ether (40-60)) to give protected 
amine 34 as a pale yellow liquid (6.55 g, 18.6 mmol, 93%). 
 
δH (400 MHz, CDCl3, mixture of Boc rotamers, ratio: 1.3:1): 0.93 (6H, d, 
J = 6.6 Hz, CH(CH3)2), 1.42 (major) and 1.48 (minor) (9H, 2 x br. s, C(CH3)3), 1.65 
(2H, appq, J = 6.7 Hz, OCH2CH2), 1.78 (1H, appsept, J = 6.7 Hz, CH(CH3)2), 2.78 
(minor) and 2.83 (major) (3H, 2 x br. s, NCH3), 4.07 (2H, t, J = 6.5 Hz, OCH2), 4.4 
(2H,  br. s, CH2N), 6.86 (1H, m, one of C6H3), 6.93 (1H, d, J = 8.3 Hz, one of C6H3), 
7.36 (1H, t, J = 8.1 Hz, one of C6H3) 
δH (400 MHz, CDCl3, 55ºC): 0.95 (6H, br. d, J = 6.5 Hz, CH(CH3)2), 1.46 
(9H, br. s, C(CH3)3), 1.67 (2H, br. q, J = 6.4 Hz, OCH2CH2), 1.8 (1H, br. appsept,  
J = 6.9 Hz, CH(CH3)2), 2.82 (3H, br. s, NCH3), 4.08 (2H, br. t,  
J = 5.9 Hz, OCH2), 4.41 (2H, br. s, CH2N), 6.89 (1H, br. d, J = 7.0 Hz, one of C6H3), 
6.94 (1H, d, J = 8.1 Hz, one of C6H3), 7.35 (1H, br. dd, J = 8.1 and 7.8 Hz, one of 
C6H3) 
δC (100 MHz, CDCl3, 55ºC): 22.5 (CH(CH3)2), 25.2 (CH(CH3)2), 28.5 
(C(CH3)3), 34.4 (NCH3), 37.8 (OCH2CH2), 48.0 (CH2N), 68.5 (OCH2), 80.3 
(C(CH3)3), 112.7 (Ar-C), 119.8 (Ar-C), 131.0 (Ar-C), 131.9 (Ar-Cq), 150.7 (NCO2), 
2 x Cq unresolved 
m/z [CI (+ve)], 353.4 ([M+H]+, 12%), 297.3 ([(M+H)−tBu]+, 100%), 253.3 
([(M+H)−Boc]+, 48%);  Found [M+H]+, 353.2078, C18H29N2O5 requires 353.2076 
ν max (CDCl3) / cm−1: 2958, 2931, 2874, 1693, 1608, 1531, 1454, 1365  
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[2-Amino-3-(3-methyl-butoxy)-benzyl]-methyl-carbamic acid tert-butyl ester 10 
 
NH2
O
N
Boc
NO2
O
N
Boc
34 10  
 
A vacuum dried amine 34 (6.4 g, 18.2 mmol, 1 eq) was dissolved in methanol (110 
cm3) under an argon atmosphere. The resulting solution was then purged with argon 
for 20 minutes and a catalytic amount of 10% Pd/C was added to it. Reaction 
mixture was then immediately degassed under reduced pressure and refilled with 
hydrogen (three times), and stirring was continued overnight under hydrogen 
atmosphere. After this time the reaction mixture was diluted with ethyl acetate and 
filtered through a pad of celite and sand, which was washed with copious amount of 
ethyl acetate. The filtrate was collected and concentrated in vacuo to give aniline 10 
as orange liquid (5.9 g, 18.2 mmol, 100% yield), which was judged pure by NMR 
spectroscopy, and reacted further without purification. 
  
δH (400 MHz, CDCl3): 0.96 (6H, d, J = 6.6 Hz, CH(CH3)2), 1.48 (9H, br. s, 
C(CH3)3), 1.7 (2H, appq, J = 6.6 Hz, OCH2CH2), 1.85 (1H, appsept,  
J = 6.7 Hz, CH(CH3)2), 2.74 (3H, s, NCH3), 4.0 (2H, t, J = 6.6 Hz, OCH2), 4.36 (2H, 
s, CH2N), 6.57-6.61 (1H, m, one of C6H3), 6.66 (1H, dd, J = 7.6 and 1.5 Hz, one of 
C6H3), 6.74 (1H, dd, J = 7.9 and 1.5 Hz, one of C6H3) 
δC (100 MHz, CDCl3): 22.8 (CH(CH3)2), 25.2 (CH(CH3)2), 28.5 (C(CH3)3), 
33.1 (NCH3), 38.3 (OCH2CH2), 49.6 (CH2N), 66.7 (OCH2), 80.0 (C(CH3)3), 110.6 
(Ar-C), 115.9 (Ar-C), 123.5 (Ar-C), 136.4 (Ar-Cq), 146.6 (Ar-Cq), 156.5 (NCO2), 1 
x Cq unresolved 
m/z [EI (+ve)], 322.2 ([M]+, 80%), 266.2 ([M−tBu]+, 53%), 222.2 
([M−Boc]+, 71%); Found [M]+, 322.2255, C18H30O3N2 requires 322.2256 
ν max (CDCl3) / cm−1: 3483, 3352, 2958, 2931, br. 1674, br. 1477, 1238  
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Dimethyl 2-(2-((tert-butoxycarbonyl(methyl)amino)methyl)-6- 
(isopentyloxy)phenylamino)maleate 11 
 
NH2
O
N
Boc
N
HO
N
CO2CH3
CO2CH3
Boc
10 11  
 
A flask equipped with reflux condenser was charged with solution of amine 10 (0.1 
g, 0.31 mmol, 1 eq) in methanol (3 cm3) under an argon atmosphere. Then DMAD 
(0.06 ml, 0.07 g, 0.5 mmol, 1.6 eq) was added and resulting reaction mixture was 
refluxed until TLC analysis indicated complete consumption of starting material (4 
hours). Heating bath was removed, reaction was allowed to cool to room temperature 
and solvent was removed in vacuo. The remaining residue was purified by flash 
column chromatography (silica gel, gradient elution, eluting with 100% petroleum 
ether (40-60) to 5% ethyl acetate in petroleum ether (40-60)) to give amine 11 as 
yellow oil (0.116 g, 0.25 mmol, 80% yield ). 
 
δH (400 MHz, CDCl3): 0.9 (6H, d, J = 6.6 Hz, CH(CH3)2), 1.45 (9H, br. s, 
C(CH3)3), 1.57 (2H, appq, J = 6.7 Hz, OCH2CH2), 1.73 (1H, appsept, J = 6.7 Hz, 
CH(CH3)2), 2.81 (3H, br. s, NCH3), 3.6 (3H, s, CO2CH3), 3.73 (3H, s, CO2CH3), 
3.86 (2H, t, J = 6.7 Hz, OCH2), 4.52 (2H, br. s, CH2N), 5.45 (1H, s, HNC=CH), 6.75 
(1H, dd, J = 8.2 and 1.0 Hz, one of C6H3), 6.79-6.81 (1H, m, one of C6H3), 7.08 (1H, 
t, J = 7.9 Hz, one of C6H3), 9.2 (1H, s, NHC=CH) 
δC (100 MHz, CDCl3): 22.6 (CH(CH3)2), 25.1 (CH(CH3)2), 28.5 (C(CH3)3), 
34.0 (NCH3), 37.7 (OCH2CH2), 48.6 (CH2N), 51.1 (CO2CH3), 52.2 (CO2CH3), 67.6 
(OCH2), 79.7 (C(CH3)3), 90.3 (HNC=CH), 111.3 (Ar-C), 119.8 (Ar-C), 126.1  
(Ar-C), 128.2 (Ar-Cq), 133.6 (Ar-Cq), 153.2 (Ar-Cq), 163.7 (CO2CH3), 170.6 
(CO2CH3), 2 x Cq unresolved 
m/z [CI (+ve)], 465.5 ([M+H]+, 100%), 323.4 
([M+H−(CO2Me)CCH(CO2Me)]+), 51%); Found [M+H]+, 465.2603, C24H37N2O7 
requires 465.2601 
ν max (CDCl3) / cm−1: 2955, 2931, 2872, 1741, 1697, 1674, 1612, 1271, 1215,  
1139  
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(±)-Dimethyl 2-(2-((tert-butoxycarbonyl(methyl)amino)methyl)-6-
(isopentyloxy)phenylamino)succinate 12 
 
N
HO
N
CO2CH3
CO2CH3
Boc
N
HO
N
CO2CH3
CO2CH3
Boc
11 12  
 
A vacuum-dried amine 11 (0.097 g, 0.21 mmol, 1 eq) was dissolved in methanol (5 
cm3) under an argon atmosphere. Resulting solution was purged with argon for 20 
minutes, and a catalytic amount of Pd(OH)2 (20 wt. %) was added to it.  Reaction 
mixture was then immediately degassed under reduced pressure and refilled with 
hydrogen (three times), and stirring was continued overnight under hydrogen 
atmosphere.  After this time the reaction mixture was diluted with diethyl ether (15 
cm3), and filtered through a pad of celite and sand, which was washed with copious 
amount of diethyl ether. The filtrate was collected and concentrated in vacuo. Crude 
amine 12, obtained as very viscous yellow oil, was subsequently used in synthesis 
without purification (0.09 g, 0.19 mmol, 90% yield).  
 
δH (400 MHz, CDCl3, 55ºC): 0.98 (6H, d, J = 6.6 Hz, CH(CH3)2), 1.48 (9H, 
s, C(CH3)3), 1.72 (2H, appq, J = 6.7 Hz, OCH2CH2), 1.83 (1H, appsept, J = 6.7 Hz, 
CH(CH3)2), 2.75 (3H, s, NCH3), 2.81 (2H, br. s, NHCHCH2), 3.65 (3H, br. s, 
CO2CH3), 3.66 (3H, br. s, CO2CH3), 3.99 (2H, t, J = 6.7 Hz, OCH2), 4.36 (1H, br. d, 
J = 15.2 Hz, one of CH2N), 4.6 (1H, br. s, NHCH), 4.63 (1H, d, J = 15.2, one of 
CH2N), 6.7 (1H, appd, J = 7.5 Hz, one of C6H3), 6.77 (1H, appd, J = 7.9, one of 
C6H3), 6.85 (1H, appt, J = 7.8 Hz, one of C6H3) 
 
δC (100 MHz, CDCl3, 55ºC): 22.7 (CH(CH3)(CH3)), 22.8 (CH(CH3)(CH3)), 
25.4 (CH(CH3)2), 28.6 (C(CH3)3), 33.6 (NCH3), 38.2 and 38.4 (OCH2CH2 and 
NHCHCH2), 49.0 (CH2N), 51.7 (CO2CH3), 52.0 (CO2CH3), 56.6 (NHCH), 67.3 
(OCH2), 79.9 (C(CH3)3), 111.7 (Ar-C), 121.6 (Ar-C), 121.7 (Ar-C), 151.3  (Cq), 
156.3  (Cq), 171.2 (CO2CH3), 173.4 (CO2CH3), 2 x Cq unresolved 
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m/z [CI (+ve)], 467.2 ([M+H]+, 70%); Found [M+H]+, 467.2761, C24H39N2O7 
requires 467.2757 
ν max (CDCl3) / cm−1: 3329, 2955, 2933, 2872, 1739, 1693, 1674, 1166, 1143  
 
 
(±)-Dimethyl 2-(2-(isopentyloxy)-6-
((methylamino)methyl)phenylamino)succinate 13 
 
N
HO
N
CO2CH3
CO2CH3
Boc
N
HO
NH
CO2CH3
CO2CH3
12 13  
 
A vacuum dried amine 12 (0.09 g, 0.19 mmol, 1 eq) was dissolved in dry DCM (2 
cm3) under an argon atmosphere, and subsequently treated with trifluoroacetic acid 
(0.015 ml, 0.022 g, 0.19 mmol, 1 eq). Resulting reaction mixture was stirred at room 
temperature until completion as indicated by TLC analysis (20 hours). After this 
time solvent was removed in vacuo, the remaining residue was taken up in fresh 
diethyl ether (5 cm3) and washed with water (5 cm3). Phases were separated and the 
organic layer was dried over anhydrous sodium sulphate, filtered off, and 
concentrated in vacuo to give amine 13 as yellow oil (0.055 g, 0.15 mmol, 82% 
yield). Amine 13 was used in the synthesis without purification. 
 
δH (400 MHz, CDCl3): 0.94 (3H, d, J = 6.6 Hz, CH(CH3)(CH3)), 0.95 (3H, 
d, J = 6.6 Hz, CH(CH3)(CH3)), 1.65 (2H, appq, J = 6.7 Hz, OCH2CH2), 1.76 (1H, 
appsept, J = 6.6 Hz, CH(CH3)2), 2.61 (3H, s, NHCH3), 2.88 (1H, dd, J = 16.9 and 5.3 
Hz, one of NHCHCH2), 2.96 (1H, dd, J = 16.9 and 5.3 Hz, one of NHCHCH2), 3.69 
(3H, s, CO2CH3), 3.72 (3H, s, CO2CH3), 3.88-4.0 (2H, m, OCH2), 4.2-4.31 (3H, m, 
CH2NH and NHCH), 6.86 (1H, dd, J = 6.0 and 3.6 Hz, one of C6H3), 6.99-7.01 (2H, 
m, two of C6H3) 
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δC (100 MHz, CDCl3): 22.6 (CH(CH3)2), 25.1 (CH(CH3)2), 32.1 (NHCH3), 
37.0 (NHCHCH2), 37.9 (OCH2CH2), 49.7 (CH2NH), 52.2 (CO2CH3), 53.0 
(CO2CH3), 57.1 (NHCH), 67.2 (OCH2), 113.3 (Ar-C), 124.1 (Ar-C), 124.6 (Ar-C), 
124.6 (Ar-Cq), 134.3 (Ar-Cq), 152.9 (Ar-Cq), 171.8 (CO2CH3), 174.0 (CO2CH3) 
m/z [FAB (+ve)], 367.4 ([M+H]+, 100%), 221.6 
([M+H]−CH(CO2CH3)CH2(CO2CH3)]+, 77%); Found [M+H]+, 367.2236, 
C19H31N2O5 requires 367.2233 
ν max (CDCl3) / cm−1: br. 3342, 2955, 2872, 1735, 1469, 1257, 1222 
 
 
(±)-Methyl 2-(9-(isopentyloxy)-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-
benzo[e][1,4]diazepin-2-yl)acetate 2 
 
O
N
H
N
O
CO2CH3NHO
NH
CO2CH3
CO2CH3
13 2  
 
Flask equipped with reflux condenser was charged with amine 13 (0.2 g, 0.55 mmol, 
1 eq) and methanol (5 cm3). The solution was purged with argon for 20 minutes and 
then treated with sodium methoxide (25 wt. % in methanol, 0.26 ml, 0.06 g, 1.1 
mmol, 2 eq) under an argon atmosphere. Resulting reaction mixture was refluxed 
until TLC analysis indicated complete consumption of starting material 13 (4 hour). 
The heating bath was removed, and the reaction was quenched with water (5 cm3), 
diluted with ethyl acetate (10 cm3) and stirred for 20 minutes at room temperature. 
The phases were separated, and the aqueous layer was extracted with fresh ethyl 
acetate (2 x 10 cm3). The combined organic fractions were washed with brine (30 
cm3), dried over anhydrous sodium sulphate, filtered off, and concentrated in vacuo 
The remaining residue was purified by flash column chromatography (silica gel, 
gradient elution, eluting with 100% petroleum ether (40-60) to 30% ethyl acetate in 
petroleum ether (40-60)) to give the benzodiazepine 2 as orange viscous oil (0.11 g, 
0.34 mmol, 62%). 
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δH (400 MHz, CDCl3): 0.95 (6H, d, J = 6.6 Hz, CH(CH3)2), 1.66 (2H, appq, 
J = 6.6 Hz, OCH2CH2), 1.8 (1H, appsept, J = 6.6 Hz, CH(CH3)2), 2.67 (1H, dd, J = 
15.9 and 6.3 Hz, one of NHCHCH2), 3.04 (1H, dd, J = 15.9 and 7.4 Hz, one of 
NHCHCH2), 3.05 (3H, s, NCH3), 3.7 (1H, d, J = 16.3 Hz, one of CH2N), 3.72 (3H, s, 
CO2CH3), 3.93-3.99 (2H, m, OCH2), 4.41 (1H, d, J = 4.7 Hz, NHCH), 5.04-5.09 
(1H, m, NHCH), 5.46 (1H, d, J = 16.3 Hz, one of CH2N), 6.54 (1H, dd, J = 7.6 and 
2.2 Hz, one of C6H3), 6.56-6.59 (1H, m, one of C6H3), 6.7 (1H, dd, J = 7.3 and 2.2 
Hz, one of C6H3) 
δC (100 MHz, CDCl3): 22.7 (CH(CH3)2), 25.2 (CH(CH3)2), 34.7 (NCH3), 
36.3 (NHCHCH2), 38.0 (OCH2CH2), 51.5 (NHCH), 52.0 (CO2CH3), 53.1 (CH2N), 
66.9 (OCH2), 110.6 (Ar-C), 116.8 (Ar-C), 119.3 (Ar-Cq), 121.3 (Ar-C), 135.0 (Ar-
Cq), 146.6 (Ar-Cq), 169.6 (CO), 171.8 (CO) 
m/z [EI (+ve)], 334.3 ([M]+, 100%); Found [M]+, 334.1891, C18H26O4N2 
requires 334.1893 
ν max (CDCl3) / cm−1: 2955, 1739, 1666, 1489  
 
 
(S)-2-Trifluoromethanesulfonyloxy-succinic acid dimethyl ester 36 
 
O
O
O
OHO H
O
O
O
OTfO H
35 36  
 
To a stirred solution of dimethyl (S)-(−)-malate 35 (4.2 ml, 5.2 g, 32 mmol, 1 eq) in 
dry dichloromethane (400 cm3) at −78 °C was added 2,6-lutidine (7.1 ml, 6.5 g, 61 
mmol, 1.9 eq) under an argon atmosphere. Resulting reaction solution was stirred for 
15 minutes at −78 °C, and then treated with trifluoromethanesulfonic anhydride (11 
ml, 18 g, 64 mmol, 2 eq). Stirring was continued at −78 °C until completion of 
reaction as indicated by TLC analysis (2 hours). After this time a cooling bath was 
removed, the reaction was quenched with water (250 cm3), and biphasic mixture was 
stirred until reaching room temperature. The phases were separated and the organic 
phase was washed with saturated aqueous CuSO4 (2 x 300 cm3), dried over 
anhydrous sodium sulphate, filtered off, and concentrated in vacuo to gave crude 
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triflate 36 as a pale brown oil (9.4 g, 32 mmol, 100% yield, 100% conversion by 
NMR), which was judged clean by NMR and used in synthesis without purification.  
 
δH (400 MHz, CDCl3): 3.06 (2H, d, J = 5.8 Hz, CH2CH), 3.76 (3H, s, CH3), 
3.88 (3H, s, CH3), 5.49 (1H, t, J = 5.8 Hz, CH2CH) 
δC (100 MHz, CDCl3): 36.7 (CH2CH), 52.7 (CH3), 53.8 (CH3), 78.6 
(CH2CH), 166.6 (CO2CH3), 168.0 (CO2CH3) 
m/z [CI (+ve)], 295.2 ([M+H]+, 100%); Found [M+H]+, 295.0098, 
C7H10O7F3S requires 295.0099 
[α]D24 −45.2 (c 1, CHCl3) 
ν max (CDCl3) / cm−1: 2357, 2333, br. 1747, 1419, 1211, 1141  
 
 
(R)-dimethyl 2-(2-((tert-butoxycarbonyl(methyl)amino)methyl)-6-
(isopentyloxy)phenylamino)succinate 37 
 
NH2
O
N
Boc
O
O
O
OTfO H
+
N
HO
N
CO2CH3
Boc
CO2CH3
3610 37  
 
A flask equipped with reflux condenser was charged with aniline 10 (6.0 g, 18.6 
mmol, 1 eq) and dry dichloromethane (200 cm3) under an argon atmosphere. While 
the solution was stirred, triflate 36 (9.4 g, 32 mmol, 1.7 eq) was added to it dropwise 
via cannula, followed by subsequent addition of 2,6-lutidine (4.1 ml, 3.8 g, 35.4 
mmol, 1.9 eq). The resulting brown reaction solution was heated at 50 °C until TLC 
analysis indicated complete consumption of starting material 10 (5 hours). After this 
time the oil bath was removed, the reaction was quenched with water (200 cm3) and 
stirred for 20 minutes at room temperature. The phases were separated and the 
aqueous layer was extracted with fresh dichloromethane (200 cm3). All the organic 
layers were combined, washed with saturated aqueous CuSO4 (2 x 350 cm3), dried 
over anhydrous sodium sulphate, filtered off and the solvent was removed in vacuo 
to give aniline 37 as brown viscous oil (8.7 g, 18.6 mmol, 100% yield), which was 
reacted further without need of purification. 
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δH (400 MHz, CDCl3, 55ºC): 0.98 (6H, d, J = 6.6 Hz, CH(CH3)2), 1.48 (9H, 
s, C(CH3)3), 1.72 (2H, appq, J = 6.7 Hz, OCH2CH2), 1.83 (1H, appsept, J = 6.7 Hz, 
CH(CH3)2), 2.75 (3H, s, NCH3), 2.81 (2H, br. s, NHCHCH2), 3.65 (3H, br. s, 
CO2CH3), 3.66 (3H, br. s, CO2CH3), 3.99 (2H, t, J = 6.7 Hz, OCH2), 4.36 (1H, br. d, 
J = 15.2 Hz, one of CH2N), 4.6 (1H, br. s, NHCH), 4.63 (1H, d, J = 15.2, one of 
CH2N), 6.7 (1H, appd, J = 7.5 Hz, one of C6H3), 6.77 (1H, appd, J = 7.9, one of 
C6H3), 6.85 (1H, appt, J = 7.8 Hz, one of C6H3) 
δC (100 MHz, CDCl3, 55ºC): 22.7 (CH(CH3)(CH3)), 22.8 (CH(CH3)(CH3)), 
25.4 (CH(CH3)2), 28.6 (C(CH3)3), 33.6 (NCH3), 38.2 and 38.4 (OCH2CH2 and 
NHCHCH2), 49.0 (CH2N), 51.7 (CO2CH3), 52.0 (CO2CH3), 56.6 (NHCH), 67.3 
(OCH2), 79.9 (C(CH3)3), 111.7 (Ar-C), 121.6 (Ar-C), 121.7 (Ar-C), 151.3  (Cq), 
156.3  (Cq), 171.2 (CO2CH3), 173.4 (CO2CH3), 2 x Cq unresolved 
m/z [CI (+ve)], 467.2 ([M+H]+, 70%); Found [M+H]+, 467.2761, C24H39N2O7 
requires 467.2757 
[α]D24 +27.7 (c 1, CHCl3) 
ν max (CDCl3) / cm−1: 3329, 2955, 2933, 2872, 1739, 1693, 1674, 1166, 1143  
 
 
(R)-dimethyl 2-(2-(isopentyloxy)-6-
((methylamino)methyl)phenylamino)succinate 38 
 
N
HO
N
CO2CH3
Boc
CO2CH3
N
HO
NH
CO2CH3
CO2CH3
37 38  
 
A vacuum dried amine 37 (0.07 g, 0.15 mmol, 1 eq) was dissolved in a 5% solution 
of HCl in ethyl acetate (2 cm3). After stirring for 1.5 hours, TLC analysis indicated 
complete consumption of the starting material 37. Reaction was quenched with 5% 
aqueous NaHCO3 (5 cm3), diluted with ethyl acetate (5 cm3), and stirred for next 10 
minutes. After this time the phases were separated, the organic phase was collected, 
washed with water (5 cm3), dried over anhydrous sodium sulphate, filtered off, and 
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concentrated in vacuo to give aniline 38 as yellow oil (0.05 g, 0.15 mmol, 100% 
yield), which was judged clean based on NMR analysis.   
 
δH (400 MHz, CDCl3): 0.94 (3H, d, J = 6.6 Hz, CH(CH3)(CH3)), 0.95 (3H, 
d, J = 6.6 Hz, CH(CH3)(CH3)), 1.65 (2H, appq, J = 6.7 Hz, OCH2CH2), 1.76 (1H, 
appsept, J = 6.6 Hz, CH(CH3)2), 2.61 (3H, s, NHCH3), 2.88 (1H, dd, J = 16.9 and 5.3 
Hz, one of NHCHCH2), 2.96 (1H, dd, J = 16.9 and 5.3 Hz, one of NHCHCH2), 3.69 
(3H, s, CO2CH3), 3.72 (3H, s, CO2CH3), 3.88-4.0 (2H, m, OCH2), 4.2-4.31 (3H, m, 
CH2NH and NHCH), 6.86 (1H, dd, J = 6.0 and 3.6 Hz, one of C6H3), 6.99-7.01 (2H, 
m, two of C6H3) 
δC (100 MHz, CDCl3): 22.6 (CH(CH3)2), 25.1 (CH(CH3)2), 32.1 (NHCH3), 
37.0 (NHCHCH2), 37.9 (OCH2CH2), 49.7 (CH2NH), 52.2 (CO2CH3), 53.0 
(CO2CH3), 57.1 (NHCH), 67.2 (OCH2), 113.3 (Ar-C), 124.1 (Ar-C), 124.6 (Ar-C), 
124.6 (Ar-Cq), 134.3 (Ar-Cq), 152.9 (Ar-Cq), 171.8 (CO2CH3), 174.0 (CO2CH3) 
m/z [FAB (+ve)], 367.4 ([M+H]+, 100%), 221.6 
([M+H]−CH(CO2CH3)CH2(CO2CH3)]+, 77%); Found [M+H]+, 367.2236, 
C19H31N2O5 requires 367.2233 
[α]D20 +16.1 (c 1, CHCl3) 
ν max (CDCl3) / cm−1: br. 3342, 2955, 2872, 1735, 1469, 1257, 1222 
 
 
(R)-methyl 2-(9-(isopentyloxy)-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-
benzo[e][1,4]diazepin-2-yl)acetate 2a 
 
 
Procedure A 
 
N
HO
NH
CO2CH3
CO2CH3
O
N
H
N
O
CO2CH3
38 2a  
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Procedure B 
 
N
HO
N
CO2CH3
Boc
CO2CH3
O
N
H
N
O
CO2CH3
37 2a  
 
Procedure A 
Flask equipped with reflux condenser was charged with amine 38 (0.66 g, 1.8 mmol, 
1 eq) and methanol (15 cm3). The solution was purged with argon for 20 minutes and 
then treated with sodium methoxide (25 wt. % in methanol, 0.63 ml, 0.15 g, 2.7 
mmol, 1.5 eq) under an argon atmosphere. Resulting reaction mixture was refluxed 
until TLC analysis indicated complete consumption of starting material 38 (1 hour). 
The heating bath was removed, and the reaction was quenched with water (15 cm3), 
diluted with ethyl acetate (30 cm3) and stirred for 20 minutes at room temperature. 
The phases were separated, and the aqueous layer was extracted with fresh ethyl 
acetate (2 x 30 cm3). The combined organic fractions were washed with brine (60 
cm3), dried over anhydrous sodium sulphate, filtered off, and concentrated in vacuo 
to give the benzodiazepine 2a as orange viscous oil (0.51 g, 1.53 mmol, 85%). Prior 
to HPLC analysis, ester 2a was purified by flash column chromatography (silica gel, 
gradient elution, eluting with 100% DCM to 3% MeOH in DCM). 
 
Procedure B 
A vacuum dried amine 37 (8.1 g, 17.4 mmol, 1 eq) was dissolved in a 5% solution of 
HCl in ethyl acetate (150 cm3). After stirring for 2 hours, TLC analysis indicated 
complete consumption of the starting material 37. Reaction was quenched with 
saturated aqueous NaHCO3 (200 cm3), diluted with ethyl acetate (100 cm3), and the 
biphasic mixture was stirred for additional 20 minutes. After this time the phases 
were separated, and the aqueous phase was extracted with fresh ethyl acetate (2 x 
300 cm3). All the organic layers were combined, dried over anhydrous sodium 
sulphate, filtered off, and concentrated in vacuo. The remaining residue was purified 
by flash column chromatography (silica gel, gradient elution, eluting with 100% 
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DCM to 5% MeOH in DCM) to give the benzodiazepine 2a as orange viscous oil 
(2.46 g, 7.36 mmol, 43%). 
 
δH (400 MHz, CDCl3): 0.95 (6H, d, J = 6.6 Hz, CH(CH3)2), 1.66 (2H, appq, 
J = 6.6 Hz, OCH2CH2), 1.8 (1H, appsept, J = 6.6 Hz, CH(CH3)2), 2.67 (1H, dd,  
J = 15.9 and 6.3 Hz, one of NHCHCH2), 3.04 (1H, dd, J = 15.9 and 7.4 Hz, one of 
NHCHCH2), 3.05 (3H, s, NCH3), 3.7 (1H, d, J = 16.3 Hz, one of CH2N), 3.72 (3H, s, 
CO2CH3), 3.93-3.99 (2H, m, OCH2), 4.41 (1H, d, J = 4.7 Hz, NHCH), 5.04-5.09 
(1H, m, NHCH), 5.46 (1H, d, J = 16.3 Hz, one of CH2N), 6.54 (1H, dd, J = 7.6 and 
2.2 Hz, one of C6H3), 6.56-6.59 (1H, m, one of C6H3), 6.7 (1H, dd, J = 7.3 and 2.2 
Hz, one of C6H3) 
δC (100 MHz, CDCl3): 22.7 (CH(CH3)2), 25.2 (CH(CH3)2), 34.7 (NCH3), 
36.3 (NHCHCH2), 38.0 (OCH2CH2), 51.5 (NHCH), 52.0 (CO2CH3), 53.1 (CH2N), 
66.9 (OCH2), 110.6 (Ar-C), 116.8 (Ar-C), 119.3 (Ar-Cq), 121.3 (Ar-C), 135.0 (Ar-
Cq), 146.6 (Ar-Cq), 169.6 (CO), 171.8 (CO) 
m/z [EI (+ve)], 334.3 ([M]+, 100%); Found [M]+, 334.1891, C18H26O4N2 
requires 334.1893 
[α]D20 +58.8 (c 1, CHCl3) 
ν max (CDCl3) / cm−1: 2955, 1739, 1666, 1489  
 
 
 
[(R)-4-Methyl-9-(3-methyl-butoxy)-3-oxo-2,3,4,5-tetrahydro-1H-
benzo[e][1,4]diazepin-2-yl]-acetic acid 59 
 
O
N
H
N
O
CO2HO
N
H
N
O
CO2CH3
2a 59  
 
An ester 2a (0.37 g, 1.11 mmol, 1 eq) was dissolved in dry diethyl ether (10 cm3) 
under an argon atmosphere. Resulting solution was purged with argon for 20 
minutes, cooled to 0 ºC and potassium trimethylsilanolate (0.71 g, 5.55 mmol, 5 eq) 
was added to it. The resulting suspension was stirred at 0 ºC for 10 minutes and then 
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at room temperature until TLC analysis indicated complete consumption of starting 
material 2a (4.5 hours). The reaction mixture was cooled back to 0 ºC and 1N HCl (1 
ml) was added dropwise. Stirring was continued for 5 minutes at 0 ºC. After this 
time the cooling bath was removed, and water (10 cm3) was added to the reaction. 
The phases were separated, the aqueous layer was acidified to pH 2 with 2N HCl, 
and extracted with fresh diethyl ether (2 x 10 cm3). The organic phases were 
combined, dried over anhydrous sodium sulphate, filtered off, and solvents were 
removed in vacuo. The remaining residue was purified by flash column 
chromatography (silica gel, gradient elution, eluting with 20% ethyl acetate in 
petroleum ether (40-60) to 70% ethyl acetate in petroleum ether (40-60)) to give acid 
59 as yellow foam (0.344 g, 1.07 mmol, 97%). 
 
δH (400 MHz, CDCl3): 0.94 (6H, d, J = 6.7 Hz, CH(CH3)2), 1.66 (2H, appq, 
J = 6.6 Hz, OCH2CH2), 1.79 (1H, appsept, J = 6.7 Hz, CH(CH3)2), 2.75 (1H, dd, J = 
15.9 and 5.8 Hz, one of CH2CO2H), 3.05 (1H, dd, J = 15.9 and 7.5 Hz, one of 
CH2CO2H), 3.08 (3H, s, NCH3), 3.71 (1H, d, J = 16.4, one of CH2N), 3.93-3.99 (2H, 
m, OCH2), 5.07 (1H, dd, J = 7.2 and 5.9 Hz, NHCH), 5.46 (1H, d, J = 16.3 Hz, one 
of CH2N), 6.54 (1H, dd, J = 7.7 and 1.6 Hz, one of C6H3), 6.59 (1H, appt, J = 7.7, 
one of C6H3), 6.71 (1H, dd, J = 7.7 and 1.6 Hz, one of C6H3) 
δC (100 MHz, CDCl3): 22.67 (CH(CH3)(CH3)), 22.69 (CH(CH3)(CH3)), 25.2 
(CH(CH3)2), 34.9 (NCH3), 36.5 (CH2CO2H), 37.9 (OCH2CH2), 51.4 (NHCH), 53.3 
(CH2N), 66.9 (OCH2), 110.7 (Ar-C), 117.0 (Ar-C), 119.0 (Ar-Cq), 121.3 (Ar-C), 
134.8 (Ar-Cq), 146.7 (Ar-Cq), 170.1 (NCO), 175.1 (CO2H) 
m/z [CI (+ve)], 321.2 ([M+H]+, 100%); Found [M+H]+, 321.1810, 
C17H25N2O4 requires 321.1814 
[α]D19 +104.8 (c 1, CHCl3) 
ν max (CDCl3) / cm−1: 3400-2500, 3406, 2955, 2928, 1716, 1660, 1639, 1491,  
1253  
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(R)-2-(dimethylamino)phenyl 2-(9-(isopentyloxy)-4-methyl-3-oxo-2,3,4,5-
tetrahydro-1H-benzo[e][1,4]diazepin-2-yl)acetate 61 
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H
N
O
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+ O
N
H
N
O
O
O
N
α
α
α
β β
β
β
59 54 61  
 
A flask, protected from light with aluminium foil, was charged with phenol 54 
(0.048 g, 0.35 mmol, 1 eq) and kept under vacuum for 1 hour. After the flask was 
refilled with argon, phenol 54 was dissolved in dry DCM (3 cm3). Resulting solution 
was purged with argon for 20 minutes, cooled to 0 °C and DMAP (0.04 g, 0.35 
mmol, 1 eq), and EDC (0.1 g, 0.53 mmol, 1.5 eq) were successively added. 
Resulting reaction mixture was stirred at 0 °C for 5 minutes. In a separate flask 
vacuum dried acid 59 (0.17 g, 0.53 mmol, 1.5 eq) was dissolved in dry DCM (3 cm3) 
and then transferred via cannula to the reaction mixture over 5 minutes. Stirring was 
continued at 0 °C for additional 10 minutes, and then overnight at room temperature. 
After this time TLC analysis confirmed complete consumption of phenol 54. The 
reaction was quenched with water (5 cm3) and resulting biphasic mixture was stirred 
for 20 minutes. The layers were separated, and aqueous layer was extracted with 
fresh DCM (2 x 5 cm3). Combined organic layers were dried over anhydrous sodium 
sulphate, filtered off, and the solvent was removed in vacuo. The remaining residue 
was purified by flash column chromatography (silica gel, gradient elution, eluting 
with 100% petroleum ether (40-60) to 30% ethyl acetate in petroleum ether (40-60)) 
to give ester 61 as pale yellow oil (0.05 g, 0.11 mmol, 31%). 
 
 δH (400 MHz, CDCl3): 0.92 (3H, d, J = 6.6 Hz, CH(CH3)(CH3)), 0.93 (3H, 
d, J = 6.6 Hz, CH(CH3)(CH3)), 1.63-1.68 (2H, m, OCH2CH2), 1.78 (1H, appsept.,  
J = 6.7 Hz, CH(CH3)2), 2.76 (6H, s, N(CH3)2), 2.96 (1H, dd, J = 16.0 and 6.7 Hz, one 
of NHCHCH2), 3.09 (3H, s, CH2NCH3), 3.35 (1H, dd, J = 16.0 and 7.0 Hz, one of 
NHCHCH2), 3.73 (1H, d, J = 16.5 Hz, one of CH2N), 3.93-4.02 (2H, m, OCH2), 4.51 
(1H, br. d, J = 4.7 Hz, NHCH), 5.18-5.23 (1H, m, NHCHCH2), 5.48 (1H, d, J = 16.3 
Hz, one of CH2N), 6.56-6.62 (2H, m, two of CH(Cα)), 6.72 (1H, dd, J = 7.5 and 1.8 
 142
Hz, one of CH(Cα)), 6.92-6.96 (1H, m, one of CH(Cβ)), 7.0 (1H, dd, J = 8.1 and 1.5 
Hz, one of CH(Cβ)), 7.06 (1H, dd, J = 8.0 and 1.5 Hz, one of CH(Cβ)), 7.13-7.18 
(1H, m, one of CH(Cβ)) 
 δC (100 MHz, CDCl3): 22.7 (CH(CH3)(CH3)), 22.75 (CH(CH3)(CH3)), 25.3 
(CH(CH3)2), 34.8 (CH2NCH3), 36.8 (NHCHCH2), 38.0 (OCH2CH2), 43.4 (N(CH3)2), 
51.8 (NHCH), 53.2 (CH2N), 67.0 (OCH2), 110.7 (Ar-C(Cα)), 117.0 (Ar-C(Cα)), 
119.0 (Ar-C(Cβ)), 119.5 (Ar-Cq), 121.4 (Ar-C(Cα)), 121.8 (Ar-C(Cβ)), 123.6 (Ar-
C(Cβ)), 126.7 (Ar-C(Cβ)), 135.1 (Ar-Cq), 143.4 (Ar-Cq), 145.4 (Ar-Cq), 146.8 (Ar-
Cq), 169.5 (CO), 169.7 (CO) 
m/z [CI (+ve)], 440.5 ([M+H]+, 5%) 275.4 ([M+H]–(CO2)C6H4(N(CH3)2))]+, 
31%); Found [M+H]+, 440.2545, C25H34N3O4 requires 440.2549 
[α]D25 +71.6 (c 1, CHCl3) 
ν max (CDCl3) / cm−1: 3414, 2955, 2924, 2870, 1759, 1662, 1496  
  
 
(R)-2-(dimethylamino)-5-nitrophenyl 2-(9-(isopentyloxy)-4-methyl-3-oxo-2,3,4,5-
tetrahydro-1H-benzo[e][1,4]diazepin-2-yl)acetate 60 
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A flask, protected from light with aluminium foil, was charged with phenol 50 (0.01 
g, 0.05 mmol, 1 eq) and kept under vacuum for 1 hour. After the flask was refilled 
with argon, phenol 50 was dissolved in dry dichloromethane (1 cm3). Resulting 
solution was purged with argon, cooled to 0 °C, and DMAP (0.006 g, 0.05 mmol, 1 
eq) and EDC (0.014 g, 0.075 mmol, 1.5 eq) were successively added to it. Resulting 
reaction mixture was stirred at 0 °C for 5 minutes. In a separate flask vacuum dried 
acid 59 (0.024 g, 0.075 mmol, 1.5 eq) was dissolved in dry dichloromethane (1 cm3) 
and then transferred via cannula to the reaction mixture over 5 minutes. Stirring was 
continued at 0 °C for additional 10 minutes, and then overnight at room temperature. 
After this time TLC analysis confirmed complete consumption of phenol 50. The 
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reaction was quenched with water (2 cm3), and resulting biphasic mixture was stirred 
for further 20 minutes. The phases were separated and aqueous layer was extracted 
with fresh dichloromethane (2 x 3 cm3). Combined organic layers were dried over 
anhydrous sodium sulphate, filtered off, and the solvent was removed in vacuo. The 
remaining residue was purified by flash column chromatography (silica gel, gradient 
elution, eluting with 100% petroleum ether (40-60) to 30% ethyl acetate in 
petroleum ether (40-60)) to give ester 60 as fluorescent yellow liquid (0.02 g, 0.04 
mmol, 80% yield ). 
 
δH (400 MHz, CDCl3): 0.92 (3H, d, J = 6.6 Hz, CH(CH3)(CH3)), 0.93 (3H, 
d, J = 6.6 Hz, CH(CH3)(CH3)), 1.63-1.69 (2H, m, OCH2CH2), 1.78 (1H, appsept,  
J = 6.7 Hz, CH(CH3)2), 2.97 (1H, dd, J = 16.2 and 5.9 Hz, one of NHCHCH2), 3.05 
(6H, s, N(CH3)2), 3.09 (3H, s, CH2NCH3), 3.35 (1H, dd, J = 16.2 and 7.8 Hz, one of 
NHCHCH2), 3.74 (1H, d, J = 16.5 Hz, one of CH2N), 3.94-4.05 (2H, m, OCH2), 4.42 
(1H, d, J = 5.0 Hz, NHCH), 5.15-5.2 (1H, m, NHCH), 5.48 (1H, d, J = 16.3 Hz, one 
of CH2N), 6.58 (1H, dd, J = 7.7 and 1.5 Hz, one of CH(Cα)), 6.62 (1H, t, J = 7.7 Hz, 
one of CH(Cα)), 6.74 (1H, dd, J = 7.8 and 1.5 Hz, one of CH(Cα)), 6.82 (1H, d,  
J = 9.2 Hz, one of CH(Cβ)), 7.9 (1H, d, J = 2.6 Hz, one of CH(Cβ)), 8.02 (1H, dd,  
J = 9.2 and 2.6 Hz, one of CH(Cβ)) 
δC (100 MHz, CDCl3): 22.7 (CH(CH3)(CH3)), 22.8 (CH(CH3)(CH3)), 25.3 
(CH(CH3)2), 34.9 (CH2NCH3), 36.6 (NHCHCH2), 38.0 (OCH2CH2), 42.5 (N(CH3)2), 
51.6 (NHCH), 53.2 (CH2N), 67.0 (OCH2), 110.7 (Ar-C(Cα)), 115.9 (Ar-C(Cβ)), 
117.3 (Ar-C(Cα)), 119.6 (Ar-Cq), 120.8 (Ar-C(Cβ)), 121.4 (Ar-C(Cα)), 123.2 (Ar-
C(Cβ)), 134.7 (Ar-Cq), 138.5 (Ar-Cq), 138.8 (Ar-Cq), 146.8 (Ar-Cq), 150.0 (Ar-
Cq), 169.3 (2 x CO) 
m/z [FAB (+ve)], 485.4 ([M+H]+, 27%), 303.3 ([M+H] – 
(HO)C6H3(NO2)(N(CH3)2))]+, 100%); Found [M+H]+, 485.2399, C25H33N4O6 
requires 485.2400 
[α]D20 +16.4 (c 1, CHCl3) 
ν max (CDCl3) / cm−1: 2956, 2885, 2879, 1764, 1662, 1599, 1494, 1321  
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2-Methylamino-phenol 56 and 2-Dimethylamino-phenol 54 
 
N
OH
NH2
OH
N
H
OH
+
545653  
 
Procedure A 
To a solution of 2-aminophenol 53 (0.5 g, 4.58 mmol, 1 eq) in methanol (40 cm3), 
was added formaldehyde (37 wt. % in water, 0.9 ml, 0.34 g, 11.45 mmol, 2.5 eq). 
After stirring at room temperature for 0.5 hour, the reaction mixture was cooled to 
−15 °C and sodium borohydride (0.52 g, 13.74 mmol, 3 eq) was added to it in 
portions. The cooling bath was removed and stirring was continued overnight at 
room temperature. After this time, another portion of formaldehyde (0.9 ml, 0.34 g, 
11.45 mmol, 2.5 eq) was added to the reaction and stirring was continued for 0.5 
hour. Then reaction was cooled to −15 °C and second portion of sodium borohydride 
(0.52 g, 13.74 mmol, 3 eq) was added. The cooling bath was removed and the 
reaction was stirred at room temperature until completion as indicated by TLC 
analysis (6 hours). The reaction was quenched with water (40 cm3) and diluted with 
diethyl ether (80 cm3). The layers were separated, aqueous layer was acidified to 
pH=5 and extracted with fresh diethyl ether (2 x 80 cm3). The organic layers were 
combined, dried over anhydrous sodium sulphate, filtered off, and carefully 
concentrated in vacuo (product 54 proved to be volatile under reduced pressure). 
Aniline 54 was judged clean by NMR analysis and was used in synthesis without 
purification (0.63 g, 4.58 mmol, 100% yield). 
 
Procedure B 
To a stirred solution of 2-aminophenol 53 (0.2 g, 1.83 mmol, 1 eq) in dry DMF (10 
cm3) were added potassium bicarbonate (0.55 g, 5.49 mmol, 3 eq) and methyl iodide 
(0.25 ml, 0.57 g, 4.03 mmol, 2.2 eq) under an argon atmosphere. The resulting 
reaction mixture was stirred overnight at room temperature. After this time, the 
reaction was quenched with water (15 cm3) and diluted with ethyl acetate (20 cm3). 
After biphasic mixture was stirred for 20 minutes, the layers were separated and the 
aqueous phase was extracted with fresh ethyl acetate (2 x 20 cm3). The organic 
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layers were combined, washed with brine (60 cm3), dried over anhydrous sodium 
sulphate, filtered off, and solvents were removed in vacuo. The residue was purified 
by flash column chromatography (silica gel, gradient elution, eluting with 100% 
petroleum ether (40-60) to 10% ethyl acetate in petroleum ether (40-60))  to give 
compound 56 as a white solid (0.11 g, 0.9 mmol, 50% yield) and 54 as colourless oil 
(0.02 g, 0.15 mmol, <10% yield). 
 
Procedure C 
To a stirred solution of 2-aminophenol 53 (0.2 g, 1.83 mmol, 1 eq) in dry DMF (10 
cm3) were added cesium carbonate (2.38 g, 7.32 mmol, 4 eq) and methyl iodide 
(0.25 ml, 0.57 g, 4.03 mmol, 2.2 eq) under an argon atmosphere. The resulting 
reaction mixture was stirred overnight at room temperature. After this time, the 
reaction was quenched with water (15 cm3) and diluted with ethyl acetate (30 cm3). 
After biphasic mixture was stirred for 20 minutes, the layers were separated and the 
aqueous phase was extracted with fresh ethyl acetate (2 x 20 cm3). The organic 
layers were combined, washed with brine (60 cm3), dried over anhydrous sodium 
sulphate, filtered off, and solvents were removed in vacuo. NMR analysis of the 
crude material revealed the exclusive formation of undesired compound 56 (white 
solid, 0.22 g, 1.8 mmol, 100% yield) that wasn’t purified.  
 
Procedure D 
To a stirred acetic anhydride (2.2 ml, 2.38 g, 23.27 mmol, 1.2 eq) was added formic 
acid (1.32 ml, 1.61g, 34.91 mmol, 1.8 eq) under an argon atmosphere. The resulting 
solution was heated at 60 °C for 2 hours, allowed to cool to room temperature, 
diluted with dry THF (15 cm3), and then cooled back to 0 °C. 2-aminophenol 53 
(2.12 g, 19.39 mmol, 1 eq) in dry THF (15 cm3) was added, and stirring was 
continued at room temperature for 40 min. Volatile organic materials were removed 
in vacuo, the remaining residue was taken up in dry THF (50 cm3) and added to a 
vigorously stirred ice-cold suspension of lithium aluminium hydride (15 ml of 3.5 M 
solution in THF/toluene, 1.99 g, 52.32 mmol, 2.7 eq) in dry THF (20 cm3), all under 
an argon atmosphere. The solution was stirring overnight at room temperature. After 
this time, the resulting solution was cooled to 0 °C and quenched by dropwise 
addition of water (2 cm3), 15% aqueous NaOH (2 cm3), and another portion of water 
(6 cm3). The resulting suspension was allowed to warm to room temperature and 
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stirring was continued for 1 hour. The suspension was then diluted with diethyl 
ether, filtered through a pad of celite, and the filtrate was washed with copious 
amount of diethyl ether, followed by ethyl acetate, and 50% methanol in ethyl 
acetate. The solvent was removed in vacuo, and crude material was filtered through a 
pad of silica (gradient elution, eluting with 40% ethyl acetate in petroleum ether (40-
60) to 100% ethyl acetate) to give compound 56. Resulting compound 56 was taken 
directly to the next reaction. 
 
To a stirred acetic anhydride (0.64 cm3, 0.7 g, 6.72 mmol, 1.2 eq) was added formic 
acid (0.38 cm3, 0.46g, 10.08 mmol, 1.8 eq) under an argon atmosphere. The resulting 
solution was heated at 60 °C for 2 hours, allowed to cool to room temperature, 
diluted with dry THF (5 cm3), then cooled back to 0 °C. 2-Methylamino-phenol 56 
(0.69g, 5.6 mmol, 1 eq) in dry THF (15 cm3) was then added, and stirring was 
continued at room temperature for 1 hour. After the volatile organic materials were 
removed in vacuo, the remaining residue was taken up in dry THF (10 cm3) and 
added to a vigorously stirred ice-cold suspension of lithium aluminium hydride (3.84 
ml of 3.5 M solution in THF/toluene, 0.51 g, 13.44 mmol, 2.4 eq) in dry THF (10 
cm3) under an argon atmosphere. The resulting reaction was stirred overnight at 
room temperature. After this time, the reaction was cooled to 0 °C and quenched by 
dropwise addition of water (0.5 cm3), 15% aqueous NaOH (0.5 cm3), and another 
portion of water (1.5 cm3). The resulting suspension was allowed to warm to room 
temperature and stirring was continued for 2.5 hour. The suspension was then diluted 
with ethyl acetate (80 cm3) and added to water (80 cm3). The layers were separated 
and aqueous phase was extracted with fresh ethyl acetate (2 x 80 cm3). The organic 
layers were combined, washed with brine (200 cm3), dried over anhydrous sodium 
sulphate, filtered off, and solvents were removed in vacuo. The remaining residue 
was purified by flash column chromatography (silica gel, gradient elution, eluting 
with 100% petroleum ether (40-60) to 3% ethyl acetate in petroleum ether (40-60)) 
to give compound 54 as colourless oil (0.23 g, 1.66 mmol, 8.5% yield).  
 
2-Methylamino-phenol 56 
δH (400 MHz, DMSO): 2.72 (3H, s, NHCH3 ), 4.78 (1H, br. s, NHCH3), 
6.41-6.46 (2H, m, two of C6H4), 6.66-6.7 (2H, m, two of C6H4), 9.18 (1H, s, OH) 
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2-Dimethylamino-phenol 54 
δH (400 MHz, CDCl3): 2.67 (6H, s, N(CH3)2), 6.86 ( 1H, ddd, J = 7.6, 7.5 
and 1.5 Hz, one of C6H4), 6.94 (1H, dd, J = 8.0 and 1.5 Hz, one of C6H4), 7.04-7.08 
(1H, m, one of C6H4), 7.17 (1H, dd, J = 7.8 and 1.5 Hz, one of C6H4) 
δC (100 MHz, CDCl3): 45.3 (N(CH3)2), 114.2 (Ar-C), 120.1 (Ar-C), 120.8 
(Ar-C), 126.3 (Ar-C), 140.2 (Cq-N(CH3)2), 151.5 (Cq-OH) 
m/z [EI (+ve)], 137.12 ([M]+, 78%); Found [M]+, 137.0837, C8H11NO 
requires 137.0841 
 
 
Acetic acid 2-dimethylamino-phenyl ester 57 
 
N
OH
N
O
O
54 57  
 
To a  solution of phenol 54 (3.85 g, 28.1 mmol, 1 eq) in dry DCM (150 cm3) cooled 
to 0 °C were added pyridine (3.4 ml, 3.3 g, 42.15 mmol, 1.5 eq), catalytic amount of 
4-dimethylaminopyridine and acetic anhydride (4.0 ml, 4.3 g, 42.15 mmol, 1.5 eq). 
The cooling bath was removed and the resulting reaction mixture was stirred 
overnight at room temperature under an argon atmosphere. After this time reaction 
was cooled back to 0 °C and another portion of pyridine (2.3 ml, 2.2 g, 28.1 mmol, 1 
eq), catalytic amount of 4-dimethylaminopyridine and acetic anhydride (2.6 ml, 2.8 
g, 28.1 mmol, 1 eq) were added to it. Stirring was continued for 4 hours at room 
temperature. After this time organics were removed in vacuo, remaining residue was 
taken up in fresh DCM (150 cm3) and washed with saturated aqueous CuSO4 (2 x 
100 cm3). The phases were separated, the organic layer was collected, dried over 
anhydrous sodium sulphate, filtered off and the solvent was removed in vacuo to give 
acetate 57 (brown liquid, 3.79 g, 75%), which was judged clean based on NMR 
analysis and used in synthesis without purification.   
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δH (400 MHz, CDCl3): 2.32 (3H, s, C(O)CH3), 2.76 (6H, s, N(CH3)2), 6.93-
7.02 (3H, m, three of C6H4), 7.16 (1H, ddd, J = 8.0, 6.8 and 2.0 Hz, one of  C6H4)  
δC (100 MHz, CDCl3): 21.2 (C(O)CH3), 43.3 (N(CH3)2), 119.1 (Ar-C), 121.9 
(Ar-C), 123.4 (Ar-C), 126.7 (Ar-C), 143.6 (Ar-Cq), 145.5 (Ar-Cq), 169.3 (CO) 
m/z [EI (+ve)], 179.11 ([M]+, 47%), 137.10 ([M−COCH3]+, 100%); Found 
[M]+, 179.0943, C10H13NO2 requires 179.0946 
ν max (CDCl3) / cm−1: 2947, 2835, 2785, 1759, 1496, 1192  
 
 
Acetic acid 2-dimethylamino-5-nitro-phenyl ester 55 
 
O2N O
N
O
N
O
O
57 55  
 
Procedure A   
To a stirred solution of triphenylphosphine (0.88 g, 3.36 mmol, 1.2 eq) in dry MeCN 
(30 cm3) were added bromine (0.17 ml, 0.54 g, 3.36 mmol, 1.2 eq) and silver nitrate 
(0.57 g, 3.36 mmol, 1.2 eq) under argon atmosphere. While the resulting mixture 
was stirred, formation of white precipitate was observed. After stirring for 10 
minutes, the reaction was treated with a solution of acetate 57 (0.5 g, 2.8 mmol, 1 eq) 
in dry MeCN under argon atmosphere and stirring was continued for 25 minutes. 
After this time the reaction was diluted with DCM and filtered through filter paper to 
remove white precipitate, which was washed with copious amount of DCM. The 
filtrate was collected and concentrated in vacuo. The remaining residue was taken up 
in fresh DCM (20 cm3), washed with 5% aqueous NaHCO3 (20 cm3) and water (20 
cm3). The layers were separated, organic layer was collected, dried over anhydrous 
sodium sulphate, filtered off, and solvent was removed in vacuo. The residue was 
purified by flash column chromatography (silica gel, gradient elution, eluting with 
100% petroleum ether (40-60) to 20% ethyl acetate in petroleum ether (40-60)) to 
give compound 55 as viscous, dense orange oil (0.26 g, 1.15 mmol, 40%).  
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Procedure B 
A solution of acetate 57 (0.27 g, 1.51 mmol, 1 eq) in dry MeCN (7 cm3) was added 
dropwise via cannula to the stirred solution of cerium (IV) ammonium nitrate (0.83 
g, 1.51 mmol, 1 eq) in dry MeCN (7 cm3) under an argon atmosphere. Resulting 
reaction mixture was stirred at room temperature until TLC analysis indicated 
complete consumption of starting material 57 (4 hours). The reaction was quenched 
with saturated aqueous K2CO3 (15 cm3) and stirred for further 20 minutes. After this 
time layers were separated and the aqueous layer was extracted with fresh EtOAc (2 
x 15 cm3). All the organic phases were combined, dried over anhydrous sodium 
sulphate, filtered off, and concentrated in vacuo. The remaining residue was purified 
by flash column chromatography (silica gel, gradient elution, eluting with 100% 
petroleum ether (40-60) to 10% ethyl acetate in petroleum ether (40-60)) to give 
compound 55 as viscous orange oil (0.1 g,  0.45 mmol, 30% yield).  
  
δH (400 MHz, CDCl3): 2.33 (3H, s, C(O)CH3), 2.99 (6H, s, N(CH3)2), 6.83 
(1H, d, J = 9.2 Hz, one of C6H3), 7.83 (1H, d, J = 2.6 Hz, one of C6H3), 8.0 (1H, dd, 
J = 9.2 and 2.6 Hz, one of C6H3) 
δC (100 MHz, CDCl3): 21.0 (C(O)CH3), 42.3 (N(CH3)2), 116.1 (Ar-C), 120.6 
(Ar-C), 123.0 (Ar-C), 138.9 (Ar-Cq), 139.0 (Ar-Cq), 150.2 (Ar-Cq), 168.6 (CO) 
m/z [CI (+ve)], 225.2 ([M+H]+, 100%); Found [M+H]+, 225.0872, 
C10H13N2O4 requires 225.0875 
ν max (CDCl3) / cm−1: 2955, 2924, 2854, 1770, 1597, 1319, 1188  
 
 
2-Dimethylamino-5-nitro-phenol 50 
 
O2N OH
N
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55 50  
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Procedure A 
To a stirred solution of acetate 55 (0.26 g, 1.16 mmol, 1 eq) in methanol (15 cm3), 
was added sodium methoxide (25 wt. % in MeOH, 0.26 ml, 0.06 g, 1.16 mmol, 1 
eq). The resulting reaction solution was stirred at room temperature until TLC 
analysis indicated complete consumption of starting material 55 (40 minutes). After 
this time the reaction was quenched with water (30 cm3), diluted with ethyl acetate 
(50 cm3) and stirred for 20 minutes. The layers were separated and aqueous layer 
was extracted with fresh EtOAc (2 x 50 cm3). All the organic layers were combined, 
dried over anhydrous sodium sulphate, filtered off, and concentrated in vacuo. The 
remaining residue was purified by flash column chromatography (silica gel, gradient 
elution, eluting with 100% petroleum ether (40-60) to 10% ethyl acetate in 
petroleum ether (40-60)) to give phenol 50 as a red solid (0.1 g, 0.55 mmol, 48%). 
 
Procedure B 
Acetate 55 (0.063 g, 0.28 mmol, 1 eq) was added to a mixture of MeOH (4 cm3) and 
water (1 cm3). The resulting mixture was heated to 30 °C until starting material 55 
was fully dissolved. Then ammonium acetate (0.17 g, 2.24 mmol, 8 eq) was added to 
the reaction at room temperature and stirring was continued for 2 days. After this 
time the reaction was diluted with ethyl acetate (10 cm3), the layers were separated 
and the aqueous layer was extracted with fresh EtOAc (2 x 10 cm3). All the organic 
layers were combined, dried over anhydrous sodium sulphate, filtered off, and 
concentrated in vacuo. The remaining residue was purified by flash column 
chromatography (silica gel, gradient elution, eluting with 100% petroleum ether (40-
60) to 7% ethyl acetate in petroleum ether (40-60)) to give phenol 50 as a red solid 
(0.048 g, 0.26 mmol, 93%). 
 
δH (400 MHz, CDCl3): 2.75 (6H, s, N(CH3)2), 7.15 (1H, d, J = 8.6 Hz, one of 
C6H3), 7.76-7.77 (1H, m, one of C6H3), 7.78 (1H, dd, J = 8.6 and 2.6 Hz, one of 
C6H3) 
δC (100 MHz, CDCl3): 44.2 (N(CH3)2), 110.2 (Ar-C), 116.4 (Ar-C), 119.8 
(Ar-C), 147.2 (Ar-Cq), 150.7 (Ar-Cq), 1 x Cq unresolved 
m/z [EI (+ve)], 182.1 ([M]+, 30%); Found [M]+, 182.0689, C8H10N2O3 
requires 182.0691 
ν max (CDCl3) / cm−1: 3600-3200, 2956, 2922, 2850, 1591, 1521, 1498, 1323  
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mp. 66-72 °C 
 
 
3-Chloro-2-(isopentyloxy)benzoic acid 27 
 
Cl
CO2H
NO2
16 27
CO2H
O
Cl
 
 
A dispersion of  NaH in oil (60% (w/w) in mineral oil, 0.5 g, 12.4 mmol, 5 eq) was 
washed three times with petroleum ether under an argon atmosphere, dried under 
vacuum and suspended in dry DMF (40 cm3). After the suspension was cooled to  
−15 °C, a solution of 3-methyl-1-butanol (0.8 ml, 0.66 g, 7.4 mmol, 3 eq) was added 
to it dropwise via syringe. Resulting reaction mixture was stirred for 10 minutes at 
−15 °C and further 1 hour at room temperature. After this time, the reaction was 
cooled to −10 °C, and a solution of acid 16 (0.5 g, 2.48 mmol, 1 eq) in dry DMF (10 
cm3) was added dropwise via cannula. Resulting reaction mixture was stirred at −10 
°C for 0.5 hour and then overnight at room temperature. After this time reaction was 
quenched with ice-cold water (50 cm3) and diluted with ethyl acetate (80 cm3). The 
fractions were separated, an aqueous fraction was acidified to pH 2, and extracted 
with fresh ethyl acetate (2 x 80 cm3). All the organic phases were combined, washed 
with brine (200 cm3), dried over anhydrous sodium sulphate, filtered off, and 
solvents were removed in vacuo. The remaining acid 27 (brown liquid) was reacted 
further without purification.  
 
 
(3-chloro-2-(isopentyloxy)phenyl)methanol 31 
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A vacuum-dried acid 27 (0.57 g, 2.48 mmol, 1 eq) was dissolved in dry THF (50 
cm3) under an argon atmosphere. Resulting solution was cooled to 0 °C and treated 
with borane-tetrahydrofuran complex (1M in THF, 7.4 ml, 7.4 mmol, 3 eq). Cooling 
bath was removed and reaction mixture was stirred overnight at room temperature. 
After this time the reaction was cooled to 0 °C, carefully quenched with ice-cold 
water (50 cm3) and 2M HCl (20 ml), and diluted with ethyl acetate (100 cm3). 
Biphasic mixture was stirred for 20 minutes and then layers were separated. The 
aqueous phase was extracted with fresh ethyl acetate (2 x 100 cm3). All the organic 
layers were combined, dried over anhydrous sodium sulphate, filtered off, and 
solvents were removed in vacuo. The remaining residue was purified by flash 
column chromatography (silica gel, gradient elution, eluting with 100% petroleum 
ether (40-60) to 10% ethyl acetate in petroleum ether (40-60)) to give alcohol 31 as 
yellow oil (0.5 g, 2.3 mmol, 93% yield from 16). 
 
δH (400 MHz, CDCl3): 0.98 (6H, d, J = 6.6 Hz, CH(CH3)2), 1.72 (2H, appq, 
J = 6.7 Hz, OCH2CH2), 1.87 (1H, appsept., J = 6.7 Hz, CH(CH3)2), 2.18 (1H, t,  
J = 6.2 Hz, OH), 4.03 (2H, t, J = 6.8 Hz, OCH2), 4.71 (2H, br. d, J = 6.2 Hz, 
CH2OH), 7.04 (1H, appt, J = 7.8 Hz, one of C6H3), 7.25-7.27 (1H, m, one of C6H3), 
7.31 (1H, dd, J = 7.9 and 1.6 Hz, one of C6H3) 
δC (100 MHz, CDCl3): 22.7 (CH(CH3)2), 25.0 (CH(CH3)2), 39.1 
(OCH2CH2), 61.5 (CH2OH), 72.6 (OCH2), 124.9 (Ar-C), 127.4 (Ar-C), 127.9 (Ar-
Cq), 130.1 (Ar-C), 136.1 (Ar-Cq), 153.4 (Ar-Cq) 
m/z [EI (+ve)], 230.1 ([M+2]+, 13%),  228.1 ([M]+, 40%), 140.0 ([M-
(OCH2CH2CH(CH3)2)]+, 100%); Found [M]+, 228.0918, C12H17O2Cl requires 
228.0917 
ν max (CDCl3) / cm−1: 3600-3150, 2928, 2870, 1446, 775  
 
 
3-chloro-2-(isopentyloxy)benzaldehyde 23 
 
31
O
Cl
OH
O
Cl
23
O
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An oxalyl chloride (0.36 ml, 0.53 g, 4.2 mmol, 2 eq) was dissolved in dry DCM (20 
cm3) under an argon atmosphere. The resulting solution was cooled to −78 °C and 
solution of DMSO (0.6 ml, 0.66 g, 8.4 mmol, 4 eq) in dry DCM (5 cm3) was added 
to it. After stirring for 0.5 hour at −78 °C, solution of alcohol 31 (0.45 g, 2.1 mmol, 1 
eq) in dry DCM (20 cm3) was added to the reaction via cannula, and stirring was 
continued for 2 hours at −78 °C. Then reaction was treated with triethylamine (2.3 
ml, 1.7 g, 16.8 mmol, 8 eq), stirred for 10 minutes at −78 °C, and allowed to warm to 
room temperature. After being stirred at room temperature for 1 hour, the reaction 
was diluted with DCM (15 cm3) and quenched with water (30 cm3). The layers were 
separated, and organic phase was washed with 0.1N HCl (40 cm3), saturated aqueous 
NaHCO3 (40 cm3), and brine (40 cm3). Organic fraction was collected, dried over 
anhydrous sodium sulphate, filtered off, and solvents were removed in vacuo. The 
remaining residue was purified by flash column chromatography (silica gel, gradient 
elution, eluting with 100% petroleum ether (40-60) to 1% ethyl acetate in petroleum 
ether (40-60)) to give aldehyde 23 as yellow liquid (0.4 g, 1.76 mmol, 84% yield). 
 
δH (400 MHz, CDCl3): 0.98 (6H, d, J = 6.6 Hz, CH(CH3)2), 1.76 (2H, appq, 
J = 6.8 Hz, OCH2CH2), 1.88 (1H, appsept., J = 6.6 Hz, CH(CH3)2), 4.12 (2H, t,  
J = 6.8 Hz, OCH2), 7.15 (1H, apptd, J = 7.8 and 0.8 Hz, one of C6H3), 7.62 (1H, dd, 
J = 7.9 and 1.7 Hz, one of C6H3), 7.74 (1H, dd, J = 7.8 and 1.7 Hz, one of C6H3), 
10.37 (1H, br. d, J = 0.8 Hz, CHO) 
δC (100 MHz, CDCl3): 22.7 (CH(CH3)2), 25.0 (CH(CH3)2), 38.7 
(OCH2CH2), 75.1 (OCH2), 125.0 (Ar-C), 126.9 (Ar-C), 129.0 (Ar-Cq), 131.2 (Ar-
Cq), 136.5 (Ar-C), 158.6 (Ar-Cq), 189.3 (CHO) 
m/z [EI (+ve)], 228.1 ([M+2]+, 18%), 226.1 ([M]+, 39%), 156.0 ([M-
((CH2CH2CH(CH3)2)]+, 100%); Found [M]+, 226.0762, C12H15O2Cl requires 
226.0761 
ν max (CDCl3) / cm−1: 2958, 2933, 2870, 1639, 1446 cm-1 
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(3-chloro-2-nitrophenyl)methanol 28 
 
Cl
CO2H
NO2
Cl
NO2
OH
16 28  
 
A flask equipped with a reflux condenser was charged with vacuum-dried 3-chloro-
2-nitrobenzoic acid 16 (0.2 g, 1 mmol, 1 eq) and dry THF (10 cm3). Resulting 
solution was cooled to 0 °C and treated with borane-tetrahydrofuran complex (1M in 
THF, 2.4 ml, 2.4 mmol, 2.4 eq) under an argon atmosphere. After the cooling bath 
was removed, the reaction mixture was stirred at room temperature for 0.5 hour and 
overnight at 40 °C. After this time the reaction was cooled to 0 °C, quenched by 
slow addition of MeOH (10 cm3) and diluted with saturated aqueous NaHCO3 (10 
cm3) and ethyl acetate (20 cm3). Biphasic mixture was stirred for 0.5 hour and then 
layers were separated. The aqueous phase was extracted with fresh ethyl acetate (2 x 
20 cm3). All the organic layers were combined, dried over anhydrous sodium 
sulphate, filtered off, and solvents were removed in vacuo. The remaining alcohol 28 
was used in synthesis without purification (yellow viscous oil). 
 
 
Tert-butyl(3-chloro-2-nitrobenzyloxy)dimethylsilane 29 
 
Cl
NO2
OH
Cl
NO2
OTBS
28 29  
 
To a stirred solution of alcohol 28 (0.17 g, 0.9 mmol, 1 eq) in dry DMF (8 cm3) were 
added imidazole (0.13 g, 1.9 mmol, 2.1 eq) and tert-butyldimethylsilyl chloride (0.15 
g, 1 mmol, 1.1 eq) under an argon atmosphere. The resulting reaction mixture was 
stirred at room temperature until TLC analysis indicated complete consumption of 
starting material 28 (3 hours). After this time, reaction was diluted with ethyl acetate 
(10 cm3) and water (10 cm3). Biphasic mixture was stirred for 20 minutes, then 
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layers were separated and aqueous phase was extracted with fresh ethyl acetate (2 x 
20 cm3). Organic layers were combined, washed with water (40 cm3), brine (40 cm3), 
dried over anhydrous sodium sulphate, filtered off, and solvents were removed in 
vacuo. The remaining residue was purified on a short column of silica gel (gradient 
elution, eluting with 100% petroleum ether (40-60) to 20% ethyl acetate in 
petroleum ether (40-60)) to give product 29 as white, crystalline solid (0.23 g, 0.76 
mmol, 84% yield from 16). 
 
δH (400 MHz, CDCl3): 0.09 (6H, s, Si(CH3)2), 0.92 (9H, s, C(CH3)3), 4.72 
(2H, d, J = 0.7 Hz, CH2O), 7.41-7.42 (2H, m, two of C6H3), 7.5-7.52 (1H, m, one of 
C6H3) 
δC (100 MHz, CDCl3): −5.4 (Si(CH3)2), 18.4 (C(CH3)3), 25.9 (C(CH3)3), 
60.9 (CH2O), 125.2 (Ar-Cq), 126.5 (Ar-C), 129.3 (Ar-C), 131.1 (Ar-C), 135.6 (Ar-
Cq), 1 x Cq unresolved 
m/z [FAB (+ve)], 302.1 ([M+H]+, 35%), 244.2 ([M−C(CH3)3]+, 100%); 
Found [M+H]+, 302.0978, C13H21NO3SiCl requires 302.0979 
ν max (CDCl3) / cm−1: 2929, 2858, 1523, 1462, 1367  
 mp. 84-86 °C 
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4-methyl-N-((5-methylfuran-2-yl)methyl)benzenesulfonamide 85 
 
O
NH2
O
HNTs
69 85  
 
To a solution of 5-methylfurfurylamine 69 (0.3 ml, 0.3 g, 2.7 mmol, 1 eq) in dry 
DCM (20 cm3) was added triethylamine (0.75 ml, 0.55 g, 5.4 mmol, 2 eq) under an 
argon atmosphere and resulting reaction solution was stirred for 10 minutes at room 
temperature. After this time the reaction was cooled to 0 °C and a solution of tosyl 
chloride (0.72 g, 3.78 mmol, 1.4 eq) in dry DCM (10 cm3) was slowly added to it. 
After stirring overnight at ambient temperature the reaction mixture was quenched 
with saturated aqueous NaHCO3 (20 cm3), diluted with water (20 cm3) and the 
fractions were separated. An aqueous layer was extracted with fresh DCM (2 x 40 
cm3). The combined organic layers were washed with brine (40 cm3), dried over 
sodium sulphate, filtered off, and concentrated in vacuo. The resulting product 85 
was taken to the next step without need for purification (pale yellow solid, 0.72 g, 
2.7 mmol, quantitative). 
 
δH (400 MHz, CDCl3): 2.12 (3H, s, furan-CH3), 2.41 (3H, s, tosyl-CH3), 4.1 
(2H, d, J = 6.0 Hz, NHCH2), 4.74 (1H, br. t, J = 5.9 Hz, NH), 5.76-5.77 (1H, m, 
furanyl-CH), 5.95 (1H, dd, J = 3.0 and 0.39 Hz, furanyl-CH), 7.25-7.28 (2H, m, two 
of C6H4), 7.69-7.72 (2H, m, two of C6H4)  
δC (100 MHz, CDCl3): 13.4 (furan-CH3), 21.6 (tosyl-CH3), 40.4 (NHCH2), 
106.3 (furanyl-CH), 109.2 (furanyl-CH), 127.3 (Ar-C), 129.6 (Ar-C), 137.1 (Cq-
SO2), 143.4 (Cq-CH3 (tosyl)), 147.6 (NHCH2Cq), 152.3 (Cq-CH3 (furan)) 
m/z [EI (+ve)], 109.0 ([M-Tosyl]+, 100%), 265.0 ([M]+, 8%); Found [M]+, 
265.0771, C13H15NO3S requires 265.0773 
 ν max (CDCl3) / cm−1: 3257, 2922, 1321, 1159 
mp. 81-83 °C 
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(±)-6-hydroxy-6-methyl-1-tosyl-1,2-dihydropyridin-3(6H)-one 86 
 
O
HNTs NTs
HO
O
85 86  
 
To a solution of m-chloroperoxybenzoic acid (stabilised with m-chlorobenzoic acid; 
0.18 g, 1.08 mmol, 1.3 eq) in dry DCM (5 cm3) at 0 ºC was added dropwise a 
solution of amine 85 (0.22 g, 0.83 mmol, 1 eq) in dry DCM (5 cm3). The resulting 
reaction mixture was stirred for 20 minutes in 0 ºC, and further 6 hours at room 
temperature under an argon atmosphere. After this time reaction was quenched by 
slow addition of saturated aqueous NaHCO3 (10 cm3) and diluted with diethyl ether 
(10 cm3). The layers were separated and the aqueous layer was extracted with fresh 
diethyl ether (2 x 10 cm3). The organic phases were combined, washed with 
saturated aqueous NaHCO3 (30 cm3), brine (30 cm3), dried over sodium sulphate, 
filtered off, and concentrated in vacuo. The obtained product 86 proved to be 
unstable; decomposition was observed within 1 hour upon storing at −4 °C (pale 
yellow solid, 100% conversion based on 1H NMR). 
 
δH (400 MHz, CDCl3):  2.25 (3H, s, C(OH)CH3), 2.41 (3H, s, tosyl-CH3), 
3.95 (2H, d,  J = 5.1 Hz, NCH2), 5.27-5.3 (1H, m, OH), 6.22 (1H, d, J = 11.8 Hz, 
CHCHC(O)), 6.41 (1H, d, J = 11.8 Hz, CHCHC(O)), 7.3 (2H, appd, J = 8.5 Hz, two 
of C6H4), 7.72-7.75 (2H, m, two of C6H4) 
 
 
N-(furan-2-ylmethyl)-4-methylbenzenesulfonamide 100 
 
O
NH2
O
HNTs
99 100  
 
Stirred solution of furfurylamine 99 (1.82 ml, 2.0 g, 20.6 mmol, 1 eq) in dry DCM 
(150 cm3) was treated with triethylamine (5.74 ml, 4.17 g, 41.2 mmol, 2 eq) under an 
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argon atmosphere. Resulting reaction mixture was stirred for 30 minutes at room 
temperature, then cooled to 0 ºC and a solution of tosyl chloride (4.71 g, 24.72 
mmol, 1.2 eq) in dry DCM (30 cm3) was added to it via cannula. The cooling bath 
was removed and stirring was continued overnight at room temperature.  After this 
time saturated aqueous NaHCO3 (80 cm3) and water (80 cm3) were added slowly to 
the reaction. The resulting phases were separated and aqueous phase was extracted 
with fresh diethyl ether (2 x 150 cm3). The organic layers were combined, washed 
with brine (200 cm3), dried over sodium sulphate, filtered off, and solvents were 
removed in vacuo. The remaining product 100 was precipitated from diethyl ether 
and taken to the next step without further purification (white solid, 5.17 g, 20.6 
mmol, quantitative). 
 
δH (400 MHz, CDCl3): 2.42 (3H, s, tosyl-CH3), 4.17 (2H, d, J = 6.0 Hz, 
NHCH2), 4.69 (1H, br. appt, J = 5.8 Hz, NH), 6.08 (1H, appdq, J = 3.2, 0.8 Hz, 
furanyl-CH), 6.21 (1H, dd, J = 3.2, 1.8 Hz, furanyl-CH), 7.24 (1H, dd, J = 1.8, 0.8 
Hz, COCH), 7.26-7.29 (2H, m,  two of C6H4), 7.7-7.73 (2H, m, two of C6H4) 
δC (100 MHz, CDCl3): 21.6 (tosyl-CH3), 40.3 (NHCH2), 108.3 (furanyl-CH), 
110.5 (furanyl-CH), 127.2 (Ar-C),  129.8 (Ar-C), 137.0 (Cq-SO2), 142.6 (furanyl-
CH), 143.6 (Cq-CH3), 149.6 (NHCH2Cq)  
m/z [CI (+ve)], 252.4 ([M+H]+, 30%), 184.3 ([TsNHCH2]+, 100%); Found 
[M+H]+, 252.0693, C12H14NO3S requires 252.0694 
 ν max (CDCl3) / cm−1: 3253, 1598, 1435, 1320, 1158  
 mp. 118-120°C 
 
 
(±)-6-hydroxy-1-tosyl-1,2-dihydropyridin-3(6H)-one 101 
 
O
HNTs
NTs
O
OH
101100  
 
The reaction flask containing furfurylamine 100 (1.95 g, 7.76 mmol, 1 eq) was kept 
under vacuum for 1 hour, refilled with argon and charged with dry DCM (40 cm3). 
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Resulting solution was cooled to 0 °C and a solution of m-chloroperoxybenzoic acid 
(stabilised with m-chlorobenzoic acid; 1.82 g, 10.55 mmol, 1.36 eq) in dry DCM (40 
cm3) was added via cannula. The reaction mixture was stirred for 20 minutes in 0 ºC, 
and then in ambient temperature until completion indicated by TLC analysis (6 
hours).  After this time, saturated aqueous NaHCO3 (80 cm3) and diethyl ether (40 
cm3) were added to the reaction and resulting biphasic mixture was stirred for 20 
minutes.  The fractions were separated, and the aqueous layer was extracted with 
fresh diethyl ether (2 x 80 cm3). The organic layers were combined, washed with 
saturated aqueous NaHCO3 (200 cm3), brine (200 cm3), dried over sodium sulphate, 
filtered off, and concentrated in vacuo. The remaining product 101 was taken 
subsequently to the next step without purification (pale yellow solid, decomposes 
within hours).  
 
δH (400 MHz, CDCl3): 2.43 (3H, s, tosyl-CH3), 3.97 (1H, d,  J = 17.6 Hz, 
one of NCH2), 4.15 (1H, d,  J = 17.6 Hz, one of NCH2), 5.98 (1H, dd, J = 4.9, 0.7 
Hz, CH(OH)), 6.07 (1H, d, J = 10.2 Hz, CHCHC(O)), 6.91 (1H, dd, J = 10.2, 4.9 Hz, 
CHCHC(O)), 7.30-7.33 (2H, m, two of C6H4), 7.7-7.72 (2H, m, two of C6H4) 
 
 
(±)-6-allyl-1-tosyl-1,2-dihydropyridin-3(6H)-one 102 
 
NTs
O
N
Ts
O
OH
101 102  
 
A solution of pyridinone 101 (2.07 g, 7.76 mmol, 1 eq) in dry DCM (80 cm3) at 0 ºC 
was treated with allyltrimethylsilane (3.7 ml, 2.66 g, 23.3 mmol, 3 eq) and boron 
trifluoride diethyl etherate (0.5 ml, 0.55 g, 3.88 mmol, 0.5 eq) under an argon 
atmosphere. The resulting reaction solution was stirred for 30 minutes in 0 ºC before 
being quenched with saturated aqueous NH4Cl (80 cm3). Resulting biphasic mixture 
was diluted with diethyl ether (50 cm3) and stirred for next 20 minutes. The layers 
were separated and aqueous layer was extracted with fresh diethyl ether (2 x 80 
cm3). The organic layers were combined, washed with water (200 cm3), brine (200 
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cm3), dried over sodium sulphate, filtered off, and solvents were removed in vacuo. 
Crude compound 102, obtained as dark orange viscous oil, was subsequently reacted 
further.  
 
 
6-allyl-1-tosyl-5-vinylpiperidin-3-one 103 
 
N
Ts
O
N
Ts
O
102 103  
 
A three-neck flask equipped with low temperature thermometer and protected from 
light with aluminium foil was charged with solution of copper iodide (2.05 g, 10.8 
mmol, 1.4 eq) in dry THF (40 cm3) under an argon atmosphere. The solution was 
then cooled to −78 °C and treated with vinylmagnesium bromide (1M in THF, 23.0 
ml, 23.1 mmol, 3 eq). Resulting reaction mixture was stirred for 5 minutes at −78 °C 
and then allowed to warm to −25 °C gradually over 20 minutes. After stirring for 5 
minutes at −25 °C, the reaction mixture was cooled back to −78 °C and solution of 
pyridinone 102 (2.2 g, 7.7 mmol, 1 eq) in dry THF (40 cm3) was slowly added to it 
via cannula. Resulting reaction mixture was stirred at −78 °C until completion as 
indicated by TLC analysis (40 minutes). After this time the cooling bath was 
removed and the reaction was left stirring for 20 minutes before was quenched with 
saturated aqueous NH4Cl (80 cm3) and diluted with diethyl ether (50 cm3). Biphasic 
mixture was stirred for another 20 minutes, then the phases were separated and an 
aqueous layer was extracted with fresh diethyl ether (2 x 80 cm3). Combined organic 
layers were washed with saturated aqueous Na2S2O3 (200 cm3), dried over sodium 
sulphate, filtered off, and solvents were removed in vacuo. The remaining residue 
was purified by flash column chromatography (silica gel, gradient elution, eluting 
with 100% petroleum ether (40-60) to 7% ethyl acetate in petroleum ether (40-60)) 
to give compound 103 as pale yellow oil (1.65 g, 5.1 mmol, 66% yield from 
protected amine 100).  
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δH (400 MHz, CDCl3): 1.68 (1H, dd, J = 16.5 and 11.8 Hz, one of 
C(O)CH2CH), 2.16 (1H, dd, J = 16.5 and 3.8 Hz, one of C(O)CH2CH), 2.31-2.38 
(1H, m, one of NCH(CH2CH=CH2), 2.42 (3H, s, tosyl-CH3), 2.43-2.5 (1H, m, 
C(O)CH2CH), 2.52-2.59 (1H, m, one of NCH(CH2CH=CH2), 3.59 (1H, d, J = 18.9 
Hz, one of NCH2), 3.86-3.91 (1H, m, NCH), 4.15 (1H, d, J = 18.9 Hz, one of NCH2), 
5.0-5.14 (4H, m, NCH(CH2CH=CH2) and CH(CH=CH2)), 5.57 (1H, ddd,  J = 18.0, 
10.2 and 7.8 Hz,  CH(CH=CH2)), 5.77-5.88 (1H, m, NCH(CH2CH=CH2), 7.29-7.31 
(2H, m, two of C6H4), 7.65-7.68 (2H, m, two of C6H4) 
 δC (100 MHz, CDCl3): 21.6 (tosyl-CH3), 37.2 (NCH(CH2CH=CH2), 40.5 
(C(O)CH2CH), 41.6 (C(O)CH2CH), 51.6 (NCH2), 57.3 (NCH), 117.5 and 119.2 
(NCH(CH2CH=CH2) and CH(CH=CH2)), 127.3 (Ar-C), 130.1 (Ar-C), 133.2 
(NCH(CH2CH=CH2), 136.4 (Cq), 137.7 (CH(CH=CH2)), 144.1 (Cq), 206.2 (CO) 
m/z [CI (+ve)], 320.2 ([M+H]+, 100%), 164.2 ([(M+H)-Ts]+, 83%); Found 
[M+H]+, 320.1314, C17H22NO3S requires 320.1320 
ν max (CDCl3) / cm−1: 2978, 2924, 1732, 1346, 1157, 1091  
 
 
(4aS,7aS)-1-tosyl-4,4a,7,7a-tetrahydro-1H-cyclopenta[b]pyridin-3(2H)-one 112 
 
N
Ts
O
N
Ts
O
H
H
103 112  
 
An oven-dried flask was charged with a pyridinone 103 (0.07 g, 0.22 mmol, 1 eq) 
and kept under vacuum for 0.5 h. After this time the flask was refilled with argon 
and starting material 103 was diluted with dry DCM (44 cm3, c 0.005 mol·dm−3). 
Resulting solution was degassed by bubbling argon through for 20 minutes and then 
treated with Ti(OPr-i)4 (13 μl, 0.012 g, 0.044 mmol, 20 mol%). After the reaction 
was stirred at room temperature for 0.5 hour, the flask was protected from light with 
aluminium foil and Grubbs second generation catalyst [Cl2(PCy3)(IMes)Ru=CHPh] 
(0.02 g, 0.022 mmol, 10 mol%) was added to it in one portion under an argon 
atmosphere. The resulting reaction mixture was heated to reflux and stirred until 
completion indicated by TLC analysis (3 hours). After this time reaction mixture was 
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allowed to cool to room temperature, quenched with saturated aqueous NaHCO3 (50 
cm3) and stirred for another 20 minutes. Then the phases were separated and the 
aqueous layer was extracted with fresh DCM (2 x 50 cm3). All the organic layers 
were combined, washed with brine (100 cm3), dried over anhydrous sodium 
sulphate, filtered off, and the solvent was removed in vacuo. The remaining residue 
was purified by flash column chromatography (silica gel, gradient elution, eluting 
with 100% petroleum ether (40-60) to 10% ethyl acetate in petroleum ether (40-60)) 
to give compound 112 as a white crystals (0.053 g, 0.18 mmol, 82% yield).  
 
δH (400 MHz, CDCl3): 2.02 (1H, dd, J = 16.5 and 14.2 Hz, one of 
C(O)CH2CH), 2.43 (3H, s, tosyl-CH3), 2.69-2.78 (2H, m, NCH and one of 
C(O)CH2CH), 2.82-2.85 (2H, m, NCHCH2), 2.92-2.99 (1H, m, C(O)CH2CH), 3.32 
(1H, d, J = 16.7 Hz, one of NCH2), 4.16 (1H, dd, J = 16.7 and 1.0 Hz, one of NCH2), 
5.66 (1H, appdq, J = 6.1 and 1.7 Hz, CH=CHCH2), 5.86-5.9 (1H, m, CH=CHCH2), 
7.34-7.36 (2H, m, two of C6H4), 7.65-7.67 (2H, m, two of C6H4) 
δC (100 MHz, CDCl3): 21.7 (tosyl-CH3), 37.1 (NCHCH2), 43.5 
(C(O)CH2CH), 46.7 (C(O)CH2CH), 57.8 (NCH2), 65.0 (NCH), 128.1 (Ar-C), 130.1 
(Ar-C), 130.2 (CH=CHCH2), 131.7 (CH=CHCH2), 132.1 (Cq), 144.4 (Cq), 202.8 
(CO) 
m/z [CI (+ve)], 292.0 ([M+H]+, 100%), 136.1 ([(M+H)-Ts]+, 79%); Found 
[M+H]+, 292.0997, C15H18NO3S requires 292.1007 
ν max (CDCl3) / cm−1: 2955, 2924, 2854, 1728, 1350, 1165, 1091  
mp. 152-154 °C (decomposition)  
 
 
(4aS,7aS)-1-tosyl-2,3,4,4a,7,7a-hexahydro-1H-cyclopenta[b]pyridin-3-ol 119 
 
N
Ts
O
H
H
N
Ts
∗ OHH
H
112 119  
 
To a stirred solution of pyridinone 112 (0.22 g, 0.75 mmol, 1 eq) in dry THF (7 cm3) 
at −78 °C, L-Selectride (1M solution in THF, 1.1 ml, 1.1 mmol, 1.45 eq) was added 
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dropwise via syringe. The resulting reaction mixture was stirred at −78 °C until 
completion indicated by TLC analysis (2 hours). After this time the cooling bath was 
removed, and reaction mixture was stirred for next 20 minutes before being 
quenched by addition of saturated aqueous NH4Cl (1.1 cm3) and water (6.6 cm3).  
The biphasic mixture was diluted with diethyl ether, and stirring was continued for 
20 minutes at room temperature. The phases were separated and the aqueous layer 
was extracted with fresh diethyl ether (2 x 10 cm3). All the organic layers were 
combined, dried over anhydrous sodium sulphate, filtered off, and concentrated in 
vacuo. The remaining residue was purified by flash column chromatography (silica 
gel, gradient elution, eluting with 100% petroleum ether (40-60) to 25% ethyl acetate 
in petroleum ether (40-60)) to give compound 119 as a white crystalline solid (0.19 
g, 0.65 mmol, 87% yield).  
 
δH (400 MHz, CDCl3): 1.22 (1H, td, J = 13.3 and 2.8 Hz, one of 
C(OH)CH2CH), 2.09-2.19 (2H, m, one of C(OH)CH2CH and NCH),  2.4 (1H, dd,  
J = 12.3 and 1.9 Hz, one of NCH2), 2.42 (3H, s, tosyl-CH3), 2.48 (1H, br. d, J = 6.6 
Hz, OH), 2.65 (1H, ddd, J = 15.0, 6.4 and 3.0 Hz, one of NCHCH2), 2.78-2.92 (2H, 
m, one of NCHCH2 and C(OH)CH2CH), 3.93 (1H, ddd, J = 12.3, 2.9 and 1.8 Hz, one 
of NCH2), 4.12 (1H, br. apps, CH(OH)), 5.65-5.67 (1H, m, alkenyl-CH), 5.75-5.79 
(1H, m, alkenyl CH), 7.32 (2H, dd, J = 8.5 and less then 1 Hz, two of C6H4), 7.65 
(2H, dd, J = 6.6 and 1.8 Hz, two of C6H4) 
δC (100 MHz, CDCl3): 21.6 (tosyl-CH3), 34.7 (C(OH)CH2CH), 36.8 
(NCHCH2), 43.7 (C(OH)CH2CH), 55.6 (NCH2), 65.5 (CH(OH)), 67.1 (NCH), 127.9 
(Ar-C), 129.8 (Ar-C), 129.9 (alkenyl CH), 132.1 (alkenyl CH), 132.9 (Cq), 143.9 
(Cq) 
m/z [EI (+ve)], 293.2 ([M]+, 48%), 138.1 ([M−Ts]+, 100%); Found [M]+, 
293.1082, C15H19NO3S requires 293.1086 
ν max (CDCl3) / cm−1: 3510, 2920, 2854, 1599, 1338, 1159, 688  
mp. 150-153 °C 
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(4aS,7aS)-3-ethoxy-1-tosyl-2,3,4,4a,7,7a-hexahydro-1H-cyclopenta[b]pyridine 
118 
 
N
Ts
∗ OH
H
N
Ts
∗ OHH
H
119 118  
 
A dispersion of  NaH in oil (60% (w/w) in mineral oil, 0.06 g, 1.44 mmol, 3 eq) was 
washed three times with petroleum ether under an argon atmosphere, dried under 
vacuum and suspended in dry DMF (3 cm3).  After the suspension was cooled to  
0 °C, a solution of alcohol 119 (0.14 g, 0.48 mmol, 1 eq) in dry DMF (3 cm3) was 
added to it dropwise via syringe.  Resulting yellow reaction mixture was stirred for 
10 minutes at 0 °C and further 45 minutes at room temperature. After the reaction 
was cooled back to 0 °C, ethyl iodide (0.1 ml, 0.19 g, 1.2 mmol, 2.5 eq) was added 
dropwise, what resulted in evolution of gas. The reaction mixture was stirred in 0 °C 
for 0.5 hour and then in room temperature until completion indicated by TLC 
analysis (2 hours). After this time saturated aqueous NH4Cl (6 cm3) was added 
slowly to the reaction mixture (caused foaming), and stirring was continued for 20 
minutes.  Biphasic mixture was diluted with diethyl ether, the phases were separated 
and the aqueous layer was extracted with fresh diethyl ether (2 x 10 cm3). All the 
organic layers were combined, dried over anhydrous sodium sulphate, filtered off, 
and solvents were removed in vacuo. The remaining residue was purified by flash 
column chromatography (silica gel, gradient elution, eluting with 100% petroleum 
ether (40-60) to 7% ethyl acetate in petroleum ether (40-60)) to give compound 118 
as white crystals (0.12 g, 0.38 mmol, 79% yield).  
 
δH (400 MHz, CDCl3): 1.15-1.19 (1H, m, one of CH(OEt)CH2CH), 1.23 
(3H, t, J = 7.0 Hz, OCH2CH3), 2.12-2.19 (1H, m, one of CH(OEt)CH2CH), 2.22 (1H, 
dd, J = 10.2 and 3.7 Hz,  NCH),  2.27 (1H, dd, J = 12.6 and 2.0 Hz, one of NCH2), 
2.42 (3H, s, tosyl-CH3), 2.62-2.68 (1H, m, one of CH=CHCH2), 2.72-2.79 (1H, m, 
one of CH=CHCH2), 2.89-2.95 (1H, m, CH(OEt)CH2CH), 3.42 (1H, dq, J = 9.1 and 
7.0 Hz, one of OCH2CH3), 3.63-3.68 (2H, m, one of OCH2CH3 and CH(OEt)), 4.09 
(1H, ddd, J = 12.6, 2.7 and 1.8 Hz, one of NCH2), 5.63-5.65 (1H, m, alkenyl CH), 
 165
5.72-5.76 (1H, m, alkenyl CH), 7.3-7.32 (2H, m, two of C6H4), 7.66-7.68 (2H, m, 
two of C6H4) 
δC (100 MHz, CDCl3): 15.5 (OCH2CH3), 21.6 (tosyl-CH3), 33.2 
(CH(OEt)CH2CH), 36.9 (CH=CHCH2), 44.0 (CH(OEt)CH2CH), 51.2 (NCH2), 63.8  
(OCH2CH3), 66.8 (NCH),  72.3 (CH(OEt)), 128.0 (Ar-C), 129.6 (alkenyl-CH), 129.7 
(Ar-C), 132.4 (alkenyl-CH), 133.6 (Cq), 143.5 (Cq) 
m/z [EI (+ve)], 321.3 ([M]+, 5%), 166.2 ([M−Ts]+, 100%); Found [M]+, 
321.1401, C17H23NO3S requires 321.1399 
ν max (CDCl3) / cm−1: 2974, 2922, 2868, 1600, 1338, 1160, 1095  
mp. 101-103 °C 
 
 
Ethyl 2-((4aS,7aS)-1-tosyl-4,4a-dihydro-1H-cyclopenta[b]pyridin-
3(2H,7H,7aH)-ylidene)acetate 113 
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A flask equipped with a reflux condenser was charged with solution of pyridinone 
112 (0.29 g, 0.99 mmol, 1 eq) in dry DCM (10 cm3), and an 
(ethoxycarbonylmethylene) triphenylphosphorane (0.45 g, 1.29 mmol, 1.3 eq) was 
added to it under an argon atmosphere.  Resulting reaction mixture was stirred at 
reflux for 48 hours.  After this time the reaction was allowed to cool to room 
temperature and solvent was removed in vacuo. The remaining residue was purified 
by flash column chromatography (silica gel, gradient elution, eluting with 100% 
petroleum ether (40-60) to 10% ethyl acetate in petroleum ether (40-60)) to give 
ester 113 as a mixture of E/Z isomers (pale yellow viscous oil, 0.3 g, 0.83 mmol, 
84% yield).  
 
δH (400 MHz, CDCl3, de retio: 1:1): 1.26 (3H, t, J = 7.1 Hz, OCH2CH3), 
1.31 (3H, t, J = 7.2 Hz, OCH2CH3), 1.88-1.98 (2H, m, one of CH2(C3) and one of 
CH2(C7)), 2.42 (6H, s, 2 x tosyl-CH3), 2.45-2.82 (9H, m, CH2(C3), CH2(C7), 2 x 
CH(C4), 2 x CH(C8) and one of CH2(C7)), 3.05 (1H, d, J = 14.0 Hz, one of NCH2), 
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3.37 (1H, dd, J = 13.9 and 1.2 Hz, one of NCH2), 3.7 (1H, dd, J = 15.8 and 4.0 Hz, 
one of CH2(C3)), 4.13 (2H, q, J = 7.1 Hz, OCH2CH3), 4.2 (2H, q, J = 7.1 Hz, 
OCH2CH3), 4.21 (1H, d, J = 13.9 Hz, one of NCH2), 5.67 (1H, d, J = 14.1 Hz, one of 
NCH2), 5.66-5.84 (6H, m, 4 x alkenyl CH, 2 x C=CHCO2Et), 7.31-7.34 (4H, m, two 
of C6H4 and two of C6H4), 7.64-7.71 (4H, m, two of C6H4 and two of C6H4) 
δC (100 MHz, CDCl3): 14.3 (2 x OCH2CH3), 21.7 (2 x tosyl-CH3), 32.0, 
37.2, 37.4, 38.5 (2 x CH2(C7) and 2 x CH2(C3)), 47.5 (CH(C4)), 48.7 (CH(C4)), 48.9 
(NCH2), 55.2 (NCH2), 60.2 (OCH2CH3), 60.5 (OCH2CH3), 65.8 (CH(C8)), 66.3 
(CH(C8)), 118.5 (C=CHCO2Et), 118.6 (C=CHCO2Et), 128.0 (Ar-C), 128.1 (Ar-C), 
129.8 (Ar-C), 129.9 (Ar-C), 130.8, 131.0, 131.1, 131.4 (4 x alkenyl CH), 132.8 (Cq), 
132.9 (Cq), 143.8 (Cq), 144.1 (Cq), 150.8 (Cq), 152.1 (Cq), 165.6 (Cq), 165.9 (Cq)      
m/z [EI (+ve)], 361.0 ([M]+, 28%), 206.1 ([M−Ts]+, 100%); Found [M]+, 
361.1344, C19H23NO4S requires 361.1348 
ν max (CDCl3) / cm−1: 2956, 2933, 2875, 2860, 1716, 1352, 1165, 1091  
 
 
2-((4aS,7aS)-1-tosyl-4,4a-dihydro-1H-cyclopenta[b]pyridin-3(2H,7H,7aH)-
ylidene)ethanol 114 
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To a solution of ester 113 (0.057 g, 0.16 mmol, 1eq) in dry diethyl ether (2 cm3) at  
0 °C, DIBAL-H (1.0 M solution in hexanes, 0.45 ml, 0.45 mmol, 3eq) was added 
dropwise via syringe under an argon atmosphere. Resulting reaction mixture was 
stirred at 0 °C until completion indicated by TLC analysis (40 minutes).  While 
maintaining temperature at 0 °C, reaction was diluted with fresh diethyl ether (2 
cm3) and quenched by careful addition of water (0.02 cm3), followed by 15% 
aqueous NaOH (0.02 cm3) and another portion of water (0.05 cm3). The cooling bath 
was removed and resulting biphasic mixture was stirred for 20 minutes at room 
temperature.  The fractions were separated, and the aqueous layer was extracted with 
fresh diethyl ether (2 x 5 cm3). All the organic layers were combined and dried over 
anhydrous magnesium sulphate, filtered off, and the solvents were removed in vacuo 
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to yield alcohol 114 as a mixture E/Z isomers (pale yellow, gummy oil, 0.053 g, 0.16 
mmol, 100% yield), which was reacted further without need of purification.  
 
 δH (400 MHz, CDCl3, de retio: 1:1): 1.57-1.63 (1H, m, one of CH2(C3)), 
1.79-1.86 (1H, m, one of CH2(C3)), 2.33-2.43 (2H, m, 2 x CH(C8), cis and trans), 
2.41 (3H, s, tosyl-CH3), 2.42 (3H, s, tosyl-CH3), 2.45-2.54 (3H, m, 2 x CH(C4) and 
one of CH2(C3)), 2.67-2.71 (4H, m, 2 x CH2(C7)), 2.75 (1H, d, J = 13.0 Hz, one of 
NCH2), 2.77-2.83 (1H, m, one of CH2(C3)), 3.12 (1H, d, J = 13.0 Hz, one of NCH2), 
4.04-4.29 (4H, m, 2 x C=CHCH2OH)), 4.15 (1H, d, J = 13.0 Hz, one of NCH2), 4.59 
(1H, d, J = 12.9 Hz, one of NCH2), 5.56-5.61 (2H, m, 2 x C=CHCH2OH)), 5.65-5.67 
(2H, m, 2 x alkenyl CH), 5.75-5.79 (2H, m, 2 x alkenyl CH), 7.3-7.33 (4H, m, two of 
C6H4 and two of C6H4), 7.65-7.68 (4H, m, two of C6H4 and two of C6H4) 
δC (100 MHz, CDCl3, de retio: 1:1): 21.6 (tosyl-CH3), 21.63 (tosyl-CH3), 
30.4 (CH2(C3)), 36.9 (CH2(C7)), 37.1 (CH2(C7)), 38.0 (CH2(C3)), 48.5 (CH(C4)), 
49.0 (NCH2), 49.7 (CH(C4)), 55.9 (NCH2), 58.4 (C=CHCH2OH), 58.47 
(C=CHCH2OH), 66.3 (CH(C8)), 66.7 (CH(C8)), 126.9 (C=CHCH2OH), 127.4 
(C=CHCH2OH), 128.0 (Ar-C), 128.1 (Ar-C), 129.7 (Ar-C), 129.8 (Ar-C), 130.3 
(alkenyl CH), 130.6 (alkenyl CH), 131.6 (alkenyl CH), 131.8 (alkenyl CH), 132.8 
(Cq), 132.9 (Cq), 134.1 (Cq(C2)), 134.3 (Cq(C2)), 143.8 (Cq), 143.9 (Cq) 
m/z [CI (+ve)], 320.5 ([M+H]+, 94%), 302.5 ([(M+H)-OH2]+, 100%); Found 
[M+H]+, 320.1323, C17H22NO3S requires 320.1320 
ν max (CDCl3) / cm−1: 3547, 2967, 2847, 1346, 1165, 1091  
 
 
Ethyl 4-oxobutanoate 141 
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O
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O
O
O
O
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To a stirred solution of ethyl 4-chloro-4-oxobutyrate 140 (3.5 ml, 4.0 g, 24.3 mmol, 1 
eq) in dry THF (200 cm3) was added 2,6-lutidine (2.8 ml, 2.6 g, 24.3 mmol, 1 eq) 
under an argon atmosphere. Resulting colourless solution was purged with argon for 
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20 minutes, and a catalytic amount of 10% Pd/C was added to it.  Reaction mixture 
was then immediately degassed under reduced pressure and refilled with hydrogen 
(three times), and stirring was continued under hydrogen atmosphere until 
completion as indicated by TLC analysis (5 hours).  After this time the reaction 
mixture was diluted with diethyl ether and filtered through a pad of celite and sand, 
which was washed with copious amount of diethyl ether. The filtrate was collected 
and concentrated in vacuo.  Resulting residue was taken up in fresh diethyl ether (80 
cm3) and washed with saturated aqueous CuSO4 (2 x 80 cm3). The layers were 
separated, and organic layer was dried over sodium sulphate, filtered off, and solvent 
was removed in vacuo. Crude aldehyde 141, obtained as volatile, orange liquid, was 
used in synthesis without purification (100% conversion by NMR, 3.0 g, 23 mmol, 
95% yield).  
 
 δH (400 MHz, CDCl3): 1.23 (3H, t, J = 7.2 Hz, OCH2CH3), 2.59 (2H, t,  
J = 6.7 Hz, CH2CH2CO2Et), 2.75-2.79 (2H, m, CH2CH2CO2Et), 4.12 (2H, q, J = 7.2 
Hz, OCH2CH3), 9.79 (1H, br. t, J = 0.6 Hz, CHO) 
 δC (100 MHz, CDCl3): 14.2 (OCH2CH3), 26.7 and 38.6 (CH2CH2CO2Et), 
60.9 (OCH2CH3), 172.3 (CO2Et), 200.2 (CHO) 
m/z [CI (+ve)], 131.15 ([M+H]+, 72%); Found [M+H]+, 131.0705, C6H11O3 
requires 131.0708 
ν max (CDCl3) / cm−1: 2964, 2908, 1734, 1261, 1087, 1020  
 
 
Ethyl 4-hydroxy-5-nitrohexanoate 142 
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A round-bottom flask was charged with THF (60 cm3) and tBuOH (60 cm3) and the 
obtained solvent mixture was degassed by purging with argon for 20 minutes. Then 
nitroethane (4.9 ml, 5.2 g, 69 mmol, 3 eq) was added to it under an argon 
atmosphere.  The resulting reaction solution was cooled to 0 °C, treated with tBuOK 
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(0.54 g, 4.8 mmol, 0.21 eq) and stirred for 10 minutes at 0 °C. Meanwhile, a solution 
of aldehyde 141 (3 g, 23 mmol, 1 eq) in dry THF (20 cm3) was prepared in a separate 
flask and added via cannula to the stirred reaction mixture at 0 °C. Resultant yellow 
suspension was stirred for additional 15 min at 0 °C and overnight at room 
temperature. After this time saturated aqueous NH4Cl (150 cm3) was poured into the 
reaction and biphasic mixture was diluted with diethyl ether (50 cm3).  The layers 
were separated and the aqueous layer was extracted with ethyl acetate (2 x 150 cm3).  
The organic phases were combined, dried over sodium sulphate, filtered off, and 
solvents were removed in vacuo. Crude nitroalcohol 142 (orange liquid, 4.62 g, 22.5 
mmol, 98% yield) was obtained as mixture (1.6/1) of diastereoisomers, which was 
reacted further without purification.  
 
δH (400 MHz, CDCl3, mixture of diastereoisomers, de retio: 1.6:1 ): 1.26 
(3H, t, J = 7.1 Hz, OCH2CH3, major), 1.26 (3H, t, J = 7.1 Hz, OCH2CH3, minor), 
1.57 (3H, d, J = 6.8 Hz, CH3CH(NO2), major), 1.58 (3H, d, J = 6.8 Hz, 
CH3CH(NO2), minor), 1.68-1.8 (3H, m, two of CH2CH2CO2Et minor, one of 
CH2CH2CO2Et major), 1.88-1.95 (1H, m, one of CH2CH2CO2Et, major), 2.52-2.55 
(2H, m, CH2CH2CO2Et, major), 2.52-2.56 (2H, m, CH2CH2CO2Et, minor), 2.73 (1H, 
d, J = 6.5 Hz, OH, major), 2.88 (1H, dd, J = 5.0 and 0.6 Hz, OH, minor), 3.96-4.02 
(1H, m, CH(OH), major), 4.15 (2H, q, J = 7.1 Hz, OCH2CH3, major), 4.15 (2H, q,  
J = 7.1 Hz, OCH2CH3, minor), 4.17-4.22 (1H, m, CH(OH), minor), 4.49-4.57 (1H, 
m, CH3CH(NO2), major), 4.49-4.57 (1H, m, CH3CH(NO2), minor) 
δC (100 MHz, CDCl3, mixture of diastereoisomers): 13.1 (CH3CH(NO2), 
minor), 14.3 (OCH2CH3, major and minor), 16.2 (CH3CH(NO2), major), 27.8 
(CH2CH2CO2Et, major), 27.9 (CH2CH2CO2Et, minor), 30.3 (CH2CH2CO2Et, major 
and minor), 61.0 (OCH2CH3, major), 61.06 (OCH2CH3, minor), 71.6 (CH(OH), 
minor), 72.3 (CH(OH), major), 86.5 (CH3CH(NO2), minor), 87.8 (CH3CH(NO2), 
major), 173.7 (CO2Et, major), 173.8 (CO2Et, minor) 
m/z [CI (+ve)], 206.3 ([M+H]+, 100%), 161.3 ([M+H-OEt]+, 35%); Found 
[M+H]+, 206.1029, C8H16NO5 requires 206.1028 
ν max (CDCl3) / cm−1: 3464, 2982, 2931, 1728, 1550, 1180  
 
 
 
 170
(E)-ethyl 5-nitrohex-4-enoate 127 
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Nitroalcohol 142 (2.8 g, 13.64 mmol, 1 eq) was dissolved in dry DCM (100 cm3) 
under an argon atmosphere and the resultant orange solution was degassed by 
purging with argon for 20 minutes, cooled to −40 °C and trifluoroacetic anhydride 
(2.1 ml, 3.15 g, 15 mmol, 1.1 eq) was added to it dropwise. Stirring was continued 
for 0.5 hour at −40 °C.  After this time the reaction was cooled to −50 °C and 
triethylamine (4.2 ml, 3.04 g, 30 mmol, 2.2 eq) was added to it via syringe over 10 
minutes. Resulting reaction mixture was stirred for 3 hours at −60 °C and further 2 
hours at −20 °C.  After this time cooling bath was removed and the reaction was 
quenched with saturated aqueous NH4Cl (100 cm3), diluted with diethyl ether (100 
cm3) and stirred until reaching room temperature. The phases were separated and the 
aqueous layer was extracted with fresh diethyl ether (2 x 100 cm3).  The organic 
layers were combined, dried over sodium sulphate, filtered off, and solvents were 
removed in vacuo. The residue was purified by flash column chromatography (silica 
gel, gradient elution, eluting with 100% petroleum ether (40-60) to 5% ethyl acetate 
in petroleum ether (40-60)) to give (E)-nitroalkene 127 as yellow liquid (1.8 g, 9.6 
mmol, 71%). 
 
 δH (400 MHz, CDCl3): 1.26 (3H, t, J = 7.2 Hz, OCH2CH3), 2.2 (3H, d,  
J = 1.0 Hz, CH3C(NO2)), 2.48-2.58 (4H, m, CH2CH2CO2Et), 4.15 (2H, q, J = 7.2 Hz, 
OCH2CH3), 7.05-7.09 (1H, m, C=CH) 
 δC (100 MHz, CDCl3): 12.7 (CH3C(NO2)), 14.3 (OCH2CH3), 23.5 (CH2), 
32.6 (CH2), 61.0 (OCH2CH3), 134.0 (C=CH), 148.7 (CH3C(NO2)), 171.9 (CO2Et) 
m/z [CI (+ve)], 188.21 ([M+H]+, 100%); Found [M+H]+, 188.0923, 
C8H14NO4 requires 188.0923 
 ν max (CDCl3) / cm−1: 2982, 2939, 1732, 1519, 1334, 1180  
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 (Z)-ethyl 5-nitrohex-4-enoate 133 
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Diphenyl diselenide (0.15 g, 0.48 mmol, 0.6 eq) was dissolved in absolute ethanol (6 
cm3) under an argon atmosphere. Resulting bright yellow solution was cooled to 0 °C 
and sodium borohydride (0.04 g, 0.96 mmol, 1.2 eq) was added to it carefully in 
portions. Stirring was continued at 0 °C until yellow reaction mixture turned 
colourless. Then the reaction was cooled to −78 °C and solution of (E)-nitroalkene 
127 (0.15 g, 0.8 mmol, 1 eq) in absolute ethanol (4 cm3) was added dropwise via 
cannula.  Resulting reaction mixture was stirred for 20 minutes at −78 °C and then 
gradually warmed up to −30 °C over 1 hour. After this time the reaction mixture was 
cooled back to −78 °C and glacial acetic acid (0.05 ml, 0.06 g, 0.96 mmol, 1.2 eq) 
was slowly added to it under an argon atmosphere. The resulting reaction mixture 
was stirred at −78 °C for 20 minutes, then the cooling bath was removed and reaction 
was allowed to slowly warm up to room temperature. The reaction was then 
quenched with water (10 cm3) and diluted with diethyl ether (10 cm3).  The phases 
were separated and the aqueous phase was extracted with fresh diethyl ether (2 x 10 
cm3).  The organic phases were combined, dried over sodium sulphate, filtered off, 
and solvents were removed in vacuo.  
The remaining residue (orange oil) was then transferred to the round-bottom flask, 
dried under reduced pressure and dissolved in fresh DCM (6 cm3). Resulting solution 
was cooled to 0 °C and hydrogen peroxide (30% solution in water, 0.73 ml, 0.82 g, 
24 mmol, 30 eq,) was added to it dropwise over 20 minutes. Stirring was continued 
for 1 hour in 0 °C.  After this time the reaction was quenched with saturated aqueous 
NaHCO3 (10 cm3) diluted with diethyl ether (10 cm3) and biphasic mixture was 
stirred for 15 minutes at room temperature.  The layers were separated and the 
organic layer was washed with saturated aqueous NaHCO3 (2 x 10 cm3).  The 
organic phase was collected, dried over sodium sulphate, filtered off, and 
concentrated in vacuo. Crude (Z)-nitroalkene 133 (yellow liquid, 0.13 g, 0.7 mmol, 
87% yield) obtained as mixture of Z/E isomers (9:1), which weren’t separable by 
flash column chromatography, was reacted further without purification.  
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 δH (400 MHz, CDCl3): 1.26 (3H, t, J = 7.2 Hz, OCH2CH3), 2.19-2.2 (3H, m, 
CH3C(NO2)), 2.5 (2H, dd, J = 7.2 and 6.9 Hz, CH2CH2CO2Et), 2.72-2.79 (2H, m, 
CH2CH2CO2Et), 4.14 (2H, q, J = 7.2 Hz, OCH2CH3), 5.9 (1H, br. t, J = 7.3 Hz, 
C=CH) 
 δC (100 MHz, CDCl3):  14.3 (OCH2CH3), 19.3 (CH3C(NO2)), 24.0 
CH2CH2CO2Et), 33.2 (CH2CH2CO2Et), 60.8 (OCH2CH3), 132.5 (C=CH), 147.4 
(CH3C(NO2)), 172.4 (CO2Et) 
m/z [CI (+ve)], 188.2 ([M+H]+, 100%); Found [M+H]+, 188.0921, C8H14NO4 
requires 188.0923 
 ν max (CDCl3) / cm−1: 2978, 2931, 2850, 1732, 1519, 1342, 1180  
 
 
Ethyl 3-((1S,2S,3S)-3-methoxy-2-methyl-2-nitro-5-oxocyclohexyl)propanoate 
151 
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An oven-dried round-bottom flask was charged with benzene (12 cm3), which was 
then degasses by freeze-pump-thaw technique (three times). At the end of last cycle 
the flask was refilled with argon and (Z)-nitroalkene 133 (0.49 g, 2.6 mmol, 1 eq) 
and Danishefsky’s diene 128 (1.26 ml, 1.1 g, 6.5 mmol, 2.5 eq) were added to it 
under an argon atmosphere. Resulting yellow reaction solution was stirred at 60 °C 
for 24 hours. After this time another portion of diene 128 (0.5 ml, 0.4 g, 2.6 mmol, 1 
eq) was added to the reaction solution and stirring was continued at 70 °C for 2 days. 
After this time the reaction was allowed to cool to room temperature and solvent was 
removed in vacuo.  
Remaining residue (orange liquid) was transferred to the round-bottom flask, dried 
under reduced pressure and dissolved in THF (13 cm3). Resulting solution was 
cooled to −10 °C and then solution of HCl (1N in water, 0.16 ml, 0.16 mmol, 0.06 
eq) in THF (13 cm3) was slowly added to it. Stirring was continued for 1 hour at −10 
°C. After this time cooling bath was removed, the reaction was quenched with 
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saturated aqueous NaHCO3 (30 cm3), diluted with diethyl ether (15 cm3) and stirred 
for 20 minutes at room temperature. The layers were separated and the aqueous layer 
was extracted with fresh diethyl ether (2 x 30 cm3). All the organic layers were 
combined, dried over anhydrous sodium sulphate, filtered off, and concentrated in 
vacuo. The remaining residue was purified by flash column chromatography (silica 
gel, gradient elution, eluting with 100% petroleum ether (40-60) to 10% ethyl acetate 
in petroleum ether (40-60)) to give compound 151 as yellow liquid (0.24 g, 0.84 
mmol, 32% yield).  
 
δH (400 MHz, CDCl3): 1.24 (3H, t, J = 7.1 Hz, OCH2CH3), 1.61-1.71 (1H, 
m, one of CH2(C7)), 1.8 (3H, s, CH3C(NO2)), 1.93-2.01 (1H, m, one of CH2(C7)), 
2.18-2.26 (1H, m, one of CH2(C8)), 2.29-2.34 (1H, m, CH(C6)), 2.4 (1H, ddd,  
J = 16.2, 8.0 and 5.6 Hz, one of CH2(C8)), 2.51-2.53 (2H, m, CH2(C5)), 2.58 (1H, 
dd, J =  15.5 and 5.9 Hz, one of CH2(C3)), 2.66 (1H, dd, J =  15.4 and 3.9 Hz, one of 
CH2(C3)), 3.4 (3H, s, CH(OCH3)), 4.12 (2H, q, J = 7.1 Hz, OCH2CH3), 4.15 (1H, dd, 
J = 5.9 and 3.9 Hz, CH(OCH3)) 
δC (100 MHz, CDCl3):  14.3 (OCH2CH3), 21.2 (CH3C(NO2)), 24.8 
(CH2(C7)), 31.8 (CH2(C8)), 40.4 (CH(C6)), 41.4 (CH2(C5)), 41.7 (CH2(C3)), 58.0 
(CH(OCH3)), 60.8 (OCH2CH3), 80.9 (CH(OCH3)), 92.2 (Cq(C1)), 172.5 (CO2Et), 
205.8 (CO) 
δH (400 MHz, C6D6): 0.9 (3H, t, J = 7.1 Hz, OCH2CH3), 1.33-1.43 (1H, m, 
one of CH2(C7)), 1.38 (3H, s, CH3C(NO2)), 1.69-1.78 (2H, m, one of CH2(C7) and 
one of CH2(C8)), 1.86-1.91 (1H, m, one of CH2(C8)), 1.93-1.97 (1H, m, one of 
CH(C6)), 2.01 (1H, ddd, J = 15.5, 6.8 and 1.4 Hz, one of CH2(C3)), 2.05 (1H, ddd,  
J = 15.6, 5.2 and 1.4 Hz, one of CH2(C5)), 2.14 (1H, ddd, J =  15.4, 9.3 and 1.0 Hz, 
one of CH2(C5)), 2.24 (1H, ddd, J = 15.5, 4.1 and 1.0 Hz, one of CH2(C3)), 2.75 
(3H, s, CH(OCH3)), 3.65 (1H, dd, J = 6.7 and 4.1 Hz, CH(OCH3), 3.85 (1H, dq,   
J = 14.3 and 7.1, one of OCH2CH3), 3.85 (1H, dq,  J = 14.3 and 7.1, one of 
OCH2CH3) 
δC (100 MHz, C6D6):  14.7 (OCH2CH3), 21.1 (CH3C(NO2)), 25.4 (CH2(C7)), 
32.0 (CH2(C8)), 41.3 (CH2(C6)), 41.6 (CH2(C5)), 42.1 (CH2(C3)), 57.7 
(CH(OCH3)), 60.9 (OCH2CH3), 80.8 (CH(OCH3)), 92.7 (Cq(C1)), 172.4 (CO2Et), 
204.2 (CO) 
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m/z [CI (+ve)], 288.3 ([M+H]+, 90%), 243.3 ([M+H-NO2]+, 87%), 211.2 
([M+H-NO2-OCH3]+, 100%); Found [M+H]+, 288.1451, C13H22NO6 requires 
288.1447 
 ν max (CDCl3) / cm−1: 2924, 2850, br. 1724, 1539  
 
 
Ethyl 3-((1S,2S,3S)-5-hydroxy-3-methoxy-2-methyl-2-
nitrocyclohexyl)propanoate 158 
 
O
H
NO2
O
O
O ∗
O
H
NO2
HO
1
3
5
6
7
8
O
O
151 158  
 
To a flask charged with polyethylene glycol (400 MW) (1 cm3), ketone 151 (0.036 g, 
0.12 mmol, 1 eq) was added under an argon atmosphere. Resulting mixture was 
purged with argon for 20 minutes, and a catalytic amount of PtO2 was added to it. 
Reaction mixture was immediately degassed under reduced pressure, refilled with 
hydrogen (three times), and stirring was continued overnight under hydrogen 
atmosphere. After this time reaction mixture was diluted with diethyl ether (5 cm3) 
and filtered through a pad of celite and sand, which was washed with copious 
amount of diethyl ether. The filtrate was collected and concentrated in vacuo. 
Remaining residue was taken up in fresh diethyl ether (10 cm3), washed with water 
(10 cm3) and brine (10 cm3). The layers were separated, and organic layer was dried 
over sodium sulphate, filtered off, and solvent was removed in vacuo. The remaining 
residue was purified by flash column chromatography (silica gel, gradient elution, 
eluting with 100% petroleum ether (40-60) to 20% ethyl acetate in petroleum ether 
(40-60)) to give alcohol 158 as yellow, very viscous oil (0.018 g, 0.06 mmol, 50% 
yield).  
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δH (400 MHz, CDCl3): 1.25 (3H, t, J = 7.2 Hz, OCH2CH3), 1.54-1.59 (1H, 
m, one of CH2(C5)), 1.59 (1H, ddd, J = 14.0, 7.8 and 2.9 Hz, one of CH2(C3)), 1.65 
(3H, s, CH3C(NO2)), 1.87-1.98 (4H, m, CH2(C7), CH(C6) and one of CH2(C5)), 2.11 
(1H, appdt, J = 14.0 and 5.4 Hz, one of CH2(C3)), 2.24-2.32 (1H, m, one of 
CH2(C8)), 2.39-2.46 (1H, m, one of CH2(C8)), 3.41 (3H, s, CH(OCH3)), 3.92-3.97 
(1H, m, CH(OH)), 3.99 (1H, dd, J = 5.3 and 2.9 Hz, CH(OCH3)), 4.13 (2H, q, J = 7.1 
Hz, OCH2CH3) 
δC (100 MHz, CDCl3): 14.3 (OCH2CH3), 22.0 (CH3C(NO2)), 25.0 
(CH2(C7)), 32.8 (CH2(C8)), 34.1 (CH2(C3)), 34.5 (CH2(C5)), 40.0 (CH(C6)), 58.1 
(CH(OCH3)), 60.6 (OCH2CH3), 65.6 (CH(OH)), 80.3 (CH(OCH3)), 92.5 (Cq(C1)), 
173.4 (CO2Et) 
m/z [CI (+ve)], 290.2 ([M+H]+, 62%); Found [M+H]+, 290.1603, C13H24NO6 
requires 290.1604 
 ν max (CDCl3) / cm−1: br. 3448, 2937, br. 1732, 1537  
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